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SNR Signal to noise ratio 
SSFP Steady-state free procession 
STS Society of Thoracic Surgeons 
SVG Saphenous vein graft 
TAPSE Tricuspid annular plane systolic excursion 
TAVI Trans-catheter aortic valve implantation 
TE Echo time 
TI Inversion time 
TR Repetition time  
VARC Valve Academic Research Consortium 
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VCG Vectorcardiogram 
VENC Velocity encoding 
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Abstract 
Introduction: Aortic stenosis (AS) is the commonest valvular lesion in the developed world and is 
associated with adverse cardiac remodelling. With its excellent accuracy and reproducibility, 
cardiovascular magnetic resonance (CMR) imaging is an ideal tool to assess cardiac remodelling and 
reverse remodelling following surgical aortic valve replacement (SAVR) and transcatheter aortic valve 
implantation (TAVI). The aims of this thesis were: 1) to evaluate gender differences  in AS and 
following aortic valve replacement, 2) to evaluate the incidence of post-procedural myocardial 
infarction following SAVR and TAVI, 3) to describe the immediate effect of TAVI on reverse 
remodelling and 4)  to assess the impact of TAVI-induced left bundle branch block (LBBB) .  
 
Methods: Between January 2009 and April 2015, patients with severe AS undergoing either TAVI or 
SAVR were prospectively recruited. Patients underwent comprehensive 1.5T CMR evaluation pre-
procedure, prior to hospital discharge and 6m post-procedure. 
 
Results: 1) Women with severe AS have a lower indexed left ventricular (LV) mass than men (65.3± 
18.4 vs. 81.5±21.3g/m2, p<0.001). 6m following valve replacement, LV mass regression is similar 
between genders (men 21.7±10.1 vs. women 18.4±11.0%, p=0.121). 2) Myocardial infarction (MI) is 
more frequent following SAVR than TAVI (n=10 (26%) vs. n=3 (5%), p=0.004). 3) Over 10% of LV 
mass regression occurs prior to hospital discharge following TAVI and is more pronounced in the 
absence of myocardial fibrosis (p=0.005). 4) TAVI-induced LBBB is associated with a reduced LVEF 
6m following TAVI compared with those with a narrow QRS (-2.1±6.9 vs. +4.6±7.8%, p=0.002). 
 
Conclusions: TAVI and SAVR are associated with favourable cardiac reverse remodelling which does 
not differ according to gender and begins prior to hospital discharge. SAVR is associated with a higher 
incidence of post-procedural MI than TAVI. TAVI-induced LBBB should be avoided where possible 
due to its unfavourable effects on cardiac reverse remodelling.   
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Chapter 1:   Introduction 
1.1.   Aortic stenosis 
Aortic stenosis (AS) can be defined as obstruction to blood flow at the level of the aortic valve leading 
to an increase in left ventricular (LV) afterload. It is a progressive, degenerative condition whereby 
there is calcification and fibrosis of the aortic valve leaflets leading to reduced systolic leaflet excursion 
and narrowing of the valve orifice. The majority of patients presenting with AS have tri-leaflet valves 
with equal size and shape of each cusp, whereby there is an equal amount of shear stress distributed to 
each valve leaflet and the aorta, with blood flow directed centrally through the aortic valve (Figure 1-1). 
Calcific tri-leaflet AS was traditionally felt to be purely a degenerative phenomenon. However, there is 
an increasing body of evidence to suggest that the process has an inflammatory [1] and genetic 
component [2]. Congenitally abnormal valves (the most common being a bicuspid valve affecting 
around 1-2% of the population) are prone to premature degeneration due to unequal shear stresses on 
the leaflets. Patients with bicuspid aortic valves typically experience symptoms in their fifth and sixth 
decades of life with tri-leaflet valves degenerating in the eighth and ninth decades. 
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Figure 1-1  Aortic valve morphology 
Panel A demonstrates a cardiovascular magnetic resonance steady state free precession 
image of a normal tri-leaflet aortic valve with unrestricted opening of the right coronary 
cusp (R), left coronary cusp (L) and non-coronary cusp (N) during ventricular systole. 
Panel B demonstrates a normally functioning bicuspid aortic valve with the anterior cusp 
(*) and posterior cusp (˄) visible. Panel C demonstrates a heavily calcified tri-leaflet aortic 
valve with restriction of all three leaflets and a reduced valve orifice. Panel D demonstrates 
a severely stenosed bicuspid aortic valve.  
 
Aortic stenosis is an increasingly common global problem due to an aging population. It affects around 
5% of adults over the age of 75 in the United States [3], with more women than men affected due to 
their longer life span. It is the most common valvular disease of the developed world now that rheumatic 
fever has largely been abolished [4]. The onset of symptoms of severe AS heralds a dismal prognosis, 
with an expected 50% survival at 2 years [5, 6]. Mechanisms for death include sudden cardiac death 
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and more commonly progressive heart failure. Even those with severe asymptomatic AS are exposed 
to a 1% annual risk of sudden cardiac death [7], with a higher risk of adverse events seen in those with 
elevated LV mass [8]. 
1.1.1.   Left ventricular response to AS 
Left ventricular hypertrophy is almost ubiquitous in severe aortic stenosis, reflecting myocardial 
adaptation to chronic elevation of afterload and allowing normalisation of wall stress [9, 10]. At a 
cellular level, there is an increase in the number of sarcomeres and an increase in myocyte size. Initially 
the LV adapts to the increase in wall stress by increasing the size of myocytes allowing maintenance of 
ejection fraction but eventually progressive LV dysfunction occurs, initially affecting diastolic and then 
systolic function (Figure 1-2). Patterns of hypertrophy can be concentric, eccentric or asymmetric and 
the degree of hypertrophy seen does not appear to correlate with the severity of AS [11].  
 
 
 
Figure 1-2  The natural history of left ventricular hypertrophy 
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Panel A: Normal LV mass and myocyte architecture. Myocytes are elongated structures 
measuring 80-100 x 10-20µm and account for around 70% of myocardial volume. They 
are surrounded by capillaries and a collagen weave or extracellular matrix. Panel B: With 
progressive exposure to pressure overload and shear stress, LV mass increases and 
myocytes become hypertrophied and an increase in sarcomeres leads to an increase in cell 
width. Eventually LV systolic dysfunction develops due to a combination of 
subendocardial ischaemia (due to reduced coronary flow reserve) and an inability of the 
myocyte to normalise wall stress by hypertrophic response alone (Panel C). On a 
histological level, myocytes are replaced by non-contractile collagen fibres with a resultant 
increase in extracellular space. 
1.1.2.   Gender and aortic stenosis 
In the normal heart, there are macroscopic and physiological differences between genders. Due to their 
smaller body size women have smaller hearts and therefore a lower stroke volume than men. Women 
have higher LV torsion and circumferential shortening compared with males due to an inherent 
difference in cardiac shape and fibre orientation [12]. Women have reduced sympathetic tone, as 
reflected by lower peripheral vascular resistance and increased parasympathetic tone in relation to men.  
Other differences include lower circulating levels of red blood cells (reflected in a lower haematocrit 
level), noradrenaline and plasma albumin in females, alongside the obvious difference in hormonal 
profile [13]. 
 
The LV responds differently to chronic pressure overload in males and females. Women are found to 
have lower indexed LV mass, less wall tension, increased trans-valvular gradients, higher pulmonary 
artery pressure and better left ventricular ejection fraction (LVEF) than their male counterparts [14-20]. 
Women develop a concentrically hypertrophied, small cavity LV [21] and men are more prone to the 
development of eccentric hypertrophy [14, 22, 23] (Figure 1-3).  
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Figure 1-3  Potential mechanisms for differing patterns of LV remodelling between 
genders in aortic stenosis 
The physiological and biochemical basis for myocyte function is different according to gender.  Males 
with severe AS are thought to have increased collagen I, III and metalloproteinases even in the context 
of normal LVEF [24]. There is increased up-regulation of profibrotic genes and fibrosis in male rodent 
hearts compared with female rodents following aortic constriction [25].  Petrov et al [26] evaluated 
biopsies from 10 human hearts with severe AS and compared them with normal controls. Men with AS 
had higher levels of collagen I, III and MMP-2 gene expression compared to females with AS or 
controls and this correlated with the degree of hypertrophy and changes in LV geometry. This suggests 
a different regulation of matrix synthesis and make up of extracellular volume according to gender. In 
order to further explore this altered extracellular volume in men, the group compared rat cardiac 
fibroblasts treated with 17β-oestradiol and found a down-regulation of collagen I and III mRNA levels 
in female rat fibroblasts but increased expression in male rat cells. This is in keeping with the finding 
that in ageing hearts without AS, there appears to be more fibrosis in male hearts [27]. Women with AS 
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may therefore develop a different form of remodelled hypertrophy distinguished by less fibrosis in the 
heart.  
 
Villari et al noted that interstitial fibrosis was more marked in male hearts with AS when compared 
with female hearts and those of controls without valvular disease [15]. There was no relationship 
between total collagen volume and systolic function. However there was an inverse relationship 
between ‘cross hatching’ (orthogonal collagen fibre meshwork) and LV systolic function. Those with 
increased cross-hatching also had stiffer hearts. In animal models, male rats were found to have 
depressed cardiac reserve compared to female rats exposed to pressure overload (aortic banding) despite 
similar levels of hypertrophy [28]. Therefore it appears that although an increase in the extracellular 
volume does not relate to reduced LVEF, once abnormal collagen architecture has developed, there is 
deterioration in systolic and diastolic LV function.  
 
One theory related to the gender differences observed in LV remodelling is the impact of sex hormones 
on the heart. Oestrogen receptors (ERs) [α and β] can be found in both male and female myocardia and 
these are felt to be implicated in the development of myocardial hypertrophy [29], with oestrogen 
binding having genomic effects on gene transcription and non-genomic effects such as protein kinase 
activation, initiation of intracellular signalling cascades and modulation of growth factor signalling [30]. 
It has been proposed that rapid signalling of the non-genomic ERα can provide protection from myocyte 
necrosis and apoptosis, at least in animal models [31].   
Testosterone exhibits an anabolic effect on the myocardium inducing myocardial hypertrophy in rodents 
[32]. Oestrogen modulates the renin-angiotensin system by decreasing renin and angiotensin-converting 
enzyme (ACE) synthesis and increasing angiotensinogen synthesis.  It is well established in animal 
studies that this impacts on the hypertensive response but may also be implicated in differences in LV 
remodelling [33].  Gender-related differences in nitric oxide (NO) expression and activity may also play 
a role. In a rat model of pressure overload, cardiac NO synthase expression is regulated differently 
between sexes. Male rats subjected to aortic banding experienced more early LV dysfunction and left 
ventricular hypertrophy (LVH) than their female counterparts which correlated with a greater early 
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increase in cardiac NO synthase 1 expression in males [34]. Female hearts appear to release less 
norepinephrine in response to myocardial stress than male hearts [35]. Although a direct link is yet to 
be established, it is evident that there is a link between circulating catecholamine levels and the 
development of LVH in the pressure overloaded ventricle [36].  There appears to be gender-related 
differences in I/D polymorphism of the ACE gene which affects serum ACE activity in patients with 
AS [37].  In women, absence of DD allele is associated with a higher LV mass whereas the opposite is 
true for men, with higher LV mass correlating with the presence of a DD genotype. These differences 
may also impact on reverse remodelling following valve replacement and may at least in part explain 
the differing patterns of reverse remodelling according to gender seen in a number of studies[38-41], 
which in turn may be an implicating factor in the improved long term outcomes seen in women 
following aortic valve intervention[42, 43].  
1.1.3.   Aortic stenosis and myocardial fibrosis 
Myocardial fibrosis (MF) is seen at autopsy in patients with AS [44] where it can be dense replacement 
fibrosis resulting from myocardial infarction or diffuse, reactive and potentially reversible, more akin 
to that seen in hypertensive cardiomyopathy [45]. In the normal heart, the extracellular space accounts 
for around 2-4% of the structural space and is composed of capillaries and a mesh of collagen fibres 
produced by myofibroblasts, providing support and structure to the surrounding cells. In the pressure 
overload state of AS, not only is there hypertrophy of the cardiomyocyte, but there is an increase in 
fibroblast collagen deposition and hence an expansion of the extracellular space. This is manifest 
clinically as myocardial fibrosis, which is initially of the diffuse reactive type, but eventually becomes 
focal and dense (akin to that following myocardial infarction) due to cellular death and apoptosis. MF 
has been reported to be present in between 27 and 63% of patients with severe AS, accounting for 3-4% 
of LV myocardium [46, 47]. The presence of myocardial fibrosis in patients with severe AS is an 
independent predictor of mortality [48]. Also, in those undergoing surgical aortic valve replacement 
(SAVR) it has been found to adversely affect prognosis and may also influence cardiovascular mortality 
following trans-catheter aortic valve implantation (TAVI) [49].  
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The association between MF and LV remodelling in AS is still under debate. An early histopathological 
study suggested that MF burden was associated with LV mass but not LVEF [50], and a CMR late 
gadolinium enhancement (LGE) study found no correlation between severity of AS and MF, but again 
found  an association with LV mass [46]. Another histopathological study found a direct relationship 
between the volume of MF and LVEF, with 40% of the myocardial mass composed of MF in those with 
severely reduced LVEF and almost 10% of cells experiencing autophagic and oncotic cell death [51] .  
1.2.   Treatment of aortic stenosis 
Surgical aortic valve replacement has been available since the 1960s [52] and was for a long time the 
only available effective treatment for patients with AS. More recently, trans-catheter therapies have 
become available for those considered inoperable or at high surgical risk [53, 54], revolutionising the 
care of a generation of elderly patients where previously, palliation was the only option. Prior to the 
advent of TAVI, balloon valvuloplasty was used in those patients deemed unsuitable for surgery, but 
the results were disappointing, only impacting on valve gradients for a matter of months [55].  
 
Various trials have been conducted to investigate whether medication can alter the time course of AS. 
The RIAS trial was a prospective, double-blind randomised control trial investigating the effects of 
ACE inhibition on LV mass regression in AS [56]. Although a modest reduction in LV mass was 
observed in the treatment arm, ACE inhibition did not slow the progression of AS or impact on exercise 
capacity. Early animal studies suggested that statin treatment may be effective at halting the progression 
of AS due to the anti-inflammatory properties of the drug [57].  Early human studies were promising 
[58, 59], however, prospective randomised control trials have been negative [60-62].  Bisphosphonates, 
due to their ability to inhibit vascular calcification, have also been proposed as potential disease 
modifiers, however, a retrospective observational study has reported negative results [63]. The 
SALTIRE II trial, a prospective randomised control trial investigating the effects of Denosumab and 
Alendronic acid on the progression of AS, is ongoing and expected to be completed in 2017.  
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1.3.   Surgical aortic valve replacement 
1.3.1.   Who should be referred for SAVR? 
SAVR remains the gold standard and definitive treatment for severe aortic stenosis and forms a Class I 
indication in the European Society of Cardiology Guidelines [64] in those with symptoms, those 
requiring coronary artery bypass surgery (CABG), surgery on another valve or the ascending aorta and 
those with a LVEF <50%. Class IIa indications for surgery include those with severe AS and an 
abnormal blood pressure response to exercise, patients with moderate AS undergoing CABG, those 
with low-flow low-gradient AS with reduced LVEF (if evidence of flow reserve is demonstrated) and, 
if the surgical risk is deemed to be low, those with very severe asymptomatic AS (peak pressure 
drop >5.5m/sec) or severe valvular calcification and rapidly progressive disease. SAVR has been shown 
to benefit patients of all ages, including those in their 10th decade [65]. Age should not be a reason, in 
its own right, to deny a patient of surgery. Frailty is however, increasingly prevalent with advancing 
age, and may pertain to a higher peri-operative mortality and morbidity [66]. Pre-operative risk can be 
reliably estimated using the Society of Thoracic Surgeons (STS) score, however, mortality may be 
underestimated in high risk patients using the EuroSCORE II scoring system [67].  
1.3.2.   Surgical AVR technique 
The first experience in aortic valve implantation involved a homograft implantation in the descending 
thoracic aorta [68]. The technique rapidly evolved and the first widespread aortic valve replacement, 
the Starr-Edwards ball and cage prosthesis, was developed in the 1960’s [69, 70]. Mechanical valve 
design has advanced over the decades, with newer bi-leaflet designs offering improved valvular 
haemodynamics and requiring lower levels of anticoagulation than earlier models. Bioprosthetic valves, 
usually fabricated from bovine or porcine pericardium, obviate the need for anticoagulation altogether 
and although less durable are often the valves of choice in the elderly population. SAVR involves the 
use of cardiopulmonary bypass and cardioplegia to allow access to the aortic valve via a median 
sternotomy. Cardioplegia can be delivered in a retrograde or antegrade fashion with differing methods 
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employed according to the preference of the centre and individual surgeon. Cardioplegic arrest and the 
systemic inflammatory response associated with cardiopulmonary bypass can cause myocardial injury 
to the hypertrophied heart of aortic stenosis which is vulnerable to ischaemia/reperfusion injury and is 
a significant cause of morbidity and mortality following surgery [71]. More modern SAVR techniques 
including off pump aortic valve bypass and minimal access surgery have been validated in large series 
but are yet to be adopted into mainstream clinical practice [72, 73].  
1.3.3.   Gender and SAVR 
The effect of gender on outcome following SAVR is difficult to accurately evaluate as most studies are 
retrospective, comprising a heterogeneous group of patients including those undergoing concomitant 
bypass grafting. Surgery in women is usually more technically demanding due to smaller annuli size, 
increased need for aortic enlargement and complications related to cardiopulmonary bypass. Also, 
women tend to be older and in a more advanced stage of the disease with greater frailty at the time of 
surgical referral. In the recently published multi-centre OBSERVANT registry that enrolled 2108 
patients undergoing TAVI and SAVR (some with concomitant CABG) across 101 heart centres, women 
represented 44% of the SAVR population [74].  Women were older, frailer and more symptomatic than 
men with less peripheral and coronary artery disease (CAD). Baseline echocardiography demonstrated 
a better LVEF, more mitral regurgitation, higher trans-valvular gradients and lower indexed aortic valve 
area (AVAi) in women with higher post-operative trans-valvular gradients. Female gender was an 
independent predictor of risk-adjusted 30-day mortality following SAVR compared with males (3.7% 
female vs. 2.2% male, p=0.043, OR 2.34). Women were more likely to undergo blood transfusions than 
men (OR 1.47), possibly due to a lower level of haemoglobin pre-operatively. Another large surgical 
series [75] reported an increased in-hospital mortality in females (3.5% females vs. 1.6% males), 
however, this difference was not significantly different following propensity matching. Women had 
shorter cardiopulmonary bypass and aortic cross clamp time, smaller prosthesis size, more tissue 
bioprostheses and more aortic enlargement procedures than men.  Most other studies evaluating isolated 
SAVR have also failed to show a difference in risk adjusted mortality according to gender [76-78], with 
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a systematic review of 28 studies failing to demonstrate gender as a prognostic indicator [79]. Females 
however do appear to have an increased morbidity following SAVR. One recent study of 6809 patients 
undergoing SAVR found a higher rate of post-operative stroke in women compared with men (3% vs. 
2.2%, p=0.031) and various studies have found that women receive more blood transfusions than men 
[74, 75, 80, 81].  
 
Although a systematic review of the outcomes of SAVR in patients with AS found that gender did not 
impact on LV mass regression and change in LVEF, the studies analysed were largely historic and 
included small studies [82]. More recent and larger studies can be seen in Table 1-1. The results are 
mixed and again contain a heterogeneous group of patients. At least in theory, females’ smaller body 
size requires smaller aortic valves which are associated with a higher post-operative trans-valvular 
gradient and subsequently less LV mass regression [83].   
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Table 1-1  Studies investigating LV remodelling according to gender 
Reference No. of patients Study design Valve lesion Valve types Intervention Effect of gender 
Hanayama 
et al, 2005 
[38] 
529 
(186 female) 
Prospective registry, follow up 
using echocardiography post-
operatively at one year and 
yearly thereafter 
Pure AS or mixed aortic 
valve disease with 
predominant stenosis 
Stented and stentless 
bioprosthesis, tilting 
disk and bi-leaflet 
mechanical valves 
SAVR with or 
without 
concomitant 
CABG 
 
Incomplete LV mass 
regression occurred less 
frequently in females; HR 0.44 
(95% CI 0.22 – 0.89) 
Vaturi et 
al, 2000 
[39] 
100 
(30 female) 
Retrospective study of patients 
undergoing SAVR for AS or 
AR. Echocardiograms 
performed pre- and post-
operatively 
Aortic stenosis, aortic 
regurgitation or mixed 
aortic valve disease. 
Tilting disc and bi-
leaflet mechanical 
valves 
SAVR with or 
without 
concomitant 
CABG 
Male gender was a predictor 
of LV mass regression on 
multivariate analysis in 
patients with pure aortic 
stenosis. 
Petrov et 
al, 2010 
[26] 
92 
(53 female) 
Prospective study with 
echocardiography performed 
before and 3-5 days following 
SAVR 
Severe isolated aortic 
stenosis 
Unknown Isolated aortic 
valve 
replacement 
Women had more LV mass 
regression early after surgery 
than men. Female gender was 
an independent predictor of 
postoperative LV mass 
regression after multivariate 
adjustment. 
AS: aortic stenosis. SAVR: surgical aortic valve replacement. CABG: Coronary artery bypass grafting. AR: Aortic regurgitation.  LV: Left ventricular.
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1.4.   Trans-catheter aortic valve implantation 
Transcatheter aortic valve implantation is a procedure that was first performed in man in 2002 [84] 
whereby a bovine or porcine pericardial aortic valve is delivered via a catheter usually from the femoral, 
subclavian or apical approach. Large sheaths (typically 14-22 French) are inserted in to the arterial 
access site and the catheter is delivered to the heart via a steerable delivery catheter. The valve is 
positioned using fluoroscopic and echocardiographic guidance. Deployment technique depends on the 
type of valve, but the end point is that the native valve leaflets are displaced towards the wall of the 
aorta and the new valve is deployed within a metal frame. The procedure originally took place under 
general anaesthetic with transoesophageal echocardiographic guidance, however, femoral access 
procedures are now routinely taking place with local anaesthetic under conscious sedation, using only 
fluoroscopy as guidance. Since their introduction, many different models have become available (Figure 
1-4). Some devices such as the Edwards Sapien and Sapien 3 (Edwards Lifesciences, Irvine, CA, USA) 
comprise a balloon expandable frame with bovine pericardial tissue valve [85]. The Medtronic 
CoreValve and Evolut-R devices (Medtronic Inc., Minneapolis, MN, USA) are made from porcine 
pericardium and the nitinol frame is self-expanding [53]. The Boston Lotus device (Boston Scientific 
Corporation, Natick, MA, USA) is made from bovine pericardium and has an adaptive seal which aims 
to reduce paravalvular aortic regurgitation at the expense of higher pacing rates, possibly due to 
increased pressure on the conduction system tissue [86].  
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Figure 1-4  Different types of TAVI bioprostheses 
Panel demonstrating the different types of TAVI bioprostheses. A: Medtronic CoreValve, 
B: Edwards Sapien, C: Boston Lotus, D: Medtronic Engager, E: Edwards Sapien 3, F: 
Medtronic Evolut R. 
1.4.1.   Patient selection for TAVI 
European Society of Cardiology guidelines suggest that TAVI can be considered as an alternative to 
SAVR in patients deemed to be at high surgical risk by the multidisciplinary heart team [64]. An STS 
score of >10% has been proposed as the cut-off for considering TAVI over SAVR, with a lower 
threshold for patients who are frail or with porcelain aorta, patent coronary artery bypass grafts or a 
hostile mediastinum. Absolute contraindications to TAVI include estimated life expectancy <1 year, 
severe concurrent valvular disease contributing to symptoms, active endocarditis, inadequate annulus 
size, LV thrombus, elevated risk of coronary ostial obstruction due to small sinuses, short distance 
between the annulus and ostia, asymmetric valvular calcification, mobile thrombi in the ascending aorta 
or arch and inadequate vascular access [64].  Both the EuroSCORE II and STS PROM score have been 
validated to predict outcome following TAVI[87]. 
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1.4.2.   Gender and TAVI 
Due to the fact that TAVI is a relatively new technique, few long-term data regarding gender differences 
are available and the findings are discordant. A subgroup analysis of the Placement of Aortic 
TraNscathetER valves (PARTNER) A trial suggested that women had improved outcomes after TAVI 
compared with SAVR [88], although it was unclear whether this effect was due to worse surgical 
outcomes or improved TAVI outcomes, or both, and further research has attempted to explore this 
relationship. In a prospective registry of 260 patients undergoing TAVI by Hayashida et al [42], women 
were of similar age to men but with less coronary disease, a higher LVEF and lower EuroSCORE. On 
Cox regression analysis, women had an improved one-year survival compared with males (76% vs. 
65%); however, baseline characteristics between the two groups were not corrected for. Humphries et 
al [43] recorded a prospective database of 641 patients undergoing TAVI over a 6 year period. Women 
pre-procedure were more frail but with less comorbidity and a higher LVEF than men. Vascular 
complications and the need for peri-procedural blood transfusion were seen more frequently in women. 
There was improved survival in women at 2 years (72.5% in women and 61.7% in men). This mortality 
benefit was maintained even when demographic, clinical and procedural factors were corrected for (HR 
0.55). Buja et al [18] studied 659 high risk patients (55.8% female, mean age 81 ± 6 years) with severe 
AS undergoing TAVI. At one year follow up there was a 63% relative risk reduction in death, 
myocardial infarction or major stroke observed in women compared with men. Cardiac reverse 
remodelling following TAVI may provide late but important differences in cardiac function in women 
pertaining to improved survival, as this mortality benefit was sustained when cardiovascular death alone 
was analysed at 12 months (3% men vs. 0.4% women, p=0.048).  More recently, Erez et al [89] 
prospectively followed 224 high risk patients with severe AS undergoing TAVI for a mean of 17 months. 
Men had an independent two fold increased risk of death at 2 years compared to women. In women, the 
presence of coronary artery disease was associated with a marked increase in mortality whereas in men 
the presence of coronary artery disease did not influence survival.  In one of the largest registries to 
date, women were found to have a similar 30 day mortality to men but an improved one year all-cause 
mortality (HR 0.75 CI 0.57-0.98, p=0.0346) despite being older [90]. Most studies have only evaluated 
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high risk patients undergoing TAVI, however, a prospective, multi-centre comparison of intermediate 
risk patients (as defined by STS score of 3-8%) undergoing TAVI and SAVR found that at one year 
follow up all-cause mortality was similar among both groups, however, women undergoing valve 
replacement appeared to have an improved survival when undergoing TAVI compared with SAVR, 
endorsing the findings of the PARTNER A trial [91]. Other studies suggest no difference in all cause 
and cardiovascular mortality following TAVI according to gender although it is clear that women 
receive more blood transfusions than men [74, 92-96]. Only one study to date has found female gender 
to be a predictor of adverse outcome at one year on Cox proportional hazard analysis [97].   
 
Women have been found to have less significant post-procedural (grade ≥ 2) aortic regurgitation than 
men in several studies [74, 94, 98, 99], likely as a result of their smaller annular size. Significant aortic 
regurgitation is known to be associated with adverse outcome and this may play a role in apparent 
gender discrepancies. Differences in LV reverse remodelling and LVEF according to gender following 
TAVI may help explain this apparent survival advantage in women but has yet to be explored fully in 
the literature. Stangl et al [41] assessed gender differences in LV reverse remodelling by 
echocardiography in a prospective cohort of 100 patients following TAVI. Women were older, smaller 
(both in height, weight and body surface area) and had a smaller aortic annulus size compared with men. 
They also had an increased ejection fraction, smaller common femoral artery size, lower cardiac output 
and less comorbidity than men. Although they found no gender difference in mortality, residual aortic 
regurgitation, pacing rates, cardiovascular or cerebrovascular events at 3 months following TAVI, as 
with some of the SAVR studies there were differences in LV reverse remodelling according to gender. 
Women had a significant improvement in LVEF following TAVI whereas men did not, although both 
genders experienced a similar amount of LV mass regression. This study, to our knowledge, is the only 
study to have explored in detail gender differences in LV reverse remodelling following TAVI.  
1.5.   Outcomes following SAVR and TAVI 
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Published figures for operative mortality in SAVR are low, with overall mortality rates in the region of 
3-4% for isolated SAVR and 4-6% for SAVR with CABG [100]. Increasing age has been strongly 
associated with reduced survival, with mortality rates of >6% reported in the over 80’s [100-102]. Peri-
operative morbidity also varies according to the patient population. In a young, low risk group of 
patients (aged 50-70 years) undergoing isolated mechanical or bioprosthetic aortic valve replacement, 
30 day stroke rate was 2%, atrial fibrillation (AF) occurred in 13%, acute kidney injury (AKI) in 2% 
and respiratory failure in 10% [103]. TAVI appears to be non-inferior to SAVR and superior to medical 
therapy. The first randomised controlled trial results (PARTNER B) were published in 2010 [54] which 
demonstrated a dramatic reduction in 12 month mortality in those randomised to TAVI compared to 
those randomised to the optimal medical management arm (30.7 vs. 50.7%, p<0.001), at the expense of 
higher rates of cerebral and peripheral vascular complications. This trial highlighted the dismal 
prognosis associated with medical treatment of severe AS and paved the way for the expansion of TAVI 
services worldwide [104]. For the first time, those at prohibitive surgical risk, or those with conditions 
such as porcelain aorta or a hostile mediastinum due to previous radiotherapy precluding conventional 
surgery (accounting for around a third of the severe AS population according to the EuroHEART survey) 
[4], were able to be offered a potentially life-saving treatment. The next PARTNER study (PARTNER 
A) [85] randomised high surgical risk patients (defined as a society for thoracic surgeons (STS) score 
of ≥ 10%) with severe symptomatic AS to either SAVR or TAVI. At 12 month follow up there were no 
significant difference in mortality or New York Heart Association (NYHA) classification between 
patients in the two groups, however, there was a significant increase in vascular complications at 30 
days and a trend towards increased major stroke rate at 12 months in the TAVI arm. A more recent 
randomised control trial comparing self-expanding TAVI with high risk SAVR found that TAVI was 
associated with a lower mortality at 1 year (14.2 vs.19.1%, p=0.04) [53]. Major vascular complication, 
the need for permanent pacemaker insertion and cardiac perforation were more common following 
TAVI than SAVR, with major bleeding, AKI and AF higher in the SAVR group. In this study, stroke 
rates were not significantly different between groups (TAVI 4.9% vs. SAVR 6.2%, p=0.46). The 
recently published NOTION trial randomised all-comers with severe symptomatic AS over the age of 
70 years to self-expanding TAVI or SAVR [105]. Mean age of the study participants was 79±5 years 
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and almost half of them were women. STS score was around 3% and EuroSCORE II around 2%, 
representing a low to intermediate risk population. At one year follow up there was no difference in all-
cause mortality, cardiovascular death or stroke rates between the two groups. Major, life-threatening or 
disabling bleeding, AF and AKI were more frequent following SAVR. Pacing rates were higher 
following TAVI, with high rates of 34.1% reported, as was aortic regurgitation (16% of the TAVI cohort 
had moderate or severe AR at one year) and minor vascular complications. The mortality rate of 4.9% 
at one year was the lowest reported to date, and may pave the way for a change in guidelines in the low 
to intermediate risk elderly population. 
1.5.1.   Myocardial infarction following TAVI and SAVR 
Clinically detectable myocardial infarction (MI) appears to be a rare consequence of both TAVI and 
SAVR. In the PARTNER A study, reported rates of MI were low in both TAVI and SAVR groups; 
representing 0.4% of the TAVI group and 0.6% of the SAVR group (P=0.69) [85]. In the recent 
NOTION trial [105], rates of post-procedural MI were numerically higher in the SAVR group but, 
(possibly due to small numbers) this failed to reach statistical significance both at one month (TAVI 
2.8% vs. SAVR 6%, p=0.20) and one year (TAVI 3.5% vs. SAVR 6%, p=0.33). Although clinically 
detected MI post-TAVI and SAVR is rare, defining peri-procedural MI in this group is challenging, 
reflected by the change in criterion for diagnosis between the VARC [106] and VARC II guidelines 
[107]. It does appear however that evidence of MI by CMR LGE has prognostic importance in other 
settings, even if clinically ‘silent’;  those with CMR evidence of new MI  following percutaneous 
coronary intervention or coronary bypass grafting have a >3 fold risk of adverse outcome regardless of 
peri-procedural troponin rise [108]. . The mechanisms for MI following aortic valve intervention remain 
incompletely defined but may be embolic, a pathogenesis which is supported by data from an 
intracoronary Doppler study [109] and possibly relate to differing anticoagulation regimes following 
surgical and transcatheter valve replacement. The low incidence of reported MI following aortic valve 
intervention may underestimate the true rate, due to difficulty in post-procedural diagnosis. In the 
sedated or intubated patient a history of chest pain cannot be established and  new conduction defects 
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on the electrocardiogram such as left bundle branch block (a result of trauma to the cardiac conduction 
system) mask diagnostic ECG changes [110, 111]. Biomarker release is also often unhelpful, with high 
levels ubiquitous following both procedures [112, 113]. Silent myocardial infarction, although well 
described following percutaneous coronary intervention [108, 114], has not been well characterised 
following SAVR and TAVI.  The only study to date using cardiac imaging to detect post-SAVR infarct 
rates, reported a new MI rate of 16% using technetium-99m pyrophosphate radionuclide scanning [115].  
Kim et al [116] reported a new MI rate of 18% following TAVI using CMR-LGE however, the study 
included a high number of patients undergoing trans-apical TAVI, and it was not clear from the study 
design whether the inevitable apical scar associated with this approach [117] was classified as new MI.  
 
When considering the risk of post-procedural MI, another pertinent question is that of the need for 
coronary revascularisation prior to or at the time of aortic valve intervention. Joint American College 
of Cardiology (ACC) / American Heart Association (AHA) guidelines previously recommended 
coronary revascularisation at the time of SAVR as a Class I indication in the presence of >70% luminal 
stenosis and as a Class IIa indication in those with a lumen stenosis above 50% [118]. The updated 2014 
guidelines [119] have downgraded the recommendation for revascularisation of luminal stenoses of >70% 
to a IIa, reflecting the emerging evidence that coronary revascularisation in a number of settings doesn’t 
improve prognosis [120]. Retrospective analyses have suggested a better long-term survival in those 
with moderate (>50% stenosis) and severe (>70% stenosis) CAD undergoing concomitant CABG at the 
time of SAVR [121], but evidence from prospective trial data are lacking, and it is not known whether 
CABG has any impact on the incidence of post-procedural MI. The need for concurrent 
revascularisation in patients with CAD undergoing TAVI is debated. Initially, full revascularisation was 
carried out due to concern regarding the risk of peri-procedural MI or myocardial injury, especially in 
the context of prolonged hypotension as a result of rapid pacing during device deployment [18, 122, 
123]. However, these fears appear unfounded, with several studies suggesting that the presence of CAD 
or non-revascularised myocardium is not associated with an increased risk of adverse events [124, 125].  
1.5.2.   Conduction system disease 
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The aortic valve lies close to the electrical conduction system of the heart and is prone to damage at the 
time of aortic valve intervention, often manifesting as new left-bundle branch block (LBBB). New 
LBBB is infrequent following SAVR, with reported rates in the region of 5% [126] but much more 
common following TAVI with rates of up to 65%, depending on valve design [127]. Trauma to the 
cardiac electrical conduction system at the time of TAVI can be a result of guide wire and catheter 
manipulation, direct pressure from the valve cage and repeated balloon valvuloplasty (both pre- and 
post-valve deployment). Given the advanced age of the patients undergoing TAVI, there may be pre-
existing conduction system disease and this extra insult at the time of TAVI is the ‘final straw’ in the 
deterioration into conduction abnormalities. On a cellular level, the mechanical trauma is thought to 
result in transient tissue inflammation and oedema. AV nodal ischaemia may also be partially 
implicated as a result of the transient global hypotension at the time of rapid atrial pacing. Post-mortem 
studies have demonstrated haematoma of the interventricular septum at the site of valve expansion and 
resultant compression of the bundle of His following TAVI [128].  
 
Following implantation of the self-expanding Medtronic CoreValve, LBBB has been reported in 29 to 
65% [129-143] with high rates of pacemaker implantation also seen with this valve design [129, 133, 
136, 143, 144]. The Edwards Sapien valve is associated with a lower rate of LBBB, with an incidence 
of 16% to 27% reported [129, 131, 144-146]. Pacing rates following Boston Lotus implantation are 
reported in the region of 29% at 30 day follow up [86], although to date no study has reported the 
incidence of LBBB in this population. The difference in pacing rates according to device type is not 
entirely understood.  It may relate in part to the differing implant sizes or the differing methods of 
deployment. The self-expanding nature of the CoreValve may provide a constant pressure (and hence 
trauma) to the left ventricular outflow tract, long after device deployment occurs, or it may be that the 
trans-femoral rather than trans-apical approach is to blame, or even the need for balloon valvuloplasty 
pre-procedure in CoreValve implantation.  Depth of TAVI implantation, device type, valve:annulus 
ratio, male gender and previous myocardial infarction have all been reported as univariate predictors of 
new LBBB [131, 133, 134, 143, 145]. Only depth of TAVI implantation has been found to be a predictor 
of post-operative LBBB on multivariable analysis [131]. Guittierez et al [145] found that patients were 
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more likely to develop post-procedural LBBB if the Medtronic CoreValve cage was located below the 
hinge point of the anterior mitral valve leaflet.  Further insights from post-procedural computed 
tomography of the Edwards Sapien valve suggests overexpansion of the bioprosthesis >15% of the 
native aortic annular area and implant depth may be implicated [147]. A short membranous septum (a 
surrogate of the distance between the aortic annulus and bundle of His), insufficient distance between 
the membranous septum and implantation depth and basal septal calcification can all predict post-TAVI 
high degree atrioventricular block [148]. Device landing zone calcification has also been associated 
with the need for post-procedure PPM implantation in those undergoing Medtronic CoreValve 
implantation [149]. There does appear to be a resolution of LBBB over time in a significant proportion 
(50% in one year) following implantation of the Edwards Sapien valve [111]. This does not appear to 
be the case after Medtronic CoreValve implantation, with no change in rates of LBBB between hospital 
discharge and 30 day follow up [150]. Data with regard to the Boston Lotus valve are scarce, but given 
the higher pacing rates reported, the effects on the conduction system are likely to be more akin to the 
Medtronic CoreValve than the Edwards Sapien [86]. 
 
TAVI-induced left-bundle branch block has been linked to reduced survival in a number of studies 
[151-154] and also increased rates of hospitalisation [111], in keeping with population based studies 
suggesting reduced overall survival in healthy individuals with LBBB [155] and in patients with heart 
failure and LBBB [156]. Other studies have failed to establish an association (Table 1-2). In the study 
by Houthuizen et al, 34.3% of patients developed new LBBB. QRS duration increased from 96ms pre-
procedure to 150ms post-procedure and those with new LBBB also had a greater increase in post-
procedure PR interval. 12 month all-cause mortality in those with new LBBB was 26.6% in contrast to 
17.5% in those without (p=0.006). TAVI-induced LBBB was one of the strongest predictors of 
mortality (HR 1.54) alongside COPD, female gender, LVEF<50% and baseline creatinine. The effect 
of TAVI-induced LBBB on mortality was similar between CoreValve and Sapien valve types. The 
mechanism for this increased mortality is debated.  One hypothesis is that LBBB is a precursor to further 
more lethal conduction abnormalities, supported by pacing studies which reported high degree 
atrioventricular block on permanent pacemaker (PPM) interrogation of those with TAVI induced LBBB 
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[157, 158]. The MARE (Ambulatory Electrocardiographic Monitoring for the Detection of High-
Degree Atrio-Ventricular Block in Patients with New-onset PeRsistent LEft Bundle Branch Block after 
TAVI by an Electrophysiological and Remote monitoring Risk-adapted Algorithm’ study 
(NCT02482844)) will attempt to address the optimal management of patients with TAVI-induced 
LBBB. Another hypothesis is that TAVI-induced LBBB leads to abnormal LV remodelling and 
ultimately heart failure death via a LBBB-induced cardiomyopathy [159]. 
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Table 1-2  Studies investigating the effect of TAVI-induced LBBB on mortality 
Author Number of 
patients 
Valve type Excluded ECG Follow up Findings 
Houthuizen, 
2012 [151] 
670 
(233 LBBB) 
Balloon-expandable 
(n=292), self-
expanding (n=387) 
Pre- or post-procedure 
PPM, pre-existing 
LBBB 
Within 7 days 
post-procedure 
Median 450 
days 
Significant increase in all-cause 
mortality in those with new LBBB 
(37.8 vs. 24.0% at one year, p=0.002). 
LBBB was independent predictor of 
all-cause mortality (HR1.54, 
confidence interval 1.12-2.10) 
 
Urena, 2012 
[160] 
202 
(61 LBBB) 
Balloon-expandable 
 
Pre-procedure PPM, 
prior intraventricular 
conduction delay 
 
LBBB at 
discharge 
Median 12 
months 
No increase in all-cause or cardiac 
mortality at 12 months in LBBB group 
Franzoni, 2013 
[161] 
238 
(63 LBBB) 
Balloon-expandable 
(n=151), self-
expanding (n=87) 
Pre-procedure PPM, 
Pre-procedure LBBB 
and RBBB 
LBBB at 
discharge 
Median 349 
days 
 
Numerical excess of deaths in LBBB 
(LBBB 8 (20%) vs. nQRS 26 (15.4%), 
but did not reach significance as under-
powered. 
 
Houthuizen, 
2014 [153] 
476 
(175 LBBB) 
Balloon-expandable 
(n=253), self-
expanding (n=301) 
Pre-procedure LBBB or 
PPM 
LBBB 12 
months post-
TAVI 
Median 915 
days 
 
LBBB associated with increased 
mortality (HR 1.49, 95% CI 1.10-2.03, 
p=0.01) 
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Nazif, 2013 
[111] 
1151 
(121 LBBB) 
Balloon-expandable 
 
Pre-existing 
intraventricular 
conduction 
abnormalities and pre-
procedure PPM 
 
LBBB at 7 days 
or hospital 
discharge 
1 year 
No significant difference in 12 month 
all-cause or cardiovascular mortality 
between nQRS and LBBB groups 
Testa, 2013 
[150] 
879 
(224 LBBB) 
Self-expanding 
 
Pre-existing LBBB, pre 
or early post-procedure 
PPM 
 
LBBB at 
discharge 
Median 438 
days 
LBBB had no effect on mortality at 30 
days or 1 year 
Urena, 2014 
[162] 
668 
(128 LBBB) 
Balloon-expandable 
Pre-existing LBBB and 
pre-procedure PPM 
LBBB at 
discharge 
Median 13 
months 
 
No increase in all-cause or 
cardiovascular mortality in LBBB at 
12 months 
 
LBBB: Left-bundle branch block, RBBB: right-bundle branch block. nQRS: Narrow QRS. PPM: Permanent pacemaker. TAVI: Trans-catheter aortic valve 
implantation.  
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1.6.   LV reverse remodelling following aortic valve intervention 
Favourable LV reverse remodelling following aortic valve replacement is prognostically important. 
Enhanced LV mass regression following SAVR has been linked to improved survival [163] and in 
patients with severe pre-TAVI hypertrophy those with greater mass regression post-procedure have a 
reduced rate of hospitalisation at 12 months [164].  Improvement in LVEF following SAVR has been 
associated with improved survival and freedom from heart failure at long term follow up [165]. 
 
LV reverse remodelling is the norm following afterload reduction, as is seen following trans-catheter 
and surgical aortic valve replacement [166]. From a physiological perspective, acute reduction in 
afterload is associated with a reduction in wall stress and left ventricular filling pressure and, on a 
cellular level, myocyte shrinkage can be spontaneously seen in hypertensive rats one week after 
treatment with anti-hypertensive agents [167]. Six months following TAVI and SAVR, there is a 
reduction in LV end systolic volume and LV mass [166, 168]. Regression of hypertrophy continues 
over 2 years following TAVI and SAVR, although the rate of regression declines [165, 169]. 
Echocardiographic studies suggest that following TAVI mass regression starts prior to hospital 
discharge; Hahn and colleagues reported a reduction of LV mass of 9 grams between baseline and pre-
discharge echocardiographic studies [169], and Petrov et al suggested more LV mass regression in 
women compared with men three days following SAVR [26]. The latter study needs to be viewed with 
a degree of scepticism, however, as the reduction in mass seen was actually a reflection of a reduction 
in cavity size rather than a reduction in wall thickness, and highlights once again the pitfalls resulting 
from the echocardiographic calculation of left ventricular mass.  Mass regression has also been reported 
2 weeks following SAVR and has been linked to improvement in diastolic indices [170]. These findings 
have been replicated at 6 month follow up; Vizzardi et al [171] reported mass regression of 31% at 6 
months, with baseline LV mass being the strongest predictor of LV mass regression. Diastolic indices 
were also improved at 6 months, with a reduction in E/E’ ratio alongside a reduction in left atrial size. 
However, echocardiographic data in this setting needs to be interpreted with caution, as numerous 
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mathematical and geometric assumptions are made when calculating LV mass from M-Mode 
echocardiography, and the effects of the TAVI and SAVR procedures on cardiac geometry are not 
completely understood. CMR data on these acute reverse remodelling changes are lacking. Crouch et 
al [172] investigated 47 patients undergoing TAVI and SAVR using pre and early post-procedure CMR. 
They reported greater aortic regurgitation and left ventricular end diastolic volume following TAVI 
compared with SAVR despite similar baseline values. In this study they did not report LV mass, which 
is surprising given the accuracy of CMR in reporting this information. They reported new LGE in 2 
patients in each group, but the nature and distribution of this was not described, nor was the relationship 
between baseline LGE and cardiac reverse remodelling.   
 
Speckle tracking, tissue Doppler and mitral annular systolic plane excursion (MAPSE) have all been 
validated as echocardiographic measures of myocardial function in patients with aortic stenosis [173]. 
Myocardial strain and strain rate have been shown to be predictors of sub-clinical LV dysfunction in 
patients with severe AS and preserved LVEF [174] and can be used to predict outcomes in this setting 
[175]. Within a week following TAVI, echocardiographic studies have suggested an improvement in 
strain when an overt change in LVEF is not seen [176].  Longitudinal strain has also been found to 
predict LV mass regression after SAVR for severe AS in patients with a preserved LVEF at baseline 
[177, 178]. Traditionally diastology and strain imaging has been the domain of echocardiography, 
however, more recently CMR techniques have been developed which are able to evaluate longitudinal 
LV function and strain [179]. Feature tracking is a novel CMR technique which works in a similar 
manner to the echocardiographic technique of speckle tracking whereby image features of the 
myocardium are automatically tracked using dedicated post-processing software. The benefit of this 
technique is that all analysis can be performed off-line on standard steady state free precession (SSFP) 
cine images acquired as standard on all CMR examinations, without the need for contrast administration 
[180]. Reasonable intra and inter-observer variability has been reported [179, 180]. CMR MAPSE has 
recently been proposed as a simple and easy measure of longitudinal function in healthy volunteers and 
patients with hypertrophic cardiomyopathy [181].   
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1.6.1.   The impact of TAVI-induced LBBB on cardiac reverse remodelling 
Although predictors of TAVI-induced LBBB (LBBB-T) have been extensively studied [127], the 
impact of LBBB-T on cardiac reverse remodelling is less well described, with studies limited to 
echocardiographic evaluation and containing a heterogeneous mix of patients including those with pre-
existing conduction abnormalities, post-procedure pacemaker insertion and trans-apical access route, 
all factors which are known to confound reverse remodelling. A PARTNER echocardiographic sub-
study investigating the effects of LBBB-T on those undergoing TAVI reported a lower LVEF at 12 
months in patients with LBBB on discharge electrocardiogram compared to those with a narrow QRS, 
however, there was an increased number of those undergoing trans-apical TAVI in the LBBB-T group 
[111]. A similar failure of improvement in LVEF following balloon-expandable TAVI was seen by 
Urena et al in 79 patients with LBBB-T at hospital discharge, again with more patients undergoing 
trans-apical TAVI in the LBBB-T group [162]. Tzikas et al [159] reported unfavourable reverse 
remodelling in 27 patients (including those with pre-existing conduction defects) following self-
expanding TAVI prior to and 6 days post-procedure. They observed an 8% difference in LVEF between 
the 2 groups. Longitudinal strain was also reduced in those with new conduction abnormalities, however 
this failed to reach statistical significance, likely due to being under-powered with a small sample size 
for an echocardiographic study [182]. Hoffman et al [183] investigated 90 patients using 2D and speckle 
tracking trans-thoracic echocardiography prior to and at 1 and 12 months following Edwards Sapien 
and Medtronic CoreValve TAVI. Patients with new conduction defects had a significantly larger 
indexed LV end systolic volume (LVESVi) at 12 months compared with those with a narrow QRS, with 
less difference in indexed left ventricular end diastolic volume (LVEDVi). New conduction defects and 
baseline LVEF were independent predictors of reduction in LVEF at 12 months. The inclusion of 
patients with trans-apical access in the majority of these studies [111, 162, 183] and those with post-
procedural pacemaker insertion [111, 159, 162, 183] is a significant confounder, given that trans-apical 
access has been linked to reduced LVEF in a number of studies [162, 184] and pacing induced LBBB 
has been shown to cause different patterns of strain to those with idiopathic LBBB [185].  To date, no 
CMR based study has attempted to investigate the impact of LBBB-T on cardiac reverse remodelling 
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following TAVI. The large sample sizes required to demonstrate even a small difference in reverse 
remodelling mean that echocardiography is not ideally placed as a research tool in this setting, with 
hundreds of patients required to detect a difference in LVEF between groups [186]. The accuracy and 
excellent reproducibility afforded by CMR SSFP cine imaging in LV quantification means that 
extremely small sample sizes (in the teens to twenties) can be used to detect treatment differences [187, 
188]. Furthermore, it is well established that the strongest predictors of reverse remodelling are the 
baseline levels of that particular parameter [166]. So, for example, those with the worst LVEF at 
baseline have a greater improvement in LVEF post-TAVI, and those with the greatest pre-TAVI LV 
mass have the greatest mass regression post-procedure [166]. Therefore, it is imperative that any study 
intending to accurately assess the impact of TAVI-induced LBBB is able to account for this by 
accurately matching subjects for these important parameters at baseline, alongside matching for gender 
and valve type (which may also impact on reverse remodelling).  
1.7.   Myocardial fibrosis and aortic valve replacement 
Initial studies investigating the natural history of myocardial fibrosis following aortic valve replacement 
were limited to histopathological studies describing samples taken either at post-mortem or from cardiac 
biopsies. The results to date are mixed and likely represent the heterogeneous mix of patients included 
and the different study designs.  A long term follow up study evaluated a small number of patients for 
6-7 years following SAVR for AS [189]. A regression in fibrosis was seen on serial myocardial biopsy 
specimens but this was incomplete and never returned to that of the control population. The degree of 
MF did not correlate with pre-operative LV ejection fraction, however, limited conclusions can be 
drawn from this study in view of the fact that the late follow up group only included 9 patients. Murine 
models have also shown increased myocyte fibrosis following aortic banding but in contrast to 
Krayenbuehl et al [189], did not report regression of fibrosis after aortic debanding [190]. Cardiac 
biopsies are easy to obtain at the time of SAVR and hence the histopathological basis of fibrosis is well 
described. Acquiring serial biopsies in humans presents difficulties and therefore is unlikely to form the 
basis of future longitudinal studies.  
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The unique ability of CMR to assess for both diffuse fibrosis and focal replacement fibrosis [191] means 
that it is well placed to investigate the longitudinal changes in MF following aortic valve replacement 
and in the future it may be able to predict those most likely to gain benefit from valve replacement in 
terms of LV reverse remodelling. The CMR literature regarding this is in its infancy and to date, 
differing results have been reported, possibly as a result of differing methodologies according to 
research group. Fairburn et al [166] found that 53% of patients undergoing aortic valve replacement 
had evidence of focal myocardial fibrosis (assessed using the CMR full width half max technique) and 
that the MF as a percentage of myocardial mass was higher in patients undergoing TAVI than SAVR.  
As with previous studies [46], the degree of aortic stenosis did not correlate with the amount of 
myocardial fibrosis present, however, MF regression was seen in patients following TAVI but not 
SAVR. Azevedo et al [191] evaluated the prognostic impact of MF (detected using CMR threshold of 
two standard deviation technique and myomectomy specimens) in patients with severe aortic valve 
disease (without concomitant coronary artery disease) undergoing valve replacement. 28 patients had 
predominantly aortic stenosis. MF was present in 61% of patients with a mean mass of 3.15±1.87% of 
total LV myocardium was reported in the aortic stenosis group. Most patients had multifocal or 
widespread MF, but the sites of MF were highly variable.  27 months following SAVR, there was no 
change in MF expressed as total LV mass (3.13±2.18% to 3.10±2.63%, p=0.93) but a reduction in 
absolute fibrosis mass (8.9±8.0 to 5.8±6.7g, p=0.005). The amount of MF at baseline inversely 
correlated with LVEF change over time (r-0.47, p=0.02). MF at baseline was an independent predictor 
of mortality on Cox regression analysis. The association between MF at baseline and mass regression 
was not explored. Limited conclusions can be drawn from these follow up data, as only a small subset 
of the original patient group underwent follow-up CMR scanning.  In another prospective follow up 
study [192]; 58 patients with symptomatic severe aortic stenosis undergoing SAVR were evaluated 
using myocardial biopsy, echocardiography and CMR. The degree of myocardial fibrosis was 
determined using myocardial biopsy taken at the time of surgery and patients were categorised into 
three groups according to the fibrosis index method of classification [193]; no fibrosis, mild fibrosis 
and severe fibrosis.  Those deemed to have severe fibrosis pre-operatively saw a reduction in their LV 
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ejection fraction post-operatively and also less regression in end diastolic wall thickness and myocardial 
mass as compared with those with mild or no fibrosis. The majority of patients with severe fibrosis 
experienced no improvement in NYHA functional class in comparison with those patients with no 
fibrosis, whom all experienced an increase in NYHA class post-operatively. All 4 patients who died 
within the follow up period had severe fibrosis. Mitral ring displacement of >7mm classified using 
echocardiography was able to predict improvement in NYHA status following SAVR whereas ejection 
fraction and diastolic function (as assessed by echocardiography) were not predictive of a better 
outcome. This may be explained by the fact that in aortic stenosis, fibrosis tends to be subendocardial. 
Subendocardial dysfunction is more accurately reflected by abnormal myocardial longitudinal function 
and only at a very late stage by a reduction in LVEF. In keeping with the results reported by Fairburn 
et al [166], fibrosis was more prominent in the basal portions on CMR analysis, where regional wall 
stress is highest due to flatter curvature of the LV [194].  
1.8.   How does CMR work? 
Cardiovascular magnetic resonance imaging is a technique based on the magnetisation of tissues to 
create images using a strong superconducting magnet cooled in liquid helium. The main strengths of 
the technique are its ability to produce high spatial resolution anatomical and functional images of the 
heart with excellent soft tissue contrast (e.g. allowing accurate LV mass and volume data to be derived 
[188]), without the need for ionising radiation. Additionally, it is able to provide tissue characterisation, 
information about flow, myocardial perfusion and vasculature, to allow comprehensive (multi-
parametric) cardiac evaluation to take place. Gadolinium based contrast agents can be used in a variety 
of applications, one of which is to delineate focal fibrosis as a result of myocardial infarction (scar) or 
a number of other replacement fibrotic or infiltrative disease processes.  
1.8.1.   Generation of images 
CMR uses three types of magnetic field; B0, a strong (typically 1.5 or 3 Tesla), static field generated by 
the superconducting solenoid, with the field inside the scanner bore aligned parallel to the central axis 
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(normally denoted the z axis), a gradient field which is switched on and off rapidly and a smaller 
magnetic field, the radiofrequency (RF) field, known as B1, typically delivered in short pulses causing 
resonation of hydrogen nuclei contained within free water and adipose tissue. These three components 
combine to provide a signal which is transformed into the CMR image. The magnetic field causes the 
protons to align themselves in a single orientation either towards or away from the magnetic field, B0, 
with a slight predominance of protons in a single direction, causing net magnetisation (M). When inside 
the static field protons resonate at the Larmor frequency (64MHz for 1.5T magnet strength), emitting a 
small radiofrequency signal. The size of the signal depends on the excess net magnetisation, which is 
in turn determined by a number of factors including the magnet field strength (B0), the proton density 
and the body temperature. In a standard 1.5 Tesla magnet, the excess of protons aligned with the field 
is approximately 4 per million, assuming a body temperature of 37oC. As the magnetisation is parallel 
with Bo at equilibrium it is not detected, and therefore of little clinical use. In order to generate a 
detectable signal, the protons are exposed to a brief radiofrequency (RF) pulse, which flips the protons 
away from their natural position along the z axis, imparting a transverse component of magnetisation 
in the x-y plane which rotates around the z axis at the Larmor frequency.  The angle of rotation is 
dependent on the strength of the RF pulse applied. Once the angle of rotation has reached a certain pre-
determined point (known as the flip angle), the RF pulse is switched off and magnetisation slowly 
returns to its equilibrium state (free induction delay), releasing energy which can be detected as a RF 
signal. This process must be repeated multiple times to allow spatial information to be encoded and 
images to be generated.  The greater the energy delivered by the RF pulse, the greater the flip angle. 
The ‘saturation pulse’ is the energy required to create a flip angle of 90o so that the net magnetisation 
is at 90o to the Z axis, i.e. maximum transverse magnetisation, at which point the protons are ‘saturated’. 
Pairs of pulses (a 90o excitation pulse and a 180o refocussing pulse)  are used to generate spin echo 
pulse sequences, whereas lower flip angle RF excitation pulses are used without refocussing pulses to 
generate gradient echo images, which produces a lower signal that can be repeated more rapidly. Static 
anatomical imaging is usually acquired using spin echo pulse sequences (black-blood imaging) and 
gradient echo pulse sequences are generally used for cine (bright blood) imaging due to their higher 
temporal resolution.  
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1.8.2.   T1 and T2 relaxation 
There are two distinct relaxation processes; recovery of longitudinal and transverse relaxation. T1 
relaxation time represents recovery of approximately two-thirds of the z-component of the 
magnetization following an RF pulse (longitudinal relaxation), until it reaches its equilibrium 
(saturation recovery). T1 relaxation time increases with increasing field strength. In the human body, 
fat has the shortest T1 relaxation time, followed by water-containing tissues with a high macromolecular 
content such as muscle. Fluid has the longest T1 relaxation time.  Spin echo T1 pulse sequences 
therefore show fat as very bright signal and as such these are useful when characterising fat filled 
structures such as lipomas or fatty infiltration.  T2 relaxation time represents the time taken for 
transverse relaxation of protons (x-y component relaxation). It is a measure of the spin-spin interaction 
of protons (protons interfering with the magnetic field of another adjacent proton) and occurs more 
quickly than T1 relaxation. Body components with dense tissue (such as LV myocardium) contain a 
high density of macromolecules leading to slower molecular tumbling facilitating proton spin-spin 
interaction (hence shorter T2 relaxation times and leading to a dark appearance) compared with 
components such as free water (which appears bright) where the protons tumble very rapidly (faster 
than the Larmor frequency) with little time for spin-spin interaction. Fat exhibits an intermediate T2 
value. T2 values increase when the tissue is inflamed due to increased water content therefore T2 
weighted imaging can be a useful modality for the assessment of myocardial oedema. Scanning 
sequence parameters can be manipulated by the operator in order to affect the relative contribution of 
different relaxation processes to signal intensity allowing careful tissue characterisation.  
 
1.8.3.   Gradient echo 
The magnetic field strength can be varied across the imaging region inside the scanner bore by applying 
magnetic gradients in any direction. This causes spatial variation in the precessional frequency, 
allowing spatial encoding of the MR signal and also causing dephasing or rephasing of the transverse 
magnetisation. Echos generated by gradient induced dephasing and rephasing are called gradient echos, 
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whereas those generated using a refocussing RF pulse are spin echos.  The echo time (TE) is the time 
from the delivery of the RF pulse to the time the echo reaches its maximum amplitude. A RF pulse is 
generated at the same time as a gradient magnetic field (the direction of which defines the slice selection 
direction), which defines a slice of tissue and determines the slice thickness. The slice thickness is 
determined by the frequency of the RF pulse (TR) and the strength of the gradient. Protons dephase at 
different frequencies when exposed to the gradient echo depending on their position along the gradient, 
a concept known as phase encoding. A further gradient is then applied at 90o, known as the frequency 
encoding gradient, allowing another dimension of information about the tissue to be obtained. Through 
this process therefore, 3 dimensions of imaging have been obtained; the slice selection, the phase-
encoding gradient and the frequency-encoding gradient, obtained from the z, y and x axis respectively.   
 
There are two main types of gradient echo; spoiled gradient echo and balanced steady state free 
precession (SSFP) imaging, the latter being the most widely used for the generation of cine images used 
for ventricular mass and volume calculation. The spoiled gradient echo pulse sequence typically has a 
short TR and TE and is partially reliant on the flow of blood to generate contrast. As a result of this the 
blood signal intensity varies throughout the cardiac cycle due to the speed and direction of flow.  This 
technique can be useful for the quantitative evaluation of jets within the heart such as in the case of 
valvular regurgitation and shunts. Endocardial definition with this technique can be variable therefore 
this pulse sequence is less reliable for the quantification of LV mass and volume data [195].  Balanced 
SSFP pulse sequences ensure that the transverse magnetisation is fully re-phased at the end of each TR 
period when the next RF pulse is applied, allowing this to be carried over into the next repetition 
culminating in a steady-state of transverse magnetisation whereby several repetition periods combine 
to create a much stronger signal. The contrast between blood and tissue generated using SSFP imaging 
is based on the ratio of the T2/T1 signal in the tissue. Structures with a high fluid or fat content have a 
higher T2/T1 ratio and hence appear bright. This, combined with the greater signal to noise ratio 
generated by the combination of transverse magnetisation from a number of TR’s allow excellent 
endocardial definition which is consistent throughout the cardiac cycle.  
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1.8.4.   Data transformation 
The information obtained from the application of the magnetic fields is stored in the image space known 
as ‘k-space’. Each point in k-space data (i.e. each sample of an echo) corresponds to a certain spatial 
frequency (and contains information from across the full field of view) rather than a spatial position.  
The location of a particular data point in k-space depends on the strength and duration of each gradient 
that has been applied from the time of transverse magnetisation generation to that when a particular 
point is measured. A mathematical algorithm, known as Fourier transformation decodes the frequency 
and phase data and transforms it digitally into the CMR image. 
 
1.8.5.   Image optimisation, signal to noise ratio and artefacts 
The matrix size, combined with the field of view and the slice thickness determines the voxel size and 
hence image resolution. The larger the voxel size, the lower the resolution of the image. On the other 
hand, in order to increase spatial resolution, the voxel size is reduced, however, this is at the detriment 
of signal, as the voxel size determines the number of protons that can be magnetised.  Signal to noise 
ratio (SNR) is the ratio of unwanted random ‘noise’ signal of the patient to the ’wanted’ signal from the 
tissue of interest.  The higher the field strength, the higher the signal that is returned from tissue and 
therefore the higher the SNR and better image quality. Therefore there is always a trade-off between 
background noise and signal, and settings including the pulse sequence and image acquisition 
parameters can be adjusted in order to optimise SNR. Artefacts can occur during CMR imaging and are 
an increasing problem with increasing magnet field strengths. Image aliasing can occur when the 
structure imaged is larger than the pre-determined field of view. These can be minimised by increasing 
the field of view (at the expense of reduced special resolution), using over-sampling techniques 
(increasing image acquisition time), changing the phase encoding direction (which may introduce 
aliasing in the opposite direction) and the use of saturation bands. Respiratory motion leads to ghosting 
artefacts, whereby motion in the chest as a result of diaphragmatic movement leads to a misplacement 
of the signal in the image (as the tissue is changing position between each TR). These artefacts can be 
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reduced by reducing scanning time (hence making breath-hold times shorter), the use of respiratory 
navigators whereby images are only acquired at a certain part of the respiratory cycle (at the expense of 
increased acquisition time) and the use of saturation bands. Metallic artefact, such as that of post-CABG 
sternal wires, metallic valve replacements, pacemaker generators, pacemaker leads and surgical clips, 
can lead to significant artefact as a result of local field distortion. Spoiled gradient echo pulse sequences 
cause less image degradation than SSFP pulse sequences and therefore should be considered if the latter 
yields non-diagnostic imaging [196].  
1.8.6.   Assessment of aortic valve disease using cardiovascular magnetic resonance imaging 
CMR is the reference standard for LV mass and volume quantitation using SSFP imaging, with low 
observer and inter-study variability [197]. The cine images obtained can be contoured using post-
processing software in order to derive an accurate assessment of left ventricular mass and volume which 
has advantages over echocardiography in that it is angle independent and not reliant on acoustic 
windows. With careful planning, aortic valve planimetry can also be performed [198]. Turbulent flow 
such as that caused by a stenotic or regurgitant aortic valve can be appreciated on SSFP imaging, but 
for quantification purposes through-plane phase contrast velocity mapping imaging is used. This spoiled 
gradient echo technique is able to map the velocity of individual protons as they move within the 
magnetic field with moving protons acquiring a phase shift proportional to their velocity. Their 
movement can be compared with that of stationary protons and as a result of this phase shift an average 
velocity can be derived for each pixel. A thin scan line is planned perpendicular to the flow of interest, 
in the case of the aortic valve this is usually at the level of the sinotubular junction (Figure 1-5). 
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Figure 1-5   Planning views for aortic valve phase contrast acquisition 
Image panel showing the two left ventricular outflow tract views used for planning an 
aortic valve phase-contrast acquisition. The yellow line represents the planning which 
takes place in the sagittal-oblique and coronal views. The vessel of interest (in this 
case the aorta) should be perpendicularly intersected in 2 planes. In the case of 
eccentric jets from stenotic valves (such as in the case of bicuspid aortic valve disease), 
off-axis planning may be required to ensure that the jet is intersected in an orthogonal 
manner.   
 
The aliasing velocity needs to be set by the operator according to the estimated peak velocity of the 
blood at the sampling site. If the blood velocity exceeds this velocity, aliasing occurs (due to the phase 
shift exceeding 1800) and can lead to artefactual flow results. Hence, it is imperative that this is 
recognised at the time of scanning and a repeat phase contrast acquisition takes place at progressively 
higher velocity encoding (VENC) speed until no aliased pixels are present. If the VENC is set too high 
the SNR is reduced which can lead to an underestimation of flow. Acquisition is triggered to the R wave 
on the Vectorcardiogram (VCG) and can be either prospectively acquired (in the case of breath held 
imaging) or retrospective (in the case of free breathing acquisitions). In prospective (breath held) phase-
contrast imaging, information from late diastole is not acquired which can lead to underestimation of 
aortic regurgitant fraction so it is recommended that free-breathing acquisitions are used for this purpose. 
Typically prospective breath held images are used for the quantification of forward flow. Therefore it 
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is imperative that studies involving flow measurements are performed by an operator with an in-depth 
understanding of the CMR evaluation of valvular heart disease. Like most CMR acquisitions, phase-
contrast imaging is susceptible to artefacts. Small errors can combine to give significant inaccuracies 
in flow [199]. The technique is also limited by reduced temporal resolution (in comparison with Doppler 
echocardiographic imaging), can be inaccurate in the case of turbulent flow such as that occurring distal 
to a stenotic aortic valve, and is susceptible to phase shift errors [200]. For these reasons, and due to 
partial volume averaging effects, peak velocities derived from phase contrast imaging across stenotic 
valves are usually lower than those seen with echocardiography and the two measures cannot be used 
interchangeably [201]. In view of this, stroke volume may be underestimated in the context of severe 
AS, and if this is used to calculate the mitral regurgitant volume, this in turn may be overestimated and 
is a limitation to all CMR studies reporting mitral regurgitation in the context of AS. Phase contrast 
imaging works well in the context of aortic regurgitation, and is an established technique for the 
assessment of aortic regurgitation following TAVI, where both transoesophageal and transthoracic 
echocardiography underestimate the degree of regurgitation due to the eccentric nature of the aortic 
regurgitant jet [203, 204]. As example of phase contrast imaging can be seen in Figure 1-6.  
 
Figure 1-6  Assessment of aortic flow using CMR 
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Panel A depicts a typical modulus image of the aortic valve in cross section. This 
is used to allow the CMR analyst to contour around the aorta in each phase of the 
cardiac cycle, with care being taken to exclude any artefact, in order to derive the 
region of interest (ROI). Panel B depicts the velocity map of the individual pixels 
during systole. Stationary tissue appears grey, with forward flow appearing white 
and backward flow represented by darker shades. The bright white in the centre 
of the image depicts the high velocity at the centre of the stenotic jet. Panel C 
depicts the flow curve generated by contouring of the modulus image. The 
positive deflection represents forward flow velocity in cm/sec (which in this case 
is elevated due to the stenotic valve) and the negative deflection represents aortic 
regurgitation, which in this case is pan-diastolic. Quantitative measures such as 
peak pressure gradient can be calculated using the Bernoulli equation, and 
regurgitant volume and fraction can also be easily derived using post-processing 
software.  
1.9.   The use of CMR for fibrosis assessment 
Until the advent of CMR, histological diagnosis (either at autopsy or from myocardial biopsy) was 
relied upon for research into myocardial fibrosis. Its invasive nature meant that its use as a research tool 
was limited, rendering longitudinal studies of MF almost impossible. CMR scanning allows in vivo 
assessment of myocardial fibrosis by means of late gadolinium enhancement imaging and more recently, 
myocardial longitudinal relaxation (T1) mapping. LGE imaging is based on the principle that 
Gadolinium-based contrast enters the extracellular matrix and then is ‘washed out’ of the extracellular 
space by capillary blood flow. In areas of fibrosis there is an increase in extracellular space due to 
myocyte shrinkage or cellular necrosis/apoptosis and therefore increased gadolinium concentration 
coupled with reduced capillary blood flow and hence accumulation of gadolinium contrast over a period 
of 8-15 minutes. Gadolinium based contrast agents reduce the T1 relaxation time and hence produce 
more signal on the image such that areas of delayed contrast washout appear ‘bright’ on CMR images 
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using inversion-recovery gradient echo pulse sequences in contrast to the normal ‘nulled’ healthy 
myocardial tissue which appears dark. Semi-automated computer software allows these areas of 
myocardial scar/fibrosis to be quantified using different threshold techniques, which are based on the 
difference in signal intensity between normal nulled myocardium and abnormal fibrosed or scarred 
regions [205]. Different methods of LGE quantification have been described in a wide range of settings, 
and no consensus has been reached in the literature regarding the optimal thresholding methods to be 
used, however, it is likely that computer aided algorithms improve accuracy compared with visual 
assessment [206]. This variation in methods often leads to the differing mass of fibrosis or infarct LGE 
reported in the literature [49, 167, 193].   
 
CMR LGE for the assessment of fibrosis has been validated using histopathological studies in patients 
with AS [193, 207]. Nigri et al [207] performed a baseline 1.5T CMR on 35 patients with severe 
symptomatic AS who subsequently had myocardial biopsy taken at the time of SAVR. The presence of 
LGE was assessed by two observers blinded to clinical and histological data. Regions of increased 
fibrosis were defined as areas of distinct hyperenhancement on subjective visual assessment. When 
compared with the histological diagnosis, CMR had a sensitivity and specificity of 67% and 82% 
respectively for the identification of myocardial fibrosis. Azevado et al [192] have validated CMR LGE 
fibrosis quantification in patients with severe AS undergoing aortic valve replacement. They used the 
threshold of 2 standard deviations technique and compared values with specimens obtained from 
myomectomy at the time of surgery. There was good agreement of MF measurements in 20 patients 
with a mean difference of 0.10% (95% CI -0.29 to 0.49%). They also reported excellent inter- and intra-
observer variability. The threshold of 5 standard deviation approach has been found to correlate best 
with visual assessment of diffuse/focal fibrosis in a large population of patients with non-ischaemic 
cardiomyopathy [208]. MF quantified using the full width at half maximum technique has been shown 
to be a predictor of mortality in patients with AS [49].  The threshold of 2 standard deviations method 
may be the best method to use for the quantification of myocardial infarction as it has been shown to 
be a powerful predictor of all-cause mortality in patients with ischaemic cardiomyopathy [209], 
however, it may overestimate infarct mass compared with other techniques [210]. 
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More recently, T1 mapping has been developed to more accurately measure diffuse myocardial fibrosis 
by quantification of extracellular volume. This technique quantifies the T1 relaxation time of each voxel 
of the displayed image using a standard scale in order to allow the practitioner to understand the 
properties of the myocardial tissue independent of function and assess for the presence of diffuse 
fibrosis. T1 maps can be acquired in a single breath hold using material-enhanced modified Look-
Locker inversion recovery (MOLLI) imaging at both 1.5 and 3 Tesla magnet strengths [211-213]. 
Native T1 values can be derived from non-contrast MOLLI imaging without the need for contrast. 
Although native T1 values have the potential to more accurately quantify the diffuse fibrosis associated 
with pressure overload states, the technique is limited by a lack of uniform reference ranges, and the 
fact that values differ according to vendor, pulse sequence and magnet strength [212]. Although various 
techniques have been developed to try and improve reproducibility and image quality such as better 
inversion pulses, motion correction and curve fitting [214], the pitfalls including artefact from partial 
voluming and reliance on good breath holding (a particular problem in the elderly aortic stenotic 
population) mean that to date, its use is limited, The addition of 15 minute post-contrast MOLLI 
imaging allows the extracellular volume fraction to be calculated provided that the blood haematocrit 
level at the time of the scan is known. Myocardial fibrosis is associated with increased T1 values on 
pre-contrast imaging and reduced T1 values on post-contrast imaging, corresponding to an increased 
measured extra-cellular volume. T1 mapping is still however considered a research technique due to 
variations in absolute values according to vendor, pulse sequence, timing of image acquisition and 
method of gadolinium administration [212]. T1 mapping has been used to characterise diffuse fibrosis 
in patients with aortic stenosis at both 1.5 and 3T field strengths [215-218] but longitudinal data on 
changes following valve replacement are lacking.  
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1.10.   Aims of the thesis 
With the advent of TAVI, there has been a renewed interest in aortic valve disease but studies of cardiac 
remodelling in AS and the response of the LV to aortic valve replacement are mainly limited to the 
more qualitative technique of echocardiographic assessment [187].  The unique ability of CMR to assess 
for fibrosis and myocardial infarction (using LGE quantitation), alongside the ability to assess flow 
(especially in the context of aortic regurgitation post-TAVI, where echocardiographic assessment is 
challenging [204]), and the novel technique of feature tracking allowing assessment of global 
longitudinal strain and dyssynchrony, mean that it is ideally placed to comprehensively study the effects 
of AS and valve replacement on cardiac reverse remodelling.  
 
The aims of the thesis are outlined for each chapter: 
 
 Chapter 3: 1) To use CMR to comprehensively evaluate the differences in cardiac remodelling in AS 
according to gender, including characterisation of the differing patterns and distribution of myocardial 
fibrosis and predictors of cardiac remodelling at baseline and 2) to evaluate cardiac reverse remodelling 
at 6 months following aortic valve replacement according to gender. 
 
Chapter 4: 1) To describe the patterns of myocardial fibrosis at baseline in patients with AS undergoing 
TAVI and SAVR and 2) to compare rates of post-procedural myocardial infarction between the two 
groups and investigate its impact on post-procedural LVEF. 
 
Chapter 5: To assess acute reverse cardiac remodelling within the first week following TAVI and its 
link to baseline myocardial fibrosis. 
 
Chapter 6:To evaluate the impact of TAVI-induced left bundle branch block on cardiac reverse 
remodelling 6 months post-procedure using standard SSFP imaging and the novel technique of CMR 
Feature Tracking to assess for cardiac dyssynchrony and global longitudinal strain.  
67 
 
 
This was achieved by obtaining CMR scans of patients with severe AS undergoing either surgical or 
trans-catheter aortic valve replacement at baseline (pre-procedure) and post-procedure at two discrete 
timepoints (prior to hospital discharge to assess for early reverse remodelling and 6 months post-
procedure for investigation of the remaining hypotheses). A comprehensive CMR was obtained, 
including cine imaging (to allow quantitation of cardiac mass, volume, function and feature tracking 
analysis), velocity encoded phase contrast imaging of the aortic valve and, in the case of the baseline 
and 6 month scans, late gadolinium enhancement imaging for the assessment of myocardial infarction 
and fibrosis.  
 
Methods common to all four chapters have been outlined in Chapter 2 (General Methods). Each topic 
has been studied and discussed in depth and forms a results chapter in its own right, with an appropriate 
introduction, methods (describing any methods specific to that particular chapter), results and 
discussion section.  
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Chapter 2:   Methods 
2.1.   Patient selection and recruitment 
Between January 2009 and April 2015 (recruitment January 2009 to March 2014; performed by other 
members of the TAVI research team, see pages 2-5), patients with severe AS undergoing either TAVI 
or SAVR with or without concomitant coronary artery bypass grafting (CABG), at a single tertiary 
center (Leeds General Infirmary, Leeds, UK) were recruited from the cardiology and cardiac surgery 
out-patient departments. As the patients undergoing TAVI are inherently older, frailer and at higher 
surgical risk than those undergoing SAVR, attempts were made to recruit SAVR patients which more 
closely matched the TAVI cohort, by selectively recruiting older patients and those with higher baseline 
co-morbidity. Severe AS was defined as an echocardiographically derived aortic valve area of ≤1.0cm2, 
peak aortic velocity of >4m/sec or mean pressure gradient of >40mmHg using standard criteria outlined 
by the American Society of Echocardiography [219]. Baseline echocardiographic data including aortic 
valve area, peak pressure gradient, mean pressure gradient, left ventricular ejection fraction and 
pulmonary artery pressure were recorded for all patients.  Decision for aortic valve intervention was 
made by a dedicated heart team including interventional and imaging cardiologists and cardiac surgeons 
[65]. In general, patients were recommended for TAVI over SAVR in the case of elevated surgical risk, 
previous coronary artery bypass surgery with patent grafts, porcelain aorta, hostile mediastinum from 
prior radiotherapy or frailty.  Inclusion and exclusion criterion for entry into the TAVI study can be 
seen in Table 2-1. Error! Reference source not found. In the case of renal failure with an estimated 
glomerular filtration rate of <30ml/min/1.73m2, patients were still recruited to take part in the study but 
intra-venous Gadolinium based contrast was not given due to the theoretical risk of nephrogenic 
systemic fibrosis [220].   
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Table 2-1  Inclusion and exclusion criteria 
Inclusion  Exclusion  
Severe AS undergoing TAVI or SAVR Contraindication to CMR e.g. non-MRI compatible 
pacemaker, intra-orbital metal, claustrophobia 
Age >18 years AS not the predominant lesion 
 Pregnancy or breastfeeding 
 Weight >130kg 
 Inability to lie flat for 60 minutes 
Inability to provide informed consent 
AS: Aortic stenosis. CMR: Cardiovascular magnetic resonance. MRI: Magnetic resonance imaging. 
TAVI: Trans-catheter aortic valve implantation. SAVR: Surgical aortic valve replacement 
 
Clinical, demographic and echocardiographic data were collected prospectively. All patients provided 
written informed consent. The patient information sheet and consent form can be seen in the Appendix. 
The study was approved by the institutional ethics committee (08/H1307/106 see Appendix) and 
complied with the declaration of Helsinki.  
2.2.   Surgical aortic valve replacement 
SAVR was performed using a standard technique on cardiopulmonary bypass via a midline sternotomy 
incision and mild systemic hypothermia (30-34oC) using intraoperative transesophageal 
echocardiography. Systemic heparinisation with standard aorto-right atrial cannulation was used to 
establish cardiopulmonary bypass. Cold blood cardioplegic arrest of the heart and pericardial carbon 
dioxide was used in all cases. The aorta was cross-clamped and aortotomy performed with the size and 
type of prosthesis being selected according to annulus size, patient characteristics, surgical and patient 
preference. Concomitant CABG was performed using a combination of left internal mammary artery 
(LIMA) and saphenous vein grafting (SVG) to significantly diseased major vessels with the aim of 
complete revascularisation in all patients, where technically possible. Procedural characteristics 
including valve type and size, cross clamp time and cardiopulmonary bypass time were collected for all 
patients. Aspirin monotherapy was prescribed for 3 months post-procedure, except in the case of atrial 
fibrillation or mechanical valve implantation, where warfarin monotherapy was administered.  
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2.3.   Trans-catheter aortic valve implantation 
TAVI was performed under general anesthetic with X-ray fluoroscopy and transoesophageal 
echocardiography guidance using the self-expanding Medtronic CoreValve, Engager and Evolut-R 
devices, the balloon expandable Edwards Sapien 3, and the mechanically expanded Boston Lotus valve 
by two experienced, high volume operators performing over 150 implants/year. Valve sizing was 
achieved by annulus measurements taken from gated cardiac computed tomography or 3D 
transoesophageal echocardiography. Trans-femoral approach was preferred but other approaches 
(subclavian, carotid, direct aortic and apical) were used if the femoral vessels were found to be 
unsuitable due to calcification, stenosis or tortuosity. Balloon valvuloplasty was performed before 
device deployment in the majority of cases and patients typically underwent 2-3 bouts of rapid right 
ventricular pacing during the implant procedure. For implants prior to 2014, general anaesthetic with 
transoesophageal and fluoroscopic guidance was used. From 2014 onwards, the majority of femoral 
implants were performed under local anaesthetic with conscious sedation using transthoracic 
echocardiographic and fluoroscopic guidance.  All patients received heparin via a standardized regimen 
to achieve and maintain an activated clotting time of >250s. Dual anti-platelet therapy (aspirin 
75mg/day and clopidogrel 75mg/day) was administered for 3-6 m post-procedure with aspirin 
monotherapy thereafter, or in the case of need for full anticoagulation (such as AF, previous venous 
thromboembolism etc.), warfarin monotherapy was prescribed. Procedural characteristics including 
invasive valve gradient, pre and post procedure diastolic blood pressure and left ventricular end diastolic 
pressure, valve type and size, procedure time, screening time and contrast dose were recorded for all 
patients.  
2.4.   CMR protocol 
Identical CMR scans were obtained on the same imaging platform at baseline and post procedure (for 
timings of follow up scans see individual methods chapters) using the same 1.5T scanner (Intera and 
Ingenia, Philips Healthcare, Best, Netherlands or Avanto, Siemens Medical Systems, Erlangen, 
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Germany). Multi-slice, multi-phase cine imaging was performed using a SSFP pulse sequence in the 
short axis (repetition time (TR) 3msec, TE 1.7msec, flip angle 600, SENSE factor 2, 8mm slice 
thickness, 0mm interslice gap, 30 phases, 192 by 192 matrix, typical field of view 340mm) to cover 
both ventricles. Cine imaging including standard 4 chamber, 2 chamber and short axis views were also 
obtained. Two left ventricular outflow tract views were obtained in sagittal-oblique and coronal views 
(3-5 slices, 6mm slice thickness, 0mm interslice gap, 30 phases, typical field of view 380mm) to allow 
planning of aortic valve Q flow imaging.  Aortic flow data were acquired using a free breathing (for 
regurgitation) and breath-hold (for forward flow) retrospectively gated phase contrast velocity encoding 
technique, sensitized for flow in the through plane direction (TR 4.3ms, TE 2.6ms, flip angle 15o, slice 
thickness 6mm, 40 phases, number of signal averages 1, typical voxel size 1.2x1.2x8mm3, depending 
on patient size). The region of interest was planned at the sinotubular junction (with care taken not to 
include aortic valve leaflets) or just above the aortic prosthesis post-replacement, orthogonal to the 
aortic valve jet. VENC was typically set at 400-500cm/sec on the baseline scan and 250cm/sec post-
procedure. If aliasing occurred at the pre-set VENC, sequential phase contrast imaging was performed 
at increasing VENC settings until the aliasing artefact had disappeared.  
 
LGE imaging using an inversion recovery-prepared T1-weighted gradient echo pulse sequence (TE 
1.79msec; TR 4.8msec; flip-angle 15o, spatial resolution 1.46 x 1.46 x 10mm) was performed with 
inversion time (TI) individually adjusted according to TI scout (Look-Locker sequence, single mid-
ventricular slice, 11mm thickness, field of view 390mm). This was planned to cover the entire left 
ventricle in short axis (10-12 short axis slices, 10mm thickness, no interslice gap, matrix 240 x 240, 
typical field of view 350mm), 10-15 minutes after 0.2mmol/kg of Gadoteric acid administered by hand 
injection (godoterate meglumine, Dotarem, Guerbet, SA, Villepinte). This agent was specifically 
chosen as it has never been reported to be associated with nephrogenic systemic fibrosis and hence felt 
to be the safest to be used in our elderly population [221]. Four chamber, two chamber and left 
ventricular outflow tract (LVOT) views were also obtained as standard. Cross cuts and phase swap 
imaging were used where necessary for further clarification of the presence/absence of LGE.  
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2.5.   CMR analysis 
CMR analysis was performed by a single operator with 5 years’ experience in CMR blinded to clinical 
and echocardiographic data, using dedicated computer software (CVI42, Circle Cardiovascular Imaging, 
Calgary, Alberta, Canada). LV endocardial and epicardial contours were manually traced (with 
trabeculation and papillary muscles excluded) in systole and diastole in order to derive end diastolic 
volume and end systolic volume measurements using the summation of discs methodology [222].  LV 
mass was calculated using Equation 1, a technique which has been validated using autopsy studies and 
has been shown to have excellent reproducibility and inter-study variability[223]. All values were 
indexed to body surface area.  LV mass was quantified without papillary muscles and trabeculations as 
it is the method used clinically in our centre and hence the method with which the investigator had most 
experience. In order to demonstrate that LV mass calculation was more reproducible without the 
inclusion of papillary muscles, inter and intra-observer reproducibility was performed on 10 randomly 
selected patients with and without the inclusion of papillary muscles.  The co-efficient of variation was 
calculated by dividing the standard deviation of the differences between measurements divided by their 
general mean and expressed as a percentage. Intra-observer variability without papillary muscle 
contouring was 3% for LV end diastolic volume (LVEDV) and 5% for LV mass (LVM) and 9% for 
LVEDV and 8% for LVM when papillary muscles were included. Similarly, inter-observer variability 
was reduced with exclusion of papillary muscle contouring (LVEDV 2%, LVM 5%) than the method 
with papillary muscles included (LVEDV 13%, LVM 9%).   
 
LV mass = (𝑒𝑝𝑖𝑐𝑎𝑟𝑑𝑖𝑎𝑙 𝑣𝑜𝑙𝑢𝑚𝑒 − 𝑒𝑛𝑑𝑜𝑐𝑎𝑟𝑑𝑖𝑎𝑙 𝑣𝑜𝑙𝑢𝑚𝑒)𝑥 1.05 
Equation 1  LV mass calculation 
Septal and lateral wall thickness were measured on the mid-ventricular short axis cine using calliper 
measurements of the septal and lateral wall at the point of maximal thickness at end diastole.  Left atrial 
volume was calculated as per Equation 2 [224] from the left atrial area and length measured on the 4 
chamber and 2 chamber cine imaging. 
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Left atrial volume (ml) = 8 (2 chamber LA area) (4 chamber LA area) / 3πL 
Where L is the shorter of the two left atrial length measurements 
Equation 2  Left atrial volume calculation 
 
 Longitudinal LV and RV function (MAPSE and tricuspid annular plane systolic excursion (TAPSE)) 
was assessed by using mitral and tricuspid annular excursion. In the 4 chamber SSFP cine image, 
atrioventricular motion was measured at the lateral junction points between the left and right atrium and 
ventricle at end systole and end diastole. The perpendicular distance between these two points was 
measured (Figure 2-1).  
 
 
Figure 2-1  Assessment of longitudinal function 
End diastole was identified and a reference line was drawn across the atrioventricular valve 
plane and forwarded across all phases of the cine image (left hand panel). A further line is 
drawn in end-systole. The distance between the two points at the tricuspid annulus 
(TAPSE), medial mitral valve annulus (MAPSE medial) and lateral mitral valve annulus 
(MAPSE lateral) was measured and expressed in mm.   
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Aortic flow was quantified using a combination of prospectively gated breath held (for flow 
measurements) and retrospectively gated free-breathing (for regurgitant measurements) cross-sectional 
phase contrast images with contouring of the aortic lumen to provide a peak forward flow velocity 
(m/sec), regurgitant volume (ml) and regurgitant fraction (%). Mitral regurgitation fraction was 
calculated according to Equation 3.  
 
Mitral regurgitation fraction = [(𝐿𝑉 𝑠𝑡𝑟𝑜𝑘𝑒 𝑣𝑜𝑙𝑢𝑚𝑒 − 𝑎𝑜𝑟𝑡𝑖𝑐 𝑠𝑡𝑟𝑜𝑘𝑒 𝑣𝑜𝑙𝑢𝑚𝑒)/
𝐿𝑉 𝑠𝑡𝑟𝑜𝑘𝑒 𝑣𝑜𝑙𝑢𝑚𝑒]*100 
Equation 3  Calculation of mitral regurgitation fraction 
For analysis of the LGE images, each short axis slice was visually inspected for the presence or absence 
of LGE by 2 operators independently blinded to clinical and procedural data. Any discrepancy between 
the two operators was reviewed by a third operator to reach a consensus decision. Phase swap, cross cut 
and other geometry images were used in order to assist in decision making where required.  The pattern 
of LGE was classified as either focal/mid-wall pattern or infarct pattern.  Patients with a mixed pattern 
of LGE were assigned to the group according to the predominant pattern of LGE. Presence of new LGE 
was determined by direct comparison of pre and post-procedure scans. In those slices deemed to have 
LGE present, epi and endocardial contours were manually drawn, with care taken to exclude artefact, 
blood pool, fat and pericardium. The auto-identification tool was then applied and an area of normal 
remote myocardium defined alongside identification of areas with increased signal intensity. Any 
hyper-intense regions felt to be related to artefact were manually excluded. The number and location of 
segments containing LGE were classified according to the AHA 17 segment model [225]. LGE 
quantification methods and a justification for their use are described in individual chapters.  
2.5.1.   Inter- and intra-observer variability 
For the assessment of inter-observer variability, two independent investigators analysed LV volume, 
mass and function on a random selection of 10 patients both pre- and post- valve replacement. For intra-
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observer variability a similar dataset from 10 patients was analysed twice by the author one month apart.  
The co-efficient of variation was calculated by dividing the standard deviation of the differences 
between measurements divided by their general mean and expressed as a percentage. Intra-observer 
variability for LV quantitation was 2.6%, 5.0% and 2.6%for LVEDV, LVM and LVEF respectively. 
Inter-observer variability 1.4%, 4.5% and 3.7% for LVEDV, LV mass and LVEF respectively. These 
findings are in keeping with reproducibility data published investigating patients with left ventricular 
systolic dysfunction and hypertrophy [188, 189]. Bland-Altman plots can be seen in Figure 2-2.  
 
Figure 2-2  Bland Altman plots for LV volume, mass and function reproducibility 
Bland-Altman Plots showing Intra- and inter-observer variability for LVEDV, 
LV mass and LVEF. The black line represents the mean of the differences 
between measurements and the red lines represent the 95% confidence intervals 
for the mean of the differences between measures.  
 
For reproducibility of LGE and aortic flow quantification, an intra-class correlation was used in order 
to compare it with values from previously published studies [226, 227]. For LGE reproducibility 10 
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studies including a mixture of those with mid-wall/focal fibrosis and infarct pattern LGE were chosen 
at random using the threshold of 5 standard deviations technique. For the aortic flow reproducibility, 9 
baseline studies were chosen at random with regurgitant fraction reproducibility performed on the non-
breath held acquisitions and peak velocity figures derived from the breath held acquisitions.  For intra-
observer variability, the same dataset was analysed by the author 1 month following the first analysis.  
The intra-class correlation (ICC) for LGE quantification was 0.979 for inter-observer variability and 
0.995 for intra-observer variability, which is in keeping with other studies of LGE quantification [226]. 
The inter-observer ICC for aortic flow quantification was 0.963 for peak velocity and 0.986 for aortic 
regurgitant fraction. The intra-observer ICC for aortic flow quantification was 1.00 for peak velocity 
and 0.983 for aortic regurgitant fraction, again these figures being congruous with the current published 
literature [202, 227]. Graphical representation of this can be seen in the Bland Altman plots displayed 
in Figure 2-3.  
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Figure 2-3 Bland Altman plots of flow, LGE and GLS reproducibility 
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Bland-Altman plots demonstrating reproducibility of LGE, aortic flow and GLS 
quantification. The black line represents the mean of the differences and the red lines 
represent the 95% confidence intervals. 
For the assessment of inter-observer variability for the Feature Tracking analysis, two independent 
investigators analysed LV GLS and time to peak radial strain on a random selection of 10 patients. For 
intra-observer a similar dataset from 10 patients was analysed twice by one investigator, one month 
apart. The coefficient of variation was calculated by dividing the standard deviation of the differences 
between measurements by their mean and expressed as a percentage. Intra-observer variability was 6.8% 
and 9.1% and inter-observer variability was 9.2% and 12.6% for GLS and time to peak radial strain 
respectively. 
2.6.   Statistical analysis and sample size 
All statistical analysis was performed using the PASW software package (V21, SPSS, IBM, Chicago, 
Illinois, USA).  Data are presented as mean±SD, median (interquartile range, IQR) or frequency 
(percentage). Data were tested for normality using the Shapiro-Wilks test.  For normally distributed 
data, two-tailed unpaired Student’s t tests were used for comparisons between groups, and paired 
Students t tests were used for intragroup comparisons. For non-normally distributed data, the Related-
Samples Wilcoxon Signed Rank Test and independent samples Mann-Whitney U test were used. To 
compare between groups an analysis of variance (ANOVA) and Tukey post-hoc tests were used. The 
Chi-squared test was used for comparing categorical variables. Pearson’s correlation coefficients were 
used to assess the correlation of dependent and independent variables.  P values <0.05 were considered 
statistically significant.  Based on the published data by Bellenger et al [189], the group size required 
to detect a 10ml change in LVEDV is 12 patients, 10 patients to detect a 10ml change in LVESV, 15 to 
detect a 3% change in LVEF and 9 to detect a 10g change in LV mass.   
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Chapter 3:   Gender differences in cardiac remodelling in severe aortic 
stenosis and reverse remodelling following aortic valve replacement 
3.1.   Abstract 
Background: Cardiac adaptation to AS appears to differ according to gender but reverse remodelling 
following aortic valve replacement has not been extensively described. The aim of the study was to 
determine using CMR imaging, whether any gender-related differences exist in AS in terms of LV 
remodelling, myocardial fibrosis and reverse cardiac remodelling after valve replacement. 
 
Methods: One hundred patients (men, n=60) with severe AS undergoing either trans-catheter or 
surgical aortic valve replacement underwent CMR scans at baseline and 6 months following valve 
replacement.   
 
Results: Despite similar baseline co-morbidity and severity of AS, women had a lower indexed LV 
mass than men (65.3 ± 18.4 vs. 81.5±21.3g/m2, p<0.001) and a smaller LVEDVi (87.3±17.5 vs. 
101.2±28.6ml/m2, p=0.002) with a similar LVEF (58.6±10.2 vs. 54.8±12.9%, p=0.178). Total 
myocardial fibrosis mass was similar between genders (2.3±4.1 vs. 1.3±1.1g, p=0.714) with a differing 
distribution according to gender. Following aortic valve replacement, men had more absolute LV mass 
regression than females (18.3±10.6 vs. 12.7±8.8g/m2, p=0.007). When expressed as a percentage 
reduction of baseline indexed LV mass, mass regression was similar between the genders (men 
21.7±10.1 vs. women 18.4±11.0%, p=0.121).  There was no gender-related difference in post-
procedural LVEF or aortic regurgitation. Gender was not found to a predictor of LV reverse remodelling 
on multiple regression analysis.   
 
Conclusions: There are significant differences in the way that male and female hearts adapt to AS. At 
6 m following aortic valve replacement, there are no gender-related differences in reverse remodelling. 
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3.2.   Introduction and study aims 
Gender related differences in LV remodelling in response to a wide range of diseases have been 
extensively explored [228], but the impact of gender on AS and following aortic valve replacement 
(AVR) is less well described. AS is the commonest valve lesion in the developed world, and with an 
ageing population its incidence is increasing [4]. AVR has been shown to reduce mortality, and improve 
patient symptoms and health related quality of life [229-231]. Evidence suggests that women have 
higher pre-operative morbidity and mortality [232] and lower referral rates [233]. It remains 
controversial as to whether gender impacts on survival following SAVR , however, females appear to 
have improved long term survival following TAVI [10, 43, 44]. The longer life expectancy of women 
or other factors such as LV remodelling and myocardial fibrosis may be implicated. Echocardiographic 
and CMR studies suggest that men and women remodel differently to the pressure overload of AS [16, 
234] and may also reverse remodel differently following AVR [26, 42].  Moreover, gender-related 
differences in MF may play a key role in any reverse remodelling [167]. The primary aim of this chapter 
was to determine whether any gender-related differences exist in severe AS in terms of LV remodelling 
in response to the valve lesion, reverse remodelling after valve replacement and MF. 
3.3.   Methods specific to this chapter 
3.3.1.   Patient recruitment 
Between January 2009 and April 2014, 135 patients with severe AS undergoing eith er SAVR with or 
without concomitant coronary artery bypass grafting or TAVR at a single tertiary centre (Leeds General 
Infirmary, Leeds, UK) were prospectively recruited.  
3.3.2.   CMR protocol and analysis 
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Identical CMR scans were obtained on the same imaging platform at baseline (median 1 day pre-
procedure, IQR 14 days) and at a median of 6 m (IQR 1 m) following aortic valve intervention using 
the same 1.5T scanner.   
 
For the purposes of categorising aortic regurgitation fraction, a threshold of >16% was used to delineate 
significant AR [235]. Significant mitral regurgitation was defined as >40% as per the American Society 
of Echocardiography guidelines [236]. A threshold of 5 standard deviations method was used for LGE 
quantitation in this study for the quantification of focal and replacement fibrosis, as it has been 
previously validated in patients with non-ischaemic cardiomyopathy [208], and in our opinion was able 
to best evaluate for the presence of both focal and replacement fibrosis (Figure 3-1). 
 
 
Figure 3-1  Differing methods of LGE quantification 
Panel showing the different methods of LGE quantification. The upper left hand panel 
shows the raw image, a single mid-ventricular short axis LGE slice, with evidence of focal 
fibrosis in the left ventricular septum at the inferior right ventricular insertion point. The 
following five panels show the differing techniques of automatic quantification. The 
threshold of 2 standard deviations and full-width half maximum technique appeared to 
overestimate the volume of fibrosis compared with visual assessment. The threshold of 5 
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standard deviation technique most closely matched visual assessment and was therefore 
chosen for this results chapter.  
3.3.3.   Statistical methods specific to this chapter 
Linear regression analysis was used to identify the main predictors of LV remodelling at baseline and 
reverse remodelling following AVR and to derive parameter estimates for those predictors and for the 
differences in gender. First, univariate regression analysis was performed using baseline measurements 
entered as covariate factors. All clinically significant variables and those with a P<0.1 on univariate 
analysis were subject to exploratory analysis to exclude those with weak or no correlation with the 
dependent variable, before entering them into a stepwise multiple linear regression model to identify 
the main predictor or combination of predictors in a multivariable model. Where multiple predictors 
were identified, the main predictor was determined through further analysis of correlations between 
variables and robustness of parameter estimates to model specification. Finally, the main predictor was 
entered with gender in a multivariable linear regression model and the resulting parameter estimates in 
the final multivariable model were compared with those for the relevant variables in the univariate 
analysis. Based on the paper by Bellenger et al [189], the sample size to detect a 10ml difference in 
LVEDV and LVESV, a 3% change in LVEF and a 10g change in LVM with a power of 90% and p<0.05 
using CMR is 12, 10, 15 and 9 respectively.  
3.4.   Results 
135 patients were recruited into the study. 60 men and 40 women with severe AS completed both 
baseline and 6-month post-procedure CMR scans. Reasons for non-completion were varied and are 
depicted in Figure 3-2. 
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Figure 3-2  Patient recruitment pathway 
SAVR: Surgical aortic valve replacement. TAVI: Trans-catheter aortic valve implantation. 
There was no significant difference between the group that completed the 6 month CMR protocol 
indicating that the demographics of the analysed patients were representative of the larger population 
(Table 3-1). Baseline demographic, clinical and echocardiographic characteristics of the final study 
population can be seen in Table 3-2.  
3.4.1.   Baseline left heart characteristics 
At baseline, women with severe AS had lower indexed LV mass (LVMi) than men (65.3± 18.4 vs. 
81.5±21.3g/m2, p<0.001) alongside smaller LVEDVi (87.3±17.5 vs. 101.2±28.6ml/m2, p=0.002) and 
LVESVi (37.3±16.6 vs. 47.9±25.6ml/m2, p=0.036). A typical example of the different patterns of 
remodelling can be seen in Figure 3-3. Further baseline differences according to gender can be seen in 
Table 3-3.  Men had more aortic regurgitation (AR) at baseline (regurgitant fraction (RFrac) men 
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15.1±12.4 vs. women 9.6±9.2%, p=0.013). Significant AR (defined as RFrac >16%) at baseline was 
seen in 23 (38%) men and 7 (18%) women (p=0.026).  There was a significant correlation between 
baseline LVMi and AR fraction in men (r=0.455, p<0.01) and in women (r=0.577, p<0.001). There was 
also a relationship between AR fraction and LVEDVi in men (r=0.433, p<0.001), but not in women 
(r=0.140, p=0.400).  When those with significant baseline AR were excluded, men still had greater 
LVMi than women (LVMi men 77.1±16.5 vs. women 61.9±13.8g/m2, p=<0.001).  Mitral regurgitation 
(MR) was similar for both genders (RFrac men 33.8±19.8 vs. women 26.9±21.3%, p=0.09). Significant 
MR was seen in 24 (40%) men and 10 (25%) women at baseline (p=0.121).   Baseline MR fraction was 
associated with baseline LVMi and LVEDVi on univariate analysis (Table 3-4), but was not found to 
be an independent predictor of baseline remodelling on multivariate analysis (Table 3-5). Gender and 
baseline aortic and mitral regurgitation fraction were univariate predictors of baseline LVMi and 
baseline LVEDVi (Table 3-4). Gender and baseline AR remained independent predictors of baseline 
LVMi on multiple regression analysis. Only baseline AR fraction was an independent predictor of 
baseline LVEDVi (Table 3-5). 
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Table 3-1  Baseline characteristics of the recruited and analysed population 
 Recruited patients  Patients completing 6m follow up 
 Total  
(n= 135) 
Men  
(n=79) 
Women  
(n= 56) 
 Total 
 (n=100) 
Men  
(n=60) 
Women  
(n=40) 
Age 77.5±7.9 75.6±7.1 80.1±8.4  77.0±8.2 75.3±7.2 79.9±8.90 
Systolic blood pressure, mmHg 131 ± 22 130 ± 22 134 ± 23  131 ± 23 129 ± 22 134 ± 24 
NYHA  3.0 ± 0.6 2.9 ±0.6 3.1 ± 0.6  2.9 ± 0.6 2.9 ± 0.6 3.0 ± 0.6 
EuroSCORE II, % 4.3 ± 4.1 3.9 ± 3.6 4.8 ± 4.8  4.0 ± 4.3 3.9 ± 3.7 4.5 ± 5.1 
Hypertension 72 (53) 40 (51) 32 (57)  55 (55) 31 (52) 24 (60) 
Diabetes 32 (24) 20 (25) 12 (21)  21 (21) 11 (18) 10 (25) 
Atrial Fibrillation 29 (22) 17 (22) 12 (21)  19 (19) 13 (22) 6 (15) 
Previous myocardial infarction 25 (19) 18 (23) 7 (13)  15 (15) 9 (15) 6 (15) 
Previous CABG 25 (19) 18 (23) 7 (13)  19 (19) 14 (23) 5 (12.5) 
Pulmonary hypertension 37 (27) 21 (27) 29 (52)  24 (24) 15 (25) 9 (22.5) 
Echocardiographic data 
AVAi, cm/m2 0.33 ± 0.1 0.33 ± 0.10 0.34 ± 0.10  0.35 ± 0.09 0.35±0.09 0.35 ± 0.10 
Aortic valve PPD, mmHg 87 ± 23 84 ± 21 91 ± 25  86 ± 22 85 ± 21 87 ± 23 
Aortic valve MPG, mmHg 50 ± 14 48 ± 13 52 ± 15  48 ± 13 48.3±12.3 49.0 ± 13.8 
Data expressed as mean±SD or number (%). NYHA: New York Heart Association. CABG: Coronary artery bypass grafting. AVA: Aortic valve area. AVAi: 
Indexed aortic valve area. PPD: Peak pressure drop. MPG: Mean pressure gradient. P values comparing total baseline population and analysed population all 
non-significant.  
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Table 3-2  Baseline characteristics of the analysed population 
 Total 
(n=100) 
Men 
(n=60) 
Women 
(n=40) 
P value for 
gender 
difference 
Age at intervention, years 77. ± 8 75 ± 7 80±9 0.004 
Length of stay, days 8.3±4.7 7.9±3.0 8.8±6.5 0.883 
BSA, m2 1.86 ± 0.2 1.96 ± 0.18 1.71 ± 0.16 <0.001 
Systolic blood pressure, mmHg 131 ± 23 129 ± 22 134 ± 24 0.20 
NYHA  2.9 ± 0.6 2.9 ± 0.6 3.0 ± 0.6 0.724 
Logistic EuroSCORE, % 14.5 ± 12.7 14.1 ± 12.4 16.0± 13.8 0.182 
EuroSCORE II, % 4.0 ± 4.3 3.9 ± 3.7 4.5 ± 5.1 0.340 
Hypertension 55 (55) 31 (52) 24 (60) 0.412 
Hypercholesterolaemia 67 (67) 44 (73) 23 (57.5) 0.10 
Diabetes 21 (21) 11 (18) 10 (25) 0.42 
Atrial Fibrillation 19 (19) 13 (22) 6 (15) 0.41 
Previous myocardial infarction 15 (15) 9 (15) 6 (15) 1 
Previous CABG 19 (19) 14 (23) 5 (12.5) 0.176 
Any coronary artery stenosis >50% 53 (53) 38 (63) 15 (38) 0.011 
Pulmonary hypertension 24 (24) 15 (25) 9 (22.5) 0.774 
Peripheral vascular disease 16 (16) 11 (18) 5 (12.5) 0.436 
Cerebrovascular disease 15 (15) 11 (18) 4 (10) 0.253 
COPD 16 (16) 13 (22) 3 (7.5) 0.058 
Echocardiographic data 
Indexed aortic valve area, cm/m2 0.35 ± 0.09 0.35 ± 0.09 0.35 ± 0.10 0.928 
Peak pressure drop, mmHg 86 ± 22 85 ± 21 87 ± 23 0.847 
Mean pressure gradient, mmHg 48±13 48±12 49±14 0.974 
Data are expressed as mean±SD or number (%). BSA: Body surface area. NYHA: New York Heart 
Association. CABG: Coronary artery bypass grafting. COPD: Chronic obstructive pulmonary disease.  
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Figure 3-3  Typical male and female ventricular remodelling in AS 
Short axis and 4 chamber cardiac magnetic resonance images of the left ventricle acquired 
at end diastole. The left sided panel depicts the typical female ventricle in severe aortic 
stenosis with a lower LV mass and a small LV cavity size (top image) and subsequent LV 
mass regression 6 months (bottom image).  The right sided panel shows a typical male 
pattern of remodelling with increased LV cavity size and greater LV mass at baseline (top 
image) and then reverse remodelling 6 months following valve replacement (bottom 
image). Both male and female ventricles exhibit reverse remodelling with LV mass 
regression 6 months following valve replacement.   
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Table 3-3  CMR data pre- and post-intervention grouped according to gender 
 Total  
n=100 
Men  
n=60 
Women  
n=40 
P Value for  
gender 
difference 
Indexed left ventricular mass, g/m2 
Pre-intervention 
Post-intervention 
 
75.1± 21.6 
59.0±15.9 
 
81.5±21.3 
63.2±15.8 
 
65.3±18.4 
52.6±14.0 
 
<0.001 
<0.001 
P Value  <0.001 <0.001 <0.001  
Left ventricular mass/volume 
Pre-intervention 
Post-intervention 
 
0.80±0.16 
0.69±0.15 
 
0.82±0.15 
0.72±0.15 
 
0.76±0.17 
0.65±0.14 
 
0.068 
0.006 
P Value <0.001 <0.001 <0.001  
Septal thickness, mm 
Pre-intervention 
Post-intervention 
 
12.2±3.1 
10.5±2.7 
 
13.3±2.8 
11.2±2.6 
 
10.5±2.8 
9.3±2.5 
 
<0.001 
<0.001 
P Value <0.001 <0.001 <0.001  
Lateral wall thickness, mm 
Pre-intervention 
Post-intervention 
 
8.0±2.2 
7.0±1.9 
 
8.6±2.1 
7.8±1.8 
 
7.1±2.1 
5.9±1.6 
 
<0.001 
<0.001 
P Value <0.001 0.001 <0.001  
Septal:Lateral wall thickness ratio 
Pre-intervention 
Post-intervention 
 
1.58±0.41 
1.57±0.47 
 
1.56±0.36 
1.49±0.38 
 
1.55±0.48 
1.68±0.58 
 
0.458 
0.174 
P Value 0.314 0.020 0.270  
LVEDVi, ml/m2 
Pre-intervention 
Post-intervention 
 
   95.6 ±25.6 
86.5±20.7 
 
101.2±28.6 
89.6±21.2 
 
87.3±17.5 
81.9±19.2 
 
0.020 
0.075 
P Value <0.001 <0.001 0.019  
LVESVi, ml/m2 
Pre-intervention 
Post-intervention 
 
43.7±23.0 
37.9±17.1 
 
47.9±25.6 
40.1±17.1 
 
37.3±16.6 
34.4±16.9 
 
0.036 
0.045 
P Value <0.001 <0.001 0.088  
Left ventricular ejection fraction, % 
Pre-intervention 
Post-intervention 
 
56.4±12.1 
58.0±10.8 
 
54.8±12.9 
56.5±10.5 
 
58.6±10.6 
60.2±11.0 
 
0.177 
0.042 
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P value 0.021 0.093 0.129  
Indexed left atrial volume, ml/m2 
Pre-intervention 
Post-intervention 
 
67.2±20.8 
62.3±20.9 
 
67.8±21.8 
60.1±20.5 
 
66.2±19.3 
65.7±21.3 
 
0.578 
0.136 
P Value <0.001 <0.001 0.477  
Absolute myocardial fibrosis mass (g) 
Pre-intervention 
Post-intervention 
 
2.0±3.3 
1.6±3.9 
 
2.3±4.1 
2.3±4.7 
 
1.3±1.1 
0.4±0.8 
 
0.714 
0.034 
P value 0.022 0.412 0.010  
Myocardial fibrosis (% LV mass)  
Pre-intervention 
Post-intervention 
 
1.2±1.5 
1.2±2.4 
 
1.2±1.8 
1.6±2.9 
 
1.2±1.1 
0.5±0.9 
 
0.435 
0.114 
P Value 0.263 0.716 0.026  
Aortic max pressure gradient, mmHg 
Pre-intervention 
Post-intervention 
 
42±36 
21±12 
 
46±43 
21±11 
 
36±16 
20±13 
 
0.171 
0.323 
P value <0.001 <0.001 <0.001  
Data are expressed as mean±SD. LVEDVi: Indexed left ventricular diastolic volume. LVESVi: Indexed 
left ventricular end systolic volume. LV: Left ventricular.  
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Table 3-4  Univariable analysis for baseline remodelling 
  Unstandardised 
coefficient 
Standard 
Error 
P 
Value 
95% CI Standardised 
Coefficient 
(Beta) 
Baseline LVMi (g/m2) 
Gender -16.15 4.122 <0.001 -24.33 to -7.97 -0.368 
Baseline AR fraction (%) 0.981 0.164 <0.001 0.657 to 1.31 0.522 
Baseline MR fraction (%) 0.461 0.097 <0.001 0.269 to 0.654 0.437 
Hypertension -0.503 4.365 0.909 -9.165 to 8.159 -0.012 
Previous MI 9.223 6.010 0.128 -2.703 to 21.150 0.153 
Systolic blood pressure, 
(mmHg) 
0.142 0.097 0.147 -0.051 to 0.335 0.148 
AVAi (cm2) -43.06 24.655 0.084 -92.058 to 5.934 -0.183 
Baseline LVEDVi (ml/m2) 
Gender -13.851 5.053 0.007 -23.878 to -3.824 -0.267 
Baseline AR fraction (%) 0.904 0.208 <0.001 0.491 to 1.317 0.405 
Baseline MR fraction (%) 0.434 0.120 <0.001 0.196 to 0.672 0.347 
AVAi (cm2) -16.323 28.769 0.572 -73.495 to 40.848 -0.060 
Hypertension 1.829 5.160 0.725 -8.419 to 12.059 0.036 
Previous MI -7.162 7.157 0.319 -21.364 to 7.041 -0.101 
LVMi: Indexed left ventricular mass. AR: Aortic regurgitant. MR: Mitral regurgitant. MI: Myocardial 
infarction. AVAi: Indexed aortic valve area.  
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Table 3-5  Multiple regression analysis - baseline remodelling 
  Unstandardised 
coefficient 
Standard 
Error 
P 
Value 
95% Confidence 
interval 
Standardised 
Coefficient 
(Beta) 
Baseline LVMi (g/m2) 
Baseline AR fraction (%) 0.878 0.180 <0.001 0.520 to 1.237 0.445 
Gender -13.37 4.139 0.002 -21.60 to -5.138 -0.295 
Baseline LVEDVi (ml/m2) 
Baseline AR fraction (%) 0.904 0.208 <0.001 0.491 to 1.317 0.405 
LVMi: Indexed left ventricular mass. AR: Aortic regurgitation. LVEDVi: Indexed left ventricular end 
diastolic volume.  
3.4.2.   Reverse remodelling following aortic valve replacement 
There was a similar length of post-procedure hospital stay between genders (men 8±3 vs. women 
9±7days, p=0.883). Reverse remodelling parameters according to gender can be seen in Table 3-3 and 
Figure 3-4. Following valve replacement there was a significant reduction in LVMi in both groups. Men 
experienced greater absolute LV mass regression than women (18.3±10.6 vs. 12.7±8.8g/m2, p=0.007), 
however, when expressed as a percentage reduction of baseline LVMi, mass regression was similar 
between the genders (men 21.7±10.1 vs. women 18.4±11.0%, p=0.121). A gender difference in absolute 
LV mass regression was still evident when those with significant baseline AR were excluded from the 
analysis (men 16.2±10.4 vs. women 11.4±8.2g/m2, p=0.034).  
 
There was no gender-related difference in post-procedural AR (RFRac men 8.4±8.0% vs women 
6.9±6.8%, p=0.406). Significant post-procedural AR was seen in 9 (15%) men and 4 (10%) of women 
(p=0.347). Men experienced a significant reduction in MR following valvular intervention whereas 
women did not (men 33.8±19.8 to 17.6±18.1%, p<0.001, women: 26.9±21.3 to 20.5±19.6%, p=0.102). 
Significant post-procedural MR was seen in 5 (8%) of men and 6 (15%) women (p=0.297). 
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Figure 3-4  Values according to gender pre- and post-valve replacement 
Values according to gender pre- and post-aortic valve replacement. Boxplots show 
median values (line within box), 50th percentile values (box outline) and maximum and 
minimum values (whiskers). LVMi: Indexed left ventricular mass. LVEF: Left 
ventricular ejection fraction. LAVOLi: Indexed left atrial volume. LVEDVi: Indexed left 
ventricular end diastolic volume. LVESVi: Indexed left ventricular end systolic volume.  
 
Results according to gender and procedure type can be seen in Table 3-6.  As prior myocardial infarction 
has been reported to affect reverse remodelling following TAVI, a further subgroup analysis was 
performed, excluding those with infarct pattern LGE at baseline, the results can be seen in Table 3-7 . 
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Table 3-6  Pre and post-procedure CMR values according to gender and procedure type 
 Total SAVR 
(n=39) 
Total TAVI 
(n=61) 
P Value SAVR 
men 
(n=28) 
TAVI men 
(n=32) 
P value SAVR 
women 
(n=11) 
TAVI women 
(n=29) 
P 
value 
LVMi, g/m2 
Pre-intervention 
Post-intervention 
 
74.0 ± 22.7 
57.8 ± 14.9 
 
75.7  ± 21.1 
59.7 ± 16.6 
 
0.701 
0.579 
 
80.3 ± 21.4 
61.7 ± 13.5 
 
82.47 ± 21.5 
64.48 ± 17.8 
 
0.696 
0.500 
 
57.8 ± 17.7 
48.0 ± 14.7 
 
68.2 ± 18.1 
54.3 ± 13.6 
 
0.113 
0.207 
P Value <0.001 <0.001  <0.001 <0.001  0.006 <0.001  
LVEDVi, ml/m2 
Pre-intervention 
Post-intervention 
 
91.2 ± 27.2 
79.1 ± 16.2 
 
98.5 ± 24.3 
91.3 ± 21.9 
 
0.164 
0.004 
 
95.6 ± 29.1 
80.7 ± 16.9 
 
106.0 ± 27.6 
97.4 ± 21.7 
 
0.166 
0.002 
 
79.7 ± 18.0 
75.2 ± 14.3 
 
90.2 ± 16.7 
84.5 ± 20.4 
 
0.090 
0.173 
P Value <0.001 0.003  0.001 0.021  0.155 0.059  
LVESVi, ml/m2 
Pre-intervention 
Post-intervention 
 
39.6 ± 23.0 
32.7 ± 12.7 
 
46.3 ± 22.7 
41.1 ± 18.8 
 
0.151 
0.016 
 
42.6 ± 24.7 
33.6 ± 12.9 
 
52.5 ± 25.9 
45.9 ± 18.4 
 
0.136 
0.004 
 
31.7 ± 16.4 
30.4 ± 12.5 
 
39.4 ± 16.4 
35.9 ± 18.2 
 
0.190 
0.359 
P Value 0.010 0.009  0.010 0.047  0.656 0.081  
LVEF, % 
Pre-intervention 
Post-intervention 
 
59.0 ± 11.2 
60.2 ± 9.3 
 
54.7 ± 12.5 
56.6 ± 11.5 
 
0.084 
0.103 
 
57.8 ± 11.5 
59.2 ± 8.9 
 
52.3 ± 13.7 
54.2 ± 11.4 
 
0.123 
0.103 
 
61.9 ± 10.1 
62.8 ± 10.2 
 
57.4 ± 10.6 
59.2 ± 11.3 
 
0.103 
0.157 
P value 0.402 0.021  0.524 0.184  0.374 0.206  
LA Voli, ml/m2          
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Pre-intervention 
Post-intervention 
61.1 ± 17.6 
57.3 ± 16.5 
71.1 ± 21.8 
65.5 ± 22.8 
0.018 
0.056 
61.2 ± 18.2 
55.1 ± 15.2 
73.5 ± 23.3 
64.3 ± 23.4 
0.027 
0.132 
60.8 ± 16.8 
62.6 ± 19.1 
68.3 ± 20.0 
66.9 ± 22.3 
0.277 
0.576 
P Value 0.033 0.004  0.007 0.001  0.484 0.556  
AR fraction, % 
Pre-intervention 
Post-intervention 
 
14.7±14.4 
9.5±8.5 
 
11.9±9.1 
6.8±6.8 
 
0.707 
0.098 
 
17.7±15.6 
10.8±9.1 
 
12.7±8.2 
4.1±1.8 
 
0.382 
0.033 
 
6.2±4.6 
6.1±5.7 
 
10.8±10.1 
7.2±7.2 
 
0.317 
0.669 
P Value <0.001 <0.001  0.072 <0.001  0.717 0.096  
Data are expressed as mean±SD. SAVR: Surgical aortic valve replacement. TAVI: Trans-catheter aortic valve implantation. LVMi: Indexed left ventricular 
mass. LVEDVi: Indexed left ventricular end diastolic volume. LVESVi: Indexed left ventricular end systolic volume. LVEF: Left ventricular ejection fraction. 
LAVoli: Indexed left atrial volume. AR: Aortic regurgitation. 
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Table 3-7  CMR values pre and post-procedure with prior infarct patients excluded 
 Men  
(n=46) 
Women  
(n=33) 
P Value for  
gender difference 
Indexed left ventricular mass, g/m2 
Pre-intervention 
Post-intervention 
 
78.7±19.1 
60.9±14.3 
 
64.1±17.7 
51.1±13.0 
 
<0.001 
<0.001 
P Value  <0.001 <0.001  
Septal thickness, mm 
Pre-intervention 
Post-intervention 
 
13.5±2.8 
10.9±2.1 
 
10.2±2.8 
9.1±2.3 
 
<0.001 
<0.001 
P Value <0.001 0.004  
Lateral wall thickness, mm 
Pre-intervention 
Post-intervention 
 
8.6±2.2 
7.6±1.8 
 
7.3±2.2 
6.0±1.7 
 
<0.001 
<0.001 
P Value <0.001 <0.001  
LVEDVi, ml/m2 
Pre-intervention 
Post-intervention 
 
94.4±24.8 
83.4±17.2 
 
83.2±15.8 
77.5±16.2 
 
0.039 
0.126 
P Value <0.001 0.039  
LVESVi, ml/m2 
Pre-intervention 
Post-intervention 
 
41.7±21.7 
35.5±13.4 
 
32.5±10.5 
29.7±9.7 
 
0.037 
0.051 
P Value 0.006 0.214  
Left ventricular ejection fraction, % 
Pre-intervention 
Post-intervention 
 
57.5±11.4 
58.3±9.6 
 
61.6±6.4 
63.0±7.2 
 
0.183 
0.023 
P value 0.604 0.386  
Indexed left atrial volume, ml/m2 
Pre-intervention 
Post-intervention 
 
66.3±23.1 
59.6±21.7 
 
64.8±18.8 
64.5±21.0 
 
0.698 
0.164 
P Value 0.002 0.675  
96 
 
Aortic max pressure gradient, mmHg 
Pre-intervention 
Post-intervention 
 
47.1±48.2 
20.5±9.3 
 
36.9±15.6 
16.5±8.1 
 
0.266 
0.060 
P value <0.001 <0.001  
Data are expressed as mean±SD. LVEDVi: Indexed left ventricular end diastolic volume. 
LVESVi: Indexed left ventricular end systolic volume.  
 
 
There was a reduction in RV longitudinal function in men and in women (Table 3-8). Change in TAPSE 
was significantly different according to procedure type (men SAVR -8.3±4.7 vs. TAVI 0.4±4.9mm, 
p<0.001, women SAVR -8.4±3.5 vs. TAVI 0.6±4.7mm, p<0.001).  
 
Table 3-8  Change in right ventricular longitudinal function 
 Total Men  
(n=60) 
Women 
(n=40) 
P Value 
TAPSE, mm 
Pre-intervention 
Post-intervention 
 
20.05 ± 5.83 
16.82 ± 6.18 
 
19.86 ± 5.77 
16.22 ± 5.77 
 
20.33 ± 5.98 
17.73 ± 6.73 
 
0.697 
0.341 
P Value <0.001 <0.001 0.005  
Data are expressed as mean±SD. TAPSE: Tricuspid annular excursion.  
3.4.3.   Myocardial fibrosis 
LGE imaging was available for 95 patients. 5 patients (male, n=4) were not given a Gadolinium-based 
contrast agent due to pre-existing renal failure with an estimated glomerular filtration rate of 
<30ml/min/1.73m2. Patients were classified at baseline according to whether they had no LGE (men 
n=14 (25%), women n=16 (41%)), infarct pattern LGE (men n=14 (25%), women n=7 (18%)) or mid-
wall/focal fibrosis pattern LGE (men n=28 (50%), women 16 (41%)).   
 
The presence or absence of infarct pattern LGE did not impact on change in LVEF (men: infarct-LGE(+) 
4.8±7.3 vs. infarct-LGE(-) 0.7±8.0%, p=0.099; women: infarct-LGE(+) 2.6±3.4 vs. infarct-LGE(-) 
1.4±7.1%, p=0.670) or LVEDVi (men: infarct-LGE(+) 13.4±22.6 vs. infarct-LGE(-) 11.0±19.8ml/m2, 
p=0.702; women: infarct-LGE(+) 3.7±19.4 vs. infarct-LGE(-) 5.8±13.1ml/m2, p=0.726).  
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Of the patients with mid-wall/focal fibrosis pattern LGE at baseline, there was a different distribution 
according to gender (Figure 3-5) but comparable total amounts when expressed as a percentage of LV 
mass (Table 3-3). Following valve replacement, only women experienced a significant reduction in total 
fibrosis burden as a percentage of LV mass (men 1.2±1.8 to 1.6±2.9%, p=0.716, women 1.2±1.1 to 
0.5±0.9%, p=0.026). The presence (MF(+)) or absence (MF(-)) of MF did not impact on change in 
LVEF (men: MF(+) 1.2±9.3 vs. MF(-) 2.6±6.5%, p=0.292; women: MF(+) 2.4±9.3 vs. MF(-) 1.2±3.9%, 
p=0.767), LVEDVi (men: MF(+) 13.5±19.4 vs. MF(-) 12.1±21.0ml/m2, p=0.823; women: MF(+) 
13.4±19.4  vs. MF(-) 12.1±21.0ml/m2, p=0.053) or LVMi (men: MF (+) -17.7±10.0 vs. MF (-) -
19.4±11.6g/m2, p=0.936; women MF (+) -14.7±6.8 vs. MF (-) -11.8±9.9 vs. -14.7±6.8g/m2, p=0.311).  
 
 
Figure 3-5  Distribution of MF according to gender 
The distribution and frequency of focal mid-wall MF for 28 men and 16 women with severe 
AS represented using the 17-segment AHA model. Focal fibrosis was greatest in the basal 
and septal regions in men (arrow) whereas women appeared to have a more varied 
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distribution. The shaded diagram represents the proportion of patients with fibrosis in each 
numbered segment; <4% white, 4-8% light grey, 8-12% dark grey, >12% black.  
3.4.4.   Predictors of reverse remodelling  
Clinical variables including patient demographics, co-morbidities and pre-operative cardiac 
measurements were analysed to determine predictors of cardiac reverse remodelling. These variables 
were each used as dependent variables in linear regression analysis.  The results of the univariate 
analysis can be seen in Table 3-9. For every dependent variable, the baseline level of the same measure 
emerged as the main predictor in a multivariable model (Table 3-10). The relationship between each 
dependent and its baseline level is shown in Figure 3-6. Gender was only implicated as a factor for left 
atrial reverse remodelling but did not appear to influence LV reverse remodelling, and its inclusion in 
the multivariable model had minimal impact on the parameter estimates for the relevant baseline.  
Procedure type or the presence of coronary artery disease did not appear to predict reverse remodelling 
on univariate analysis. Baseline AR fraction was an independent predictor of change in LVMi alongside 
baseline LVMi, but was not an independent predictor in the multivariate model for any other reverse 
remodelling parameter. Results of the multiple regression analysis can be seen in Table 3-10.  
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Table 3-9  Univariable analysis - predictors of LV reverse remodelling 
 Unstandardised 
coefficient 
Standard 
Error 
P 
Value 
95% CI Standardised 
Coefficient 
(Beta) 
Change in LVMi (g/m2) 
Baseline LVMi (g/m2) 0.342 0.033 <0.001 0.276 to 0.408 0.719 
Baseline LVEDVi (ml/m2) 0.194 0.036 <0.001 0.123 to 0.264 0.482 
Baseline LVESVi (ml/m2) 0.139 0.043 0.002 0.054 to 0.225 0.311 
Baseline fibrosis mass (g) 0.944 0.393 0.021 0.152 to 1.735 0.344 
Baseline AR fraction (%) 0.400 0.082 <0.001 0.237 to 0.562 0.446 
Gender -5.59 2.032 0.007  -9.622 to -1.558 -0.268 
Procedure type -0.111 2.118 0.958 -4.314 to 4.092 -0.005 
Any CAD >50% -0.613 2.069 0.767 -4.719 to 3.492 -0.030 
Post-procedure PPD (mmHg) 0.011 0.090 0.907 -0.168 to 0.189 0.012 
Post-procedure MR fraction 
(%) 
0.005 0.056 0.928 -0.106 to 0.116 0.009 
Post-procedure AR fraction 
(%) 
0.151 0.137 0.272 -0.120 to 0.422 0.112 
Change in LVEDVi (ml.m2) 
Baseline LVEDVi (ml/m2) 0.43 0.06 <0.001 0.31 to 0.54 0.600 
Baseline LVESVi (ml/m2) 0.4 0.069 <0.001 0.262 to 0.538 0.503 
Baseline LVMi (g/m2) 0.355 0.077 <0.001 0.202 to 0.509 0.421 
Baseline LVEF (%) -0.408 0.146 0.006 -0.698 to -0.117 -0.271 
Baseline fibrosis mass (g) 1.92 0.79 0.02 0.32 to 3.51 0.346 
Baseline AR fraction (%) 0.608 0.149 <0.001 0.311 to 0.904 0.384 
Gender -6.17 3.69 0.09 -13.4 to 1.16 -0.166 
Procedure type -4.81 3.73 0.2 -12.2 to 2.58 -0.129 
Any CAD >50% -1.938 3.671 0.599 -9.223 to 5.348 -0.053 
Post-procedure MR fraction 
(%) 
-0.076 0.100 0.447 -0.274 to 0.122 0.447 
Baseline AR fraction (%) 0.221 0.245 0.369 -0.265 to 0.707 0.091 
Change in LVESVi (ml/m2) 
Baseline LVEDVi (ml/m2) 0.374 0.047 <0.001  0.281 to 0.467 0.627 
Baseline LVESVi (ml/m2) 0.442 0.05 <0.001 0.342 to 0.541 0.665 
Baseline LVMi (g/m2) 0.294 0.065 <0.001 0.166 to 0.423 0.417 
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Baseline LVEF (%) -0.62 0.11 <0.001 -0.839 to -0.410 -0.494 
Baseline AR fraction (%) 0.457 0.127 <0.001 0.206 to 0.709 0.346 
Gender 4.884 3.088 0.117 -11.012 to 1.243 0.158 
Procedure type -1.678 3.136 0.594 -7.901 to 4.545  -0.054 
Any CAD >50% 0.768 3.068 0.803 -5.321 to 6.857 0.025 
Post-procedure MR fraction 
(%) 
-0.054 0.083 0.515 -0.220 to 0.111 -0.066 
Baseline AR fraction (%) 0.168 0.205 0.413 -0.238 to 0.574 0.083 
Change in LVEF (%) 
Baseline LVEDVi (ml/m2) 0.098 0.028 0.001 0.043 to 0.153 0.337 
Baseline LVESVi (ml/m2) 0.153 0.029 <0.001 0.095 to 0.210 0.472 
Baseline LVMi (g/m2) 0.103 0.033 0.299 0.037 to 0.939 0.299 
Baseline LVEF (%) -0.291 0.054 <0.001 -0.399 to -0.183 -0.476 
Baseline AR fraction (%) 0.097 0.064 0.134 -0.031 to 0.225 0.152 
Gender -0.094 1.523 0.951 -3.116 to 2.927 -0.006 
Procedure type 0.677 1.528 0.658 -2.355 to 3.709 0.045 
Any CAD >50% 0.921 1.492 0.538 -2.039 to 3.881 0.062 
Post-procedure MR fraction 
(%) 
-0.043 0.040 0.292 -0.123 to 0.037 -0.107 
Baseline AR fraction (%) -0.061 0.100 0.540 -0.260 to 0.137 -0.062 
Change in LA Voli (ml/m2) 
Baseline LVEDVi (ml/m2) 0.157 0.05 0.002 0.058 to 0.256 0.305 
Baseline LVESVi (ml/m2) 0.155 0.057 0.008 0.042 to 0.268 0.268 
Baseline LVMi (g/m2) 0.120 0.061 0.052 0.001 to 0.241 0.197 
Baseline LA Voli (ml/m2) 0.205 0.061 0.001 0.084 to 0.327 0.324 
Baseline AR fraction (%) 0.282 0.117 0.017 0.051 to 0.514 0.242 
Gender -7.031 2.657 0.010 -12.314to -1.759 -0.261 
Procedure type 2.004 2.759 0.469 -3.469 to 7.481 0.074 
Any CAD >50% 2.831 2.685 0.294 2.500 to 8.162 0.107 
AVAi (cm/m2) -26.162 15.012 0.084 -56.094 to 3.583 -0.184 
Post-procedure MR fraction 
(%) 
0.001 0.075 0.986 -0.148 to 0.150 0.002 
Baseline AR fraction (%) 0.031 0.179 0.862 -0.324 to 0.387 0.018 
LVMi: Indexed left ventricular mass. AR: Aortic regurgitant. MR: Mitral regurgitant. CAD: Coronary 
artery disease. LVEDVi: Indexed left ventricular end diastolic volume LVESVi: Indexed left 
ventricular end systolic volume. LA Voli: Indexed left atrial volume. LVEF: Left ventricular ejection 
fraction. AVAi: Indexed aortic valve area. 
101 
 
 
Table 3-10  Multivariable analysis 
  Unstandardised 
coefficient 
Standard 
Error 
P Value 95% CI Standardised 
Coefficient 
(Beta) 
Change in LVMi (g/m2) 
Baseline LVMi (g/m2) 0.342 0.051 <0.001 0.239 to 0.445 0.719 
Change in LVEDVi (ml/m2) 
Baseline LVEDVi (ml/m2) 0.429 0.088 <0.001 0.251 to 0.607 0.600 
Change in LVESVi (ml/m2) 
Baseline LVESVi (ml/m2) 1.713 0.298 <0.001 1.122 to 2.305 2.595 
Baseline LVEF (%) 1.655 0.339 <0.001 0.982 to 2.328 1.320 
Baseline LVEDVi (ml/m2) -0.490 0.150 0.002 -0.788 to -0.192 -0.827 
Change in LVEF (%) 
Baseline LVEF (%) -0.291 0.054 <0.001 -0.399 to -0.183 -0.487 
Change in LA Voli (ml/m2) 
Baseline LA Voli (ml/m2) 0.197 0.061 0.002 0.076 to 0.319 0.322 
Gender -6.440 2.721 0.020 -11.851 to -1.028 -0.236 
LVMi: Indexed left ventricular mass. AR: Aortic regurgitant. LVEDVi: Indexed left ventricular end 
diastolic volume LVESVi: Indexed left ventricular end systolic volume. LA Voli: Indexed left atrial 
volume. LVEF: Left ventricular ejection fraction. AVAi: Indexed aortic valve area. 
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Figure 3-6  Relationship between cardiac remodelling parameters 
Relationship between cardiac reverse remodelling parameters following aortic valve 
replacement and baseline parameters displayed according to gender. A. Relationship 
between change in LVMi and baseline LVMi. B. Relationship between change in LVEDVi 
and baseline LVEDVi. C. Relationship between change in LVEF and baseline LVEF. D. 
Relationship between change in LAVoli and baseline LAVoli. E. Relationship between 
change in LVESVi and baseline LVESVi. 
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3.5.   Discussion 
This study is the first using the reference standard of CMR to accurately assess the influence of gender 
on differences in LV remodelling in AS and the impact on reverse remodelling following AVR.   
3.5.1.   Baseline cardiac remodelling in AS according to gender 
The baseline CMR results demonstrating differing patterns of ventricular remodelling in response to 
AS are consistent with the published echocardiographic and CMR literature [14, 16, 234]. We have 
demonstrated that men and women with severe AS and similar co-morbidities remodel in different ways; 
women exhibit lower LV mass with a smaller LV cavity size, whereas men are prone to the development 
of a larger cavity size, greater LV wall thickness and increased LV mass. This pattern of remodelling 
is seen despite similar valvular gradients between groups but may be in part related to differing degrees 
of baseline aortic regurgitation. Hormonal influences may also be involved, with oestrogen limiting 
hypertrophy up to the menopause and its subsequent lack leading to accelerated (and possibly therefore 
different) patterns of hypertrophy in post-menopausal women compared to men [237].  
3.5.2.   Reverse remodelling according to gender 
In contrast to other studies evaluating gender in AS, our male and female groups were similar in terms 
of co-morbidity, cardiac risk score, NYHA classification and echo derived valve gradients. Only age, 
baseline aortic regurgitation and, expectedly, coronary artery disease prevalence and body size differed 
between the two groups. Previous reports of referral bias for men over women are seen again in our 
population, with males accounting for 74% of the SAVR population [233]. In our study, men and 
women had similar reverse remodelling 6 months following valve replacement. Multiple regression 
analysis suggested that the main predictor of reverse remodelling for each category was the baseline 
level of that variable. So, the greater absolute LV mass regression seen in men was a result of the fact 
that men have more LV mass at baseline than their female counterparts, rather than a gender-related 
difference per se.  Stangl et al found a better LVEF at baseline and a more favourable LV remodelling 
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response in women upon serial echocardiography following TAVI, but their female population had 
higher pre-TAVI aortic valve gradients than men, which may explain the greater degree of mass 
regression seen [42]. In an echocardiographically based study of 92 patients undergoing SAVR for 
isolated AS, Petrov et al [26] found a similar LVMi at baseline in men and women, but a greater degree 
of LVM regression in women after SAVR. This study was based on measurements taken only 3 days 
post-SAVR. The change in LVM reported was a reflection of a change in cavity size rather than a 
change in wall thickness and it could be that the LVM regression reported was actually a reflection of 
the mathematical assumptions made by the echocardiographic estimation of LVM. Our study provides 
more robust data than that of Petrov et al; CMR is a well validated and accurate technique for LVM 
quantification, which does not rely to the same extent on mathematical assumptions and is independent 
of any change in cardiac geometry which may take place in the peri-operative period. Furthermore, the 
follow up of 6m (rather than 3 days), our larger sample size and the inclusion of other parameters of 
hypertrophy assessment in our study such as wall thickness, means that more robust conclusions about 
gender-related differences in reverse remodelling can be drawn.  
 
AR has previously been suggested as a modulator of reverse remodelling following valve replacement 
and has been proposed as a mechanism for less favourable outcomes in men in the TAVI literature 
[238].  In our study, men had more AR at baseline which may in part contribute to their increased LV 
cavity size and mass pre-intervention. The AR regurgitant fraction following valve replacement was 
similar between genders which may explain why our findings differ from those of Stangl et al where 
rates of residual AR were much higher in men than women [42].  A significant reduction in valve 
gradients was observed in both genders, with no significant difference in CMR derived peak valve 
gradient according to gender, suggesting that patient prosthesis mismatch was not an implicating factor 
in remodelling parameters according to gender.  Furthermore, post-procedure valve gradient was not 
associated with change in LVMi on univariate analysis. A reduction in mitral regurgitation was seen in 
men but not women. This, alongside the reduction in left atrial size seen in men but not women, may 
reflect a greater improvement in LV cavity pressure, trans-mitral gradient and mitral valve tethering 
forces in men. The assessment of mitral regurgitation in the context of severe aortic stenosis can be 
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unreliable due to the underestimation of stroke volume using Q flow methodology and it is therefore 
possible that the reduction in MR seen in men was a result of this rather than a true finding. However, 
one would expect that these limitations should apply to both men and women equally, adding weight to 
the argument that this is a true, rather than artefactual observation.  
3.5.3.   Right ventricular function 
Men and women both experienced a reduction in right ventricular longitudinal function. However, 
subgroup analysis revealed that this was due to the procedure type (SAVR) rather than a gender related 
effect. It is well described that SAVR causes a reduction in right ventricular function [167, 239], 
although the cause is not entirely clear, it may be linked to loss of pericardial support, prolonged 
cardiopulmonary bypass or right ventricular ischaemia (or a combination of all three). TAVI, at least in 
most studies, does not appear to impact on right ventricular function [167, 239], although reports are 
contradictory [173]. Our female group, likely due to their advanced age and possibly due to referral 
bias, comprised a higher proportion undergoing TAVI than the male group. Given the strong association 
of procedure type on right ventricular function and the uneven split of procedure type in each gender 
group, any inferences to gender in this setting may be inaccurate. 
3.5.4.   Myocardial Fibrosis 
Myocardial fibrosis has been implicated in adverse clinical outcomes following both TAVI and SAVR 
[49, 50]. Men and women had similar levels of MF at baseline, in keeping with findings from previous 
studies [192, 193] but with differing distributions. Our study shows that females develop a varied pattern 
of MF whereas men display most fibrosis in the basal and septal regions, suggesting that the 
pathogenesis may differ. The proportion of patients with MF was in keeping with those reported in 
previous studies; Rudolph et al [47] investigated 21 patients with AS and found MF in 62% once infarct 
pattern LGE had been excluded.  Our absolute values for MF were lower than in previously reported 
studies [47, 49], however, these studies used different methods of MF quantification which most likely 
accounts for the increased values reported, rather than a true difference in absolute levels of MF.  
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Following AVR, there was a significant reduction in absolute MF and also MF as a proportion of LV 
mass in women but not in men. This finding is surprising given the greater degree of absolute LV mass 
reduction in the male cohort. Further studies exploring gender differences in MF are required to explain 
this finding. It is possible that the MF regression is different according to gender, with the more varied 
distribution ‘female’ pattern showing an early tendency to regress. It is also possible that the regression 
in females is a reflection of the fact that more females underwent trans-catheter rather than surgical 
valve replacement, as it has previously been suggested that MF regression is seen following TAVI but 
not SAVR [167].  Failure of MF regression following AVR has been reported previously.  Weidemann 
et al found no fibrosis regression following SAVR and also reported LV mass regression regardless of 
MF or MF burden [193].  Moreover, in our study the MF burden accounted for a very small proportion 
of total LV mass at both baseline and follow-up, so one may not expect such a small amount of fibrosis 
to impact significantly on reverse remodelling. Given the limitations of MF quantification using CMR, 
it is also possible that the finding could have been artefactual; larger studies and those including ECV 
calculation may help further explore this.  
3.6.   Limitations 
Patients in the two groups were similarly matched in terms of co-morbidities and clinical characteristics 
but were not comparable in terms of age. Due to age and referral patterns, the proportions of each gender 
undergoing TAVI and SAVR were different thus hampering any direct comparison between the 
procedures. Due to their differing implant techniques and flow dynamics, there may be important 
differences between remodelling parameters in SAVR and TAVI, however, the procedure type did not 
influence reverse remodelling on univariate analysis. There was numerically (but not statistically 
significant) greater post-procedural AR in those undergoing TAVI compared with SAVR and therefore 
it is possible that this influenced findings given the different proportion of men and women undergoing 
each procedure.  A quarter (26%) of the study population did not complete the study protocol mainly 
due to permanent pacemaker implantation, which may have introduced bias, although the analysed 
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population did not differ in terms of baseline characteristics from the original population. The post-
procedure scan occurred 6 months following valve replacement; although it is well documented that the 
majority of reverse remodelling occurs within the first 6 months [240], this could still be too early to 
detect any subtle differences between the genders. The follow up may also be too short to demonstrate 
reversal of MF. Caution may need to be exercised in the interpretation of mitral regurgitation pre-
intervention. Mitral regurgitant fraction in the context of severe AS may be overestimated using CMR 
phase contrast imaging due to underestimation of aortic forward flow when sampling high velocities 
[202]. Any inferences related to MF are restrained to the technique of LGE imaging with its limited 
spatial resolution and variable inter-scan reproducibility. Our inter and intra-observer variability were 
in keeping with the published literature, supporting the notion that the MF findings are genuine, 
however, we accept that this is a valid limitation of any paper reporting quantification of MF mass. T1 
mapping is superior at detecting the often diffuse fibrosis seen in the pressure overloaded ventricle. T1 
mapping was not widely performed at the time of the study design and absolute T1 values can vary 
between vendors, software release, pulse sequence and contrast agent making comparisons difficult in 
multivendor studies. This study was not designed as a clinical outcomes trial, but larger-scale mortality 
data would be useful to identify any independent prognostic markers between the sexes. 
  
108 
 
Chapter 4:   Post-procedural myocardial infarction following surgical and 
trans-catheter aortic valve replacement – insights from cardiovascular 
magnetic resonance imaging 
4.1.   Abstract 
Background: Myocardial injury assessed using cardiac biomarker release is ubiquitous following 
SAVR and TAVI, preventing accurate discrimination between focal MI and global injury. 
Cardiovascular magnetic resonance late gadolinium enhancement imaging, a more sensitive method of 
detecting post-procedural MI, was used to compare rates of new MI following trans-catheter and 
surgical aortic valve replacement.  
Methods: Identical CMR scans were obtained at baseline and 6 months post-procedure in ninety-six 
patients undergoing SAVR (n=39) and TAVI (n=57).  
Results: The rate of new MI was greater following SAVR than TAVI (SAVR, n=10 (26%) vs. TAVI, 
n=3 (5%), p=0.004). Infarct mass was similar between groups (SAVR 1.1±0.6 vs. TAVI 2.0g±1.4g, 
p=0.395), as was infarct mass as a percentage of LV mass (SAVR 1.0±0.4% vs. TAVI 2.2±1.3%, 
p=0.268).  None of the SAVR and one of the TAVI infarcts were detected clinically. New MI did not 
impact on LVEF in either group (SAVR: LGE(+) 2.2±4.7% vs. LGE(-) 0.90±8.0%, p=0.437, TAVI: 
LGE(+)-0.9±6.0 vs. LGE(-) 2.0±7.8%, p=0.420). 34 patients (60%) in the TAVI group had non-
revascularised coronary artery disease at the time of TAVI, of whom 3 (9%) had new MI.   
Conclusions: MI is an infrequent complication of TAVI but may be more common following SAVR. 
Infarct size is small following both procedures and does not impact on change in LVEF. The low new 
infarct rate in TAVI, especially in the context of high rates of non-revascularised CAD, is reassuring 
and strengthens the notion that coronary revascularisation prior to TAVI may be unnecessary. 
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4.2.   Introduction 
Surgical aortic valve replacement remains the recommended technique for those with severe 
symptomatic AS.  However, trans-catheter aortic valve implantation is now a viable alternative for those 
at high surgical risk [65], with thousands of implants taking place annually [241].  Myocardial injury 
assessed using cardiac biomarker release is associated with an adverse outcome following both cardiac 
surgery [242] and trans-catheter intervention [243]. Mechanisms for myocardial injury during SAVR 
and TAVI are varied and depicted in Figure 4-1. Cardiac biomarker release is almost ubiquitous in 
patients following both procedures [113, 114] preventing accurate discrimination between release due 
to focal myocardial infarction and global/diffuse myocardial injury. Furthermore, the importance of 
coronary artery disease and completeness of revascularisation prior to TAVI is debated [244]. 
Cardiovascular magnetic resonance imaging is the reference standard imaging test to evaluate the 
incidence of post-procedural MI using the late gadolinium enhancement technique [245, 246], and can 
be relied upon to detect even tiny amounts of myocardial scar [118]. As well as quantification of scar 
mass, infarct transmurality can be determined alongside accurate localization of infarct territory. Our 
study aimed to compare rates of new MI, using CMR LGE imaging before and 6 months following 
TAVI and SAVR.  
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Figure 4-1  Mechanisms of myocardial injury following TAVI and SAVR 
Potential mechanisms for myocardial injury following TAVI and SAVR. All 
mechanisms of myocardial injury can lead to a cardiac biomarker release. Mechanisms 
which can lead to focal MI and can be assessed using LGE CMR are shown in red.  
4.3.   Methods specific to this chapter 
Between January 2009 and April 2014, 130 patients with severe AS undergoing either SAVR or TAVI 
with or without concomitant coronary artery bypass grafting at a single tertiary centre (Leeds General 
Infirmary, Leeds, UK) were prospectively recruited. The presence of significant CAD was determined 
by the occurrence of >50% stenosis by visual estimation in any major epicardial vessel (>2.5mm 
diameter) on a pre-procedural coronary angiogram. Angiographic data were acquired from the report 
of the clinician performing the angiogram. Patients unable to receive Gadolinium based contrast due to 
renal dysfunction (estimated glomerular filtration rate <30ml/min/1.73m2) were excluded from this 
study.  
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4.3.1.   CMR protocol 
Identical CMR scans were obtained on the same imaging platform at baseline (median 1 day pre-
procedure, interquartile range (IQR) 14 days) and at a median of 6 months (IQR 1 month) following 
aortic valve intervention using the same 1.5T scanner (Intera, Philips Healthcare, Best, Netherlands or 
Avanto, Siemens Medical Systems, Erlangen, Germany).   
4.3.2.   CMR analysis 
The location and transmural extent of LGE according to the 17-segment American Heart Association 
model was recorded.  Quantification of MI was performed using computer-assisted planimetry (cmr42, 
Circle Cardiovascular Imaging, Calgary, Alberta, Canada).  Pixels with image intensities of >2SD 
above the mean of image intensities in a remote myocardial region in the same image were considered 
to represent infarction.  Infarct mass was expressed in grams of tissue and as percentage of overall LV 
mass as determined by cine imaging.   The threshold of two standard deviations method was chosen 
due to evidence suggesting that this method is most closely linked with prognosis in chronic myocardial 
infarction [209].  
4.4.   Results 
4.4.1.   Patient demographic, procedural and clinical data 
130 patients were recruited into the study. 96 patients with severe AS undergoing either TAVI (n=57) 
or SAVR (n=39) completed both baseline and 6 month post-procedure CMR scans. Reasons for non-
completion of the CMR protocol were varied and are depicted in Figure 4-2. 
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Figure 4-2  Patient recruitment pathway 
TAVI: Transcatheter aortic valve implantation. SAVR: Surgical aortic valve replacement 
There was no significant difference between the recruited and analyzed study population in terms of 
age (p=0.204), length of stay (p=0.621), gender (p=0.459), indexed aortic valve area (p=0.556) or 
EuroSCORE II (p=0.210), indicating that our analyzed patients were representative of the larger 
population. No patients had a hospital admission with acute coronary syndrome or underwent any 
revascularisation procedure between hospital discharge and the 6 months follow up scan. Demographic, 
clinical, angiographic and echocardiographic data can be seen in Table 4-1. Patients in the SAVR group 
were younger, less symptomatic, with less co-morbidity and were at lower surgical risk than their TAVI 
counterparts. The SAVR group had less 3 vessel disease than those undergoing TAVI and were less 
likely to be taking beta-blockers or ACE inhibitors at the time of recruitment. 16 patients (41%) in the 
SAVR group underwent concurrent CABG.  The mean cross-clamp time and cardiopulmonary bypass 
time was 79±38min and 108±45min respectively. The majority of SAVR patients underwent 
113 
 
bioprosthetic (n=34, 87%) rather than mechanical (n=5, 13%) aortic valve replacement; with a mean 
valve size of 22±2mm.  
 
In the TAVI group, access was most commonly via the femoral route (n=49, 86%) with 5 (9%) 
procedures performed via the subclavian approach and one performed by each of direct aortic, apical 
and carotid arterial access routes. The majority of TAVI implants were Medtronic CoreValve (n=45, 
79%) with the remaining implants being Boston Lotus (n=11, 19%) and Medtronic Engager (n=1, 2%).  
 
Table 4-1  Baseline demographic, clinical, echocardiographic and angiographic characteristics 
 SAVR n=39 TAVI n= 57 P Value 
Age, years 72±7 80±7 <0.001 
Length of hospital stay, days 8.8±2.9 7.7±4.2 0.003 
Gender, male, n (%) 28 (72) 31 (54) 0.085 
Body surface area, m2 1.96±0.19 1.80±0.20 <0.001 
Body mass index, kg/m2 28.4±4.2 27.4±3.9 0.252 
NYHA classification 2.6±0.5 3.1±0.5 <0.001 
Echocardiographic parameters 
Indexed aortic valve area, cm2/m2 0.32±0.15 0.34±0.10 0.528 
Mean pressure drop, mmHg 46±11 50±15 0.328 
Clinical risk score 
Logistic EuroSCORE 5.58±2.79 19.93±13.50 <0.001 
EuroSCORE II 1.35±0.49 5.70±4.85 <0.001 
Angiographic data 
Any epicardial stenosis >50%, n (%) 16 (41) 34 (60) 0.121 
3 vessel disease, n (%) 2 (5) 15 (26) 0.008 
LAD stenosis >50% 11(28) 26 (46) 0.103 
LCx stenosis >50% 7 (18) 20 (35) 0.078 
RCA stenosis >50% 8 (21) 21 (37) 0.102 
Co-morbidity 
Hypertension 27 (69) 26 (46) 0.022 
Diabetes 7 (18) 13 (23) 0.565 
Hypercholesterolaemia 30 (77) 35 (61) 0.110 
Atrial fibrillation 5 (13) 15 (26) 0.110 
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Previous myocardial infarction 4 (10) 10 (18) 0.320 
Prior cardiac surgery 1 (3) 18 (32) <0.001 
Previous PCI 3 (8) 15 (26) 0.022 
Peripheral vascular disease 2 (5) 14 (25) 0.012 
Cerebrovascular disease 7 (18) 9 (16) 0.780 
Pulmonary hypertension 3 (8) 20 (35) 0.002 
Medication 
Beta-blocker 11 (28) 32 (56) 0.012 
ACE inhibitor 24 (62) 22 (39) 0.019 
Statin 22 (56) 43 (75) 0.072 
Data expressed as mean ± SD or number (%). SAVR: Surgical aortic valve replacement. TAVI: Trans-
catheter aortic valve replacement. NYHA: New York Heart Association. LAD: Left anterior descending 
artery. LCx: Left circumflex artery. RCA: Right coronary artery. PCI: Percutaneous coronary artery.  
ACE: Angiotensin converting enzyme. 
4.4.2.   Baseline late gadolinium enhancement imaging 
24 (42%) patients in the TAVI group had infarct pattern LGE at baseline with an average mass of 
14.2±10.4g or 10.0±7.9% of total LV mass. Of these only 7 (12%) had a clinical history of MI with a 
further 8 (14%), 13 (23%) and 10 (18%) having a history of percutaneous coronary intervention, CABG 
and atrial fibrillation respectively. 9 (23%) SAVR patients had infarct pattern LGE at baseline with a 
mean mass of 19.7±14.3g or 11.3±6.9% of total LV mass. Of these only 2 (5%) had a history of MI and 
a single (3%) patient had a history of atrial fibrillation. 
4.4.3.   New infarct rate following SAVR and TAVI 
The rate of new MI defined by LGE (LGE (+)) was greater in the SAVR group than the TAVI group 
(SAVR, n=10 (26%) vs. TAVI, n=3 (5%), p=0.004). Absolute mean infarct mass was similar between 
the two groups (SAVR 1.1g±0.6g vs. TAVI 2.0g±1.4g, p=0.395) as was infarct mass as a percentage of 
LV mass (SAVR 1.0±0.4% vs. TAVI 2.2±1.3%, p=0.268). Details of individual new infarct patients 
can be seen in Figure 4-3. Baseline and 6 month cardiac parameters according to LGE status are shown 
in Table 4-2. Two of the TAVI LGE (+) patients had pre-existing infarct pattern LGE on the baseline 
scan. In both these cases the pre-existing infarct was in the inferior (RCA) territory, with the new post-
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procedure infarcts occurring in the left anterior descending artery (AHA segments 1 and 7) and left 
circumflex artery (AHA segments 11 and 12) territories respectively. None of the SAVR LGE (+) 
patients had infarct pattern LGE on their baseline scans.   
 
 
Figure 4-3  New myocardial infarction according to procedure type 
New infarct mass expressed in absolute terms and as a percentage of left 
ventricular mass according to procedure type. The red dots represent individual 
patients and the blue dot represents the only clinically detected MI according to 
VARC criteria.  
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Table 4-2  Basic clinical, echocardiographic and CMR characteristics according to new LGE status 
 
SAVR LGE(+) 
n=10 (26%) 
SAVR LGE(–) 
n=29 (74%) 
P value 
TAVI LGE(+) 
n=3 (5%) 
TAVI LGE(–) 
n=54 (95%) 
P value 
Length of hospital stay, days 7.1±1.5 9.4 ± 3.0 0.047 14.7±11.6 7.5±3.3 0.059 
Male, n (%) 7 (70) 21 (72) 0.884 2 (67) 29 (54) 0.412 
Age, years 73.7±6.8 70.8±7.6 0.273 83.3±9.1 80.1±6.5 0.423 
NYHA Class 2.7±0.5 2.6±0.6 0.812 3.3±0.6 3.1±0.5 0.575 
EuroSCORE II 1.38±0.51 1.35±0.49 0.831 6.14±3.29 5.46±5.19 0.648 
Previous PCI, n (%) 1 (10) 2 (7) 0.751 2 (67) 13 (24) 0.103 
Echocardiographic parameters       
Indexed aortic valve area, cm2/m2 0.35±0.09 0.37±0.09 0.712 0.28±0.14 0.34±0.10 0.307 
Mean pressure drop, mmHg 50±9 45±11 0.120 50±14 51±14 0.978 
Baseline CMR findings       
LVMi , g/m2 76.4±21.4 73.4±23.7 0.815 64.8±6.6 76.4±21.9 0.483 
LVEDVi, ml/m2 90.5± 24.6 91.7±28.8 0.962 88.6±21.8 100.2±24.5 0.427 
LVESVi, ml/m2 34.7±13.3 41.2±25.5 0.862 33.4±14.3 47.2±22.9 0.274 
LVEF, % 62.2±7.0 57.9±12.3 0.692 63.1±7.8 54.5±12.4 0.361 
LA Voli, ml/m2 62.8±13.2 60.4±19.2 0.696 72.4±4.7 73.0±23.3 0.964 
6 m post-procedure CMR findings       
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LVMi, g/m2 62.4±17.0 56.8±14.4 0.446 48.5±5.1 60.2±17.0 0.203 
LVEDVi, ml/m2 82.6±9.1 78.8±17.7 0.579 76.6±28.9 91.6±21.2 0.243 
LVESVi, ml/m2 28.7±6.5 34.1±14.1 0.456 30.8±20.4 41.2±17.6 0.307 
LVEF, % 64.4±5.4 58.8±10.0 0.120 62.2±10.6 56.5±11.1 0.290 
LA Voli, ml/m2 63.2±11.4 55.4±17.5 0.224 63.6±5.5 67.3±24.0 0.794 
Data expressed as mean±SD unless otherwise stated. SAVR: surgical aortic valve replacement. LGE: Late gadolinium enhancement.  TAVI: Trans-
catheter aortic valve implantation. NYHA: New York Heart Association. PCI: Percutaneous coronary intervention. CMR: Cardiovascular Magnetic 
Resonance Imaging. LVMi: Indexed left ventricular mass. LVEDVi: Indexed left ventricular end diastolic volume. LVESVi: Indexed left ventricular end 
systolic volume. LVEF: Left ventricular ejection fraction. LAVoli: Indexed left atrial volume.  
118 
 
4.4.4.   TAVI 
There were 3 new infarcts in the TAVI population (Table 4-3); all 3 patients had significant pre-existing 
CAD, and all three patients were taking beta-blockers pre-procedure. One patient underwent 
simultaneous PCI during the TAVI procedure. Only one TAVI patient had a clinically detectable post-
procedural MI according to Valve Academic Research Consortium (VARC) criteria [107] (Figure 4-3 
& Figure 4-4). Change in LVEF according to new MI status was similar between groups (LGE (+) -
0.9±6.0 vs. LGE (-) 2.0±7.8%, p=0.420). Valve size (LGE (+) 27±4 vs. LGE (-) 28±2mm, p=0.933), 
procedure time (LGE (+) 135±23 vs. LGE (-) 161±51min, p=0.511), contrast dose (LGE (+) 126±51 
vs. LGE (-) 143±48ml, p=0.343), fluoroscopy time (LGE (+) 26±6 vs. LGE (-) 25±8min, p=0.454) or 
valvuloplasty rate (LGE (+) 100% vs. LGE (-) 91%, p=0.581) were not different according to LGE 
status.   
 
 
Figure 4-4  Example of new MI demonstrated using LGE CMR 
Panel A depicts a horizontal long axis late gadolinium enhancement image of the left 
ventricle prior to TAVI, the septal and lateral left ventricular walls are seen, with no 
evidence of scar, depicted by the uniform dark appearance of the myocardium. Panel B 
shows the same patient 6 months following TAVI with an area of trans-mural 
hyperenhancement (LGE) indicative of MI (red arrow). 
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Table 4-3  Characteristics of patients undergoing TAVI and SAVR with new MI on 6 month follow up CMR 
 Sex Age AF DM CAD  
>50% 
Valve type Grafts AHA 
segment 
Trans-murality 
of infarct 
Further information 
TAVI 1 M 82 N Y Y MCV - 1, 7 25-50% Severe LAD lesion not amenable to PCI 
TAVI  2 F 93 Y N Y MCV - 15 25-50% PCI to LCx at time of TAVI procedure 
TAVI  3 M 75 N N Y BL - 11,12 >75% 
(Figure 4-4) 
Clinical MI according to VARC criteria; chest pain post-
procedure with new lateral wall hypokinesis and Troponin I 
elevation of 26,548ng/L. Previous CABG with occluded LCx 
and patent SVG to OM on pre-TAVI angiography. 
 
 
SAVR 1 M 81 N N N Tissue N 5 25-50%  
SAVR 2 M 77 N N N Tissue N 17 >75%  
SAVR 3 M 75 N N N Tissue N 14 >75%  
SAVR 4 M 66 N N Y Tissue N 14 >75% Previous CABG with 3 x patent grafts at time of SAVR 
SAVR 5 M 70 N N N Tissue N 13 25-50% Previous PCI to LAD. Patent stent at time of SAVR 
SAVR 6 F 82 N N N Mechanical N 15 25-50%  
SAVR 7 M 79 N N N Tissue N 14 50-75%  
SAVR 8 F 77 N N N Tissue N 13 25-50%  
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AF: Atrial fibrillation. DM: Diabetes Mellitus. CAD: Coronary artery disease. AHA: American Heart Association. TAVI: Trans-catheter aortic valve implantation. MCV: 
Medtronic CoreValve. TF: Trans-femoral. LAD: Left anterior descending artery. PCI: Percutaneous coronary intervention. LCx: Left circumflex artery. BL: Boston Lotus. 
MI: Myocardial infarction. VARC: Valve Academic Research Consortium. CABG: Coronary artery bypass grafting. SVG: Saphenous vein graft. OM: Obtuse marginal. 
LIMA: Left internal mammary artery. SVG: Saphenous vein graft 
SAVR 9 F 62 N N N Tissue N 13 >75%  
SAVR 
10 
M 68 N Y Y Tissue Y 9 25-50% LIMA to LAD and SVG to OM at time of SAVR 
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4.4.5.   SAVR  
There were 10 new infarcts in the SAVR population, one of whom had significant CAD and was 
revascularised at the time of surgery. Individual SAVR patient characteristics of those with new 
LGE confirmed MI are shown in Table 4-3. None of the SAVR LGE (+) events were detected 
clinically. Patients undergoing CABG were less likely to have a new MI than those not requiring 
concurrent revascularisation (CABG 6% vs. no CABG 39%, p=0.021) There was no difference 
in change in LVEF according to new LGE status (LGE (+) 2.2±4.7% vs. LGE (-) 0.90±8.0%, 
p=0.437). Mean cardiopulmonary bypass time (LGE (+) 88.5±31.1 vs. LGE (-) 114.5±47.4min, 
p=0.112) and aortic cross clamp time (LGE (+) 66±25 vs. LGE (-) 84±42min, p=0.164) were 
similar. There was no difference in baseline AS severity (peak pressure drop LGE (+) 87±18 vs. 
LGE (-) 79±20mmHg, p=0.120), baseline LVEF (LGE (+) 62.2±7.0 vs. LGE (-) 57.9±12.3%, 
p=0.692) or beta-blocker use (LGE (+) n=3 (30%) vs. LGE (-) n=12 (41%), p=0.666) between 
the groups.  
4.5.   Discussion 
This study is the first to demonstrate comparative post-procedural MI rates following TAVI and 
contemporary SAVR using LGE CMR imaging. We have shown that TAVI was associated with 
a significantly lower rate of post-procedural MI than SAVR, despite the TAVI population being 
older with more co-morbidity. We have also demonstrated a low new MI rate in those undergoing 
TAVI with non-revascularised coronary artery disease, suggesting that TAVI may be safely 
performed in patients with significant CAD without prior percutaneous coronary intervention.  
4.5.1.   TAVI 
Despite high rates of non-revascularised CAD, the rate of new MI in the TAVI population was 
low. Out of 34 patients undergoing TAVI with non-revascularised CAD at the time of the TAVI 
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procedure, only 3 (9%) had new MI on 6 month follow up, one of which may have been a result 
of concomitant percutaneous revascularisation during the TAVI procedure rather than due to the 
TAVI procedure itself. This study suggests that the risk of MI being precipitated by periods of 
global hypotension during TAVI in the context of coronary stenosis is lower than previously 
thought. Our findings are consistent with other studies suggesting that coronary revascularisation 
pre-TAVI does not improve outcome.  For example, Rodes-Cabau et al [243] did not find any 
influence of the presence of prior CAD and pre-procedural revascularisation completeness on 
myocardial injury (defined using biomarker release) following TAVI. Masson et al [125] found 
that the presence of CAD or non-vascularised myocardium was not associated with an increased 
risk of adverse events. Although pre- and peri- TAVI revascularization does not appear to be 
warranted on the grounds of preventing myocardial damage, it may still be considered in patients 
whereby symptoms could be attributed to coronary stenoses rather than the aortic valve disease. 
In this case, and especially in the context of anginal symptoms, it may be that percutaneous 
coronary intervention results in relief of symptoms saving the patient (and the healthcare 
economy) the potential risk and cost of the more invasive TAVI procedure.  
 
Our new infarct rate of 5% in the TAVI arm was much lower than the 18% suggested by a similar 
sized study by Kim et al [117].  Their study included a large number of patients (43%) with a 
trans-apical access route and it is not clear from their methodology whether scar related to the 
trans-apical access site was included in their LGE quantification. Trans-apical TAVI is associated 
with a 2-4 times increased level of post-procedure troponin release compared with the trans-
femoral route [243] and apical LGE has been found to be almost universal on CMR imaging 
following trans-apical TAVI, with a mean mass of 2.8±1.6g [118]. The new infarct mass 
described by Kim et al [117] was almost double that observed in our study.  However, the post-
procedure scan was performed 7 days rather than 6 month post-procedure as in our study, which 
may account for some differences as mass of infarcted myocardium can be overestimated in the 
acute phase by CMR LGE imaging [115].  Kim et al [117] also reported a reduction in LVEF in 
those patients with new infarct pattern LGE.  This was not found in our study. The fact that a 
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1.8% loss of LV myocardium pertained to a 10% reduction in global LVEF in their study is 
surprising and suggests that the presence of new LGE was a surrogate marker for other adverse 
procedure-related factors. Our new infarct TAVI population did not show a significant difference 
in LVEF according to LGE status; this could simply reflect the small sample size, however, other 
studies have also failed to demonstrate a correlation between myocardial injury and ejection 
fraction [113, 247].  
 
Our low new infarct rate in the TAVI group is further corroborated by a recent study by Kahlert 
et al [110] which investigated 15 patients undergoing trans-femoral TAVI using a Doppler wire 
positioned in the left anterior descending artery for the entire TAVI procedure. They described 
micro-embolic coronary artery showers (High-intensity Transient Signals) at all stages of the 
procedure. On pre- and post-procedural CMR scanning, only one patient had a detectable MI, 
which was described as a tiny mid-myocardial area of LGE in the lateral wall. There was no 
correlation between the number of High-intensity Transient Signals and troponin release; 
however, there were positive correlations between post-procedural troponin elevation and the 
duration of rapid pacing and time to blood pressure recovery.  
 
As there were only 3 new infarcts in our TAVI group, mechanistic insights are difficult to derive. 
Histopathological specimens of embolic debris captured during TAVI suggest that the debris 
consists of a mixture between thrombotic material and aortic wall/valve debris [248] and therefore 
embolic or atherosclerotic plaque rupture at the time of the procedure are both plausible 
explanations. Emboli formed on the valve post-procedure (the greatest risk for this being the first 
few weeks post-operatively when the valve surface is yet to endothelialise) could also be 
implicated. Only one patient (2%) in the TAVI group had a clinically detected MI which fulfilled 
VARC criteria, with none in the SAVR group. This finding is in keeping with the low rates of 
clinically detected peri-procedural MI observed in the PARTNER study [86].   
4.5.2.   SAVR 
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To our knowledge the new infarct rate using CMR LGE following SAVR has not been previously 
investigated. Our new infarct rate of 26% is in keeping with the small study of 28 patients by Lim 
et al, who found a CMR LGE new infarct rate of 32% 6 months following CABG [249] and a 
small radionuclide study reporting an new infarction rate of 16% following SAVR [116].  Whilst 
the infarcts were small with no significant effect upon LVEF, our study is able to offer novel 
insights into the cause of new MI during SAVR. Only one of the SAVR LGE (+) patients had a 
mechanical valve.  Given the higher thrombogenicity of metal valves, it is plausible that improper 
anti-coagulation post-procedure was implicated in this case, however, the remaining 9 infarcts 
were in patients undergoing bioprosthetic valve implantation. Spasm of the left internal mammary 
artery graft has been postulated as a cause [250] but only 1 of 10 patients in the SAVR LGE (+) 
group underwent arterial grafting, ruling this out as an important mechanism. In fact, only 3 of 
the SAVR LGE (+) patients had pre-existing CAD, and those in the SAVR LGE (+) group were 
less likely to undergo concomitant CABG than those in the SAVR LGE (-) group, meaning that 
bystander coronary disease or the CABG procedure itself are unlikely to represent significant 
contributing factors. None of the patients in the SAVR LGE (+) group had atrial fibrillation, 
making an embolic (left atrial) source of infarction also unlikely. The systemic inflammation 
response syndrome (SIRS) is more common following SAVR than TAVI [251] and SIRS is 
associated with a 11-13% rate of myocardial injury [252]. Considering all these factors, embolism 
from valve debris at the time of valve excision, or embolism from the bioprosthetic valve leaflets 
at some point following surgery (in the context of the hypercoagulable state associated with SIRS 
[253]) may thus be the most plausible mechanism.  
 
In the SAVR group, all of the infarcts were small, with a mean overall mass of just over one gram. 
Perhaps it is not surprising, therefore, that those with new infarcts had no significant deterioration 
in LVEF compared with those without. Interestingly, and in agreement with the findings of Lim 
et al [249], there was no difference in aortic cross clamp time, cardiopulmonary bypass time or 
pre-procedure beta blocker rates between the two groups.   
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4.5.3.   Baseline late gadolinium enhancement 
The rates of pre-existing MI were high in both the TAVI and SAVR population, representing 
42% and 23% respectively. Many of those with evidence of pre-existing infarct pattern LGE had 
no clinical history of MI, despite the mean mass of infarct accounting for over 10% of myocardial 
mass. Kim et al [117] found an even higher pre-existing infarct rate of 66% in a group of patients 
undergoing TAVI, again with the majority of patients not having a clinical history of MI.  
4.5.4.   Anticoagulation strategy 
Unless there was another indication for warfarin at the time of discharge (such as atrial fibrillation 
or mechanical valve implantation), patients were discharged on aspirin and clopidogrel dual anti-
platelet (DAPT) regime in the case of TAVI and aspirin monotherapy in the case of SAVR. This 
is an inherent difference between the groups and could possibly account for the differing rates of 
MI observed. A study of over 400 patients undergoing tissue aortic valve replacement 
demonstrated clinically detected embolic (the majority comprising retinal or cerebral emboli) 
event rates of 12% following SAVR bioprosthesis implantation [254], with a quarter of those 
being on aspirin at the time of the event. The mechanism for the embolisation is not entirely 
established, but may be related to lack of endothelialistaion of the valve leaflets, which exposes 
the patient to an elevated risk in the early post-operative period, especially as there may be a 
hypercoagulable state at this time-point due to a systemic inflammatory response [253]. A study 
of the Carpentier-Edwards porcine valve following up patients on no anticoagulation over a 
period of 12 years reported a major neurological event in 5% patients, almost half of which 
occurred in the first 5 days of surgery [255].  A prospective comparison of warfarin against 
ticlopidine, suggested a lower rate of thromboembolism with ticlopidine (0.5% pt-year) compared 
with warfarin (3% pt-year) following SAVR, at the expense of higher bleeding rates [256]. The 
efficacy of a dual anti-platelet regime (DAPT) following bioprosthetic SAVR compared with 
aspirin monotherapy in the prevention of embolic events has never been tested. In a study of 135 
patients with a mechanical aortic valve receiving DAPT, a thrombosis rate of 2.5% per pt-year 
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was reported [257]. Interestingly in this study, 8 patients died from myocardial infarction, 
although whether this was a result of atherosclerotic plaque rupture and subsequent coronary 
artery thrombosis or embolism from the valve itself was not clear.   
Anti-coagulation strategies have been more thoroughly investigated following TAVI. Currently, 
empirical DAPT following TAVI is the norm. However, recent studies comparing DAPT with 
aspirin monotherapy challenge the need for this aggressive anti-platelet strategy. A recent meta-
analysis comparing the two treatment strategies has shown low rates of 30 day stroke (DAPT 
2.4% vs aspirin only 1.4%, p=0.56) and 30-day spontaneous MI (DAPT 0.3% vs aspirin 
monotherapy 0.8%, p=0.59) in both groups [258]. Findings at 6 months were similar.  The failure 
of these trials to show benefit of DAPT over aspirin alone mean that the differences in MI rates 
following TAVI and SAVR may not be adequately explained by the varied anticoagulation 
regimes. Indeed, our low new infarct rate at 6 month follow-up compared with higher rates on 
early CMR scans previously reported [114], suggests that late post-procedure valve embolism is 
unlikely to be a significant contributing factor. Only a head to head randomized control trial 
comparing aspirin and DAPT following SAVR and TAVI will help establish whether the post-
procedure anticoagulation strategy impacts on embolisation.  
It also warrants discussion that a numerically larger (but not statistically significantly different) 
number of patients in the TAVI arm had atrial fibrillation and hence were warfarinised at the time 
of discharge. It may be that that warfarin in this setting afforded better embolic protection and 
could have influenced the findings of the study.  
4.5.5.   Clinical context 
The impact of new infarct pattern LGE following aortic valve intervention is not yet known. 
Although it may be a benign condition, especially given the small percentage of myocardium 
affected, the presence of LGE following coronary revascularisation has been linked to reduced 
survival (26) and evidence of even a small amount of LGE (mean LV mass 1.4%) in patients 
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presenting with signs or symptoms of coronary artery disease has been associated with a >7-fold 
risk of major adverse events [259]. Further studies are required to explore whether the presence 
of LGE following aortic valve intervention is associated with an adverse outcome, and if this is 
found to be the case, strategies for improved myocardial protection at the time of surgery or 
reduced embolisation in the post-procedure phase should be developed.  
 
Biomarker release is almost ubiquitous following aortic valve intervention due to the global insult 
to the ventricle from a number of mechanisms (Figure 4-1). Barbash et al [113] found elevated 
troponin in 98% of 150 patients following TAVI.  The high sensitivity of the cardiac biomarkers 
impedes their ability to detect focal MI following valve intervention [247]. This combined with 
the fact that non-ischaemic ECG changes develop frequently following valve implantation due to 
trauma to the myocardial conduction system [111, 112], makes the detection of true peri-
procedural MI as suggested by the VARC definition [107] challenging. Thus our study 
demonstrates the potential clinical utility of CMR LGE in the diagnosis of peri-procedural MI. 
Our findings also serve to reassure operators that TAVI is not associated with high rates of MI, 
even in the context of non-revascularised CAD, and that the strategy of proceeding to TAVI 
without prior percutaneous revascularisation is unlikely to expose the patient to excessive risk. 
4.6.   Limitations 
As with all observational studies of SAVR and TAVI at the current time, the groups are not 
matched in terms of age, co-morbidity or surgical risk, due to the current selection criteria for 
TAVI implantation. The death rate 6 months following TAVI was double that of the SAVR 
population, which reflects the increased frailty of the TAVI population. Autopsy data were not 
available and therefore this may be a source of bias. The high post-procedural permanent 
pacemaker rate following TAVI is a common limitation to all CMR based TAVI studies [117]. 
Nonetheless, it is also a potential source of significant bias.  Our study did not include biomarker 
data, as it has been shown to have little relationship with myocardial infarction in the post-TAVI 
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and SAVR period, however, these data may have been helpful in delineating the timeline of the 
myocardial infarctions observed. Our follow up scan was at 6 months following the procedure, 
therefore it is difficult to be certain that the infarcts occurred at the time of the procedure and not 
in the 6 month follow-up, although none of our patients had an admission with acute coronary 
syndrome or underwent coronary revascularisation in the time between hospital discharge and 
follow up CMR.   
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Chapter 5:   Acute cardiac reverse remodelling following Trans-
Catheter Aortic Valve Implantation 
5.1.   Abstract 
Introduction: Despite the wealth of data demonstrating the positive effects on cardiac reverse 
remodelling at medium and long term follow up, the immediate effects of the reduction of 
afterload afforded by TAVI are yet to be comprehensively described using CMR imaging. Also, 
the link between myocardial fibrosis (MF) and acute LV mass regression is unknown.  
Methods: Fifty-seven patients with symptomatic severe AS undergoing TAVI underwent paired 
CMR scans prior to and 4 days post-procedure. LV mass, volume and function were measured. 
LGE imaging was performed to assess for the presence of and pattern of MF.  
Results: Fifty-three (95%) patients experienced an acute reduction in LV mass. LVMi regressed 
by 10.1±7.1% from 76±15.5 to 68.4±14.7g/m2 (p=<0.001). Those with no LGE experienced the 
most post-procedure mass regression (13.9±7.1%) compared to those with mid-wall/focal fibrosis 
pattern LGE (7.4±5.8%) and infarct pattern LGE (7.2±7.0%) (p=0.005). There was no overall 
change in LVEF (55.1±12.1 to 55.5±10.9%, p=0.867), however a significant improvement in 
LVEF was seen in those with abnormal (<55%, n=24 (42%) baseline LVEF (43.2±8.9 to 
46.7±10.5%, p=0.027). Longitudinal function also improved following TAVI in those with no 
fibrosis (9.68±1.99 to 11.17±2.77mm, p=0.046) whereas in those with mid-wall/focal fibrosis 
LGE (10.79±2.82 to 10.29±1.75mm, p=0.499) and infarct pattern LGE (10.69±3.78 to 
11.69±3.15, p=0.161) there was no change.  Baseline LVMi (p=0.005) and MF (p<0.001) were 
strong independent predictors of early LVMi regression.  
Conclusions: LV reverse remodelling occurs within the first week following TAVI, with 
significant LV mass regression in the total population and an improvement in LVEF in those with 
pre-existing LV impairment. Those without MF at baseline experience greater LV mass 
regression than those with fibrosis. 
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5.2.   Introduction 
Left ventricular hypertrophy is almost ubiquitous in severe aortic stenosis, reflecting myocardial 
adaptation to chronic elevation of afterload allowing normalisation of wall stress [9, 10]. At a 
cellular level, there is an increase in the number of sarcomeres and an increase in myocyte size. 
Increased LV mass is associated with reduced survival [260]. SAVR and more recently TAVI 
have been shown to lead to LV mass regression at medium and long term follow-up [167, 261]. 
Early mass regression following TAVI is associated with reduced hospitalisation [165] and the 
degree of regression of hypertrophy after aortic valve replacement is a positive prognostic 
indicator [164]. Despite the wealth of data demonstrating the positive effects on cardiac reverse 
remodelling at medium and long term follow-up, the acute effects of the reduction of afterload 
afforded by TAVI are yet to be comprehensively described using CMR imaging. From a 
physiological perspective, acute reduction in afterload is associated with a reduction in wall stress 
and left ventricular filling pressure and at a cellular level, myocyte shrinkage can be seen within 
the first week in animal models [168]. In view of this, the accurate nature of CMR LV mass 
quantification would be well placed to assess this response in humans and test the hypothesis of 
early mass regression following acute afterload reduction. The relationship between baseline 
myocardial fibrosis and LV reverse remodelling remains poorly understood [193, 262, 263].  The 
unique ability of CMR LGE imaging to assess for myocardial fibrosis may allow us to predict 
which patients are most likely to derive an immediate benefit from TAVI.  
 
The aim of this study was to describe the acute changes seen in left ventricular systolic 
performance, as well as changes in LV mass seen within the first week following TAVI and its 
link with myocardial fibrosis.  
5.3.   Methods specific to this chapter 
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Sixty-five patients with severe symptomatic aortic stenosis undergoing TAVI were enrolled 
between December 2012 and April 2015 at a single tertiary centre (Leeds General Infirmary, 
Leeds, UK).   
5.3.1.   TAVI Procedure 
Patients underwent Medtronic CoreValve or Evolut R (Medtronic Inc., Minneapolis, Minnesota) 
or Boston Lotus (Boston Scientific Corporation, Natick, MA) valve implantation. Trans-femoral 
was the default approach with other techniques (subclavian and direct aortic) chosen in the case 
of unsuitable femoral access. Descriptions of the devices and technical aspects of the procedure 
have been described elsewhere [85, 254-256]. Valve sizing was achieved by annulus 
measurements taken from gated cardiac computed tomography or 3D transoesophageal 
echocardiography. All procedures were performed by two experienced operators. Left ventricular 
end diastolic pressure (LVEDP) was measured invasively both at the beginning and at the end of 
the procedure.  A clinically significant reduction in LVEDP was defined as ≥5mmHg.  
5.3.2.   CMR Protocol and analysis 
CMR scans were performed on the same imaging platform (Philips Healthcare, Best, Netherlands) 
pre-procedure (median 1 day, IQR 0 days) and immediately post-procedure (median 4 days, IQR 
1 day), prior to hospital discharge. The pre-procedure scan included late gadolinium enhancement 
imaging as described in the general methods section. The immediate post-procedure scan protocol 
was a shortened protocol which was designed to acquire cardiac mass, volume, function and flow 
data at an acceptable scan length, given the fact that patients were in the early stages of recovery 
from a major intervention. Therefore immediately post-procedure, the scan protocol consisted of 
multi-slice, multi-phase cine imaging using a SSFP pulse sequence in the short axis (8mm 
thickness, 0 mm gap, 30 phases, matrix 192x192, typical field of view 340mm) to cover both 
ventricles, standard 2, 3 and 4 chamber SSFP cine images and through-plane velocity encoded 
phase contrast imaging planned just above the TAVI bioprosthesis valve cage (typical VENC 
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250cm/sec, retrospective gating, slice thickness 6mm, 40 phases). LGE imaging was not 
performed for the immediate post-procedure scan.  
5.3.3.   Statistical analysis 
As per the paper by Bellenger et al [189], 9 patients are required to detect a 10g change in LV 
mass using CMR with a power of 90% and p<0.05. In the same study, the number of patients 
required to detect a 3% change in LVEF was 15.  
5.4.   Results 
Of the recruited patients, 57 (88%) completed both pre-procedure and early post-procedure scan 
protocols. Reasons for non-completion of the study protocol included pacemaker implantation 
(n=3), peri-procedural death (n=2), poor image quality due to arrhythmia (n=1) and 
claustrophobia (n=2). The analysed study population did not differ from the drop-out population 
in terms of age (79±8 vs. 79±7yrs, p=0.916), baseline indexed aortic valve area (0.33±0.09 vs. 
0.34±0.09cm/m2, p=0.747) or EuroSCORE II (4.47±3.40 vs. 4.55±3.46%, p=0.891), indicating 
that the demographics of the analysed patients were representative of the larger population. Basic 
demographic, clinical and echocardiographic characteristics of the final study population can be 
seen in Table 5-1. Procedural characteristics can be seen in Table 5-2.  
Table 5-1  Basic demographic, clinical and echocardiographic characteristics 
 Analysed population (n=57) 
Age, years 79±8 
Length of stay, days 7.2±7.0 
Gender, male (%) 30 (53) 
NYHA classification 3.0±0.4 
Logistic EuroSCORE, % 18.4±11.3 
EuroSCORE II, % 4.6±3.5 
Body surface area, m2 1.84±0.23 
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Body mass index, kg/m2 27.9±4.80 
Atrial Fibrillation 11 (19) 
Diabetes Mellitus 9 (16) 
Hypertension 24 (42) 
Previous myocardial infarction 15 (26) 
Previous coronary artery bypass grafting 12 (21) 
Prior percutaneous coronary intervention 17 (30) 
Peripheral vascular disease 14 (25) 
Pulmonary hypertension 23 (40) 
Echocardiographic data 
Indexed aortic valve area, cm/m2 0.34±0.09 
Peak aortic valve velocity, m/sec 4.7±0.6 
Aortic valve mean pressure gradient, mmHg 51±13 
Peak aortic velocity >5m/sec 14 (25) 
Data are expressed as mean ±SD or number (%). NYHA: New York Heart association.  
Table 5-2  Procedural characteristics 
 Analysed population, n=57 
TAVI type  
Medtronic CoreValve 
Boston Lotus 
Medtronic Evolut-R 
26 (45.6) 
26 (45.6) 
5 (8.8) 
TAVI access route  
Femoral 
Subclavian 
Direct aortic 
Procedure details 
49 (86) 
7 (12) 
1 (2) 
Valve size, mm 27±3 
Procedure time, mins 171±120 
Contrast volume, mls 132±52 
Invasive haemodynamics  
Invasive aortic valve gradient pre-TAVI, mmHg 53±21 
Systolic blood pressure pre-TAVI, mmHg 133±23 
Diastolic blood pressure pre-TAVI, mmHg 50±9 
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Diastolic blood pressure post-TAVI, mmHg 52±10 
Data are expressed as mean±SD or number (%). TAVI: Trans-catheter aortic valve implantation. 
 
5.4.1.   Baseline CMR characteristics 
Baseline LVEF was 55.1±12.1% and mean indexed LV mass was 76.2±15.5g/m2 with an LV 
mass:LVEDV ratio of 0.80±0.15. There was no difference between baseline LVMi or LVEF 
according to severe (aortic peak velocity <5m/sec) or very severe (peak velocity >5m/sec) aortic 
stenosis (LVMi severe 74.9±14.8 vs. very severe 80.2±17.5g/m2, p=0.272, LVEF severe 54±13 
vs. very severe 57±8%, p=0.725).  LGE imaging was available for 53 patients. 4 (7%) patients 
did not receive a Gadolinium-based contrast agent due to pre-existing renal failure with an 
estimated glomerular filtration rate of <30ml/min/1.73m2.  14 patients (26%) had evidence of 
myocardial infarction pattern LGE, 19 patients (36%) had mid-wall/focal fibrosis pattern LGE 
and the remaining 20 (38%) had no evidence of LGE. Examples of the differing patterns of LGE 
can be seen in Figure 5-1.  
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Figure 5-1  Differing patterns of myocardial fibrosis 
LV short axis CMR images demonstrating the different patterns of LGE. Panel A. 
The LV myocardium appears black with no evidence of LGE. Panel B: The red arrow 
depicts focal fibrosis at the anterior right ventricular insertion point. Panel C: A 
typical mid wall LGE pattern (red arrow). Panel D: Infarction pattern LGE, with the 
red arrow demonstrating an anterior myocardial infarction of around 50% trans-
murality.   LV: Left ventricle. RV: Right ventricle.  
Those with no fibrosis at baseline had a lower pre-procedure LVEDP (18±5mmHg) than those 
with infarct pattern LGE (21±8mmHg) and mid wall/focal fibrosis LGE (24±8mmHg), one-way 
ANOVA (F=3.249, p=0.047) but there was no significant difference between the different 
fibrosis groups in terms of baseline LVMi (no LGE 74.3±15.7, mid-wall/focal fibrosis LGE 
77.6±55.8, infarct pattern LGE 73.1±13.7g/m2, F=0.390, p=0.679) or baseline LVEF (no LGE 
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57.8±10.7, mid-wall/focal fibrosis LGE  55.8±14.5, infarct pattern LGE 51.3±10.6%,  F=1.162, 
p=0.321). 
5.4.2.   Invasive pressure measurements 
There was a moderate positive correlation between baseline LVMi and pre-implant LVEDP 
(r=0.367, p=0.005) (Figure 5-2), but no relationship between pre-implant LVEDP and LVEF (r=-
0.067, p=0.619) or AVAi (r=0.002, p=0.986). TAVI was associated with a minorreduction in 
LVEDP from 21±8mmHg at the start of the procedure to 19±6mmHg following device 
deployment (p=0.009). Those with a clinically significant reduction in LVEDP (defined 
as >5mmHg) had a greater baseline LVMi (LVEDP reduction 85.6±14.1 vs. no LVEDP reduction 
72.2±14.5g/m2, p=0.002) and had a significant reduction in LV cavity size (LVEDVi) post-
procedure (LVEDP reduction: 8.7±16.0 vs. no LVEDP reduction 0.24±11.4ml/m2, p=0.028) 
compared to those without a reduction in LV filling pressure. There was no relationship between 
post-procedure LVEDP and post-procedure aortic regurgitation fraction (r=0.186, p=0.173).  
 
Figure 5-2  Relationship between baseline LVMi and LVEDP 
Scatterplot demonstrating the relationship between baseline indexed left ventricular 
mass (LVMi) and pre-procedure left ventricular end diastolic pressure (LVEDP).  
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5.4.3.   Post-procedure CMR 
CMR derived values pre and early post-procedure can be seen in Table 5-3. 
 
 
 
 
 
 
 
 
Table 5-3  Pre and post-procedure CMR characteristics 
 Pre-procedure 
N=57 
Post-procedure 
N=57 
P Value 
Mitral annular displacement, mm 10.3±2.8 11.0±2.6 0.134 
LVEDVi, ml/m2 97.8±24.3 95.1±18.9 0.226 
LVESVi, ml/m2 45.7±22.6 43.6±18.3 0.268 
LVSVi, ml/m2 52.1±11.0 51.2±9.1 0.454 
LVEF, % 55.1±12.1 55.5±10.9 0.867 
LVMi, g/m2 76.2±15.5 68.4±14.7 <0.001 
LV mass/LVEDV 0.76±0.15 0.73±0.15 <0.001 
Indexed left atrial volume, ml/m2 75.4±24.7 70.4±23.1 0.042 
Max pressure gradient, mmHg 44±15 18±9 <0.001 
Aortic regurgitation fraction, % 12.3±9.4 7.6±6.5 0.005 
Data are expressed as mean±SD. LVEDVi: Indexed left ventricular end diastolic volume. 
LVESVi: Indexed left ventricular end systolic volume. LVSVi: Indexed left ventricular stroke 
volume. LVEF: Left ventricular ejection fraction. LVMi: Indexed left ventricular mass. 
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Fifty-three (95%) patients experienced an acute reduction in LV mass. Indexed LV mass 
regressed by 10.1±7.1% from 76±15.5 to 68.4±14.7g/m2 (p=<0.001).  Those in the highest 
quartile of baseline LVMi had more absolute LVMi regression than those in the lowest quartile 
(10.5±5.8 vs. 6.4±1.3g/m2, p=0.045). LV mass regression did not differ according to sex (men 
7.8±5.4 vs. women 7.7±6.0g/m2, p=0.980) or classification of aortic stenosis (severe 8.0±5.7 vs 
very severe 7.0±5.5g/m2, p=0.556). Baseline AVAi (r=0.126, p=0.348), post-procedural aortic 
regurgitation (r=-0.136, p=0.321), post-procedural valve gradient (r=-0.005, p=0.969), or systolic 
blood pressure (r=-0.041, p=0.767) did not appear to be associated with LV mass regression.  
Patients with a history of hypertension (n=24 (42%)) experienced more LV mass regression than 
those with no hypertension (9.6±5.1 vs. 6.4±5.8g/m2, p=0.038).  9 (16%) patients had significant 
post-procedure aortic regurgitation (defined as an AR fraction >16% [235]).  There was a trend 
towards greater LVMi regression in those without significant post-procedural aortic regurgitation 
(LVMi regression significant AR 4.5±5.4 vs. no significant AR 8.5±5.6g/m2, p=0.051).  
 
There was no overall change in LVEF (Table 5-3), however, when split according to baseline 
LVEF, classified as normal (baseline LVEF>55%, n=33 (58%)) and abnormal (baseline 
LVEF<55%, n=24 (42%)), a significant improvement in LVEF was seen in those with an 
abnormal baseline LVEF (43.2±8.9 to 46.7±10.5%, p=0.027), mainly driven by an increase in 
LVESVi (Figure 5-3).  
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Figure 5-3 Bar graphs showing reverse remodelling according to baseline LVEF 
Bar graphs depicting change in LVEF, LVEDVi and LVESVi according to baseline LVEF pre and post-TAVI. The error bars depict the 95% 
Confidence Intervals. LVEF: Left ventricular ejection fraction. LVEDVi: Indexed left ventricular end diastolic volume. LVESVi: Left ventricular 
end systolic volume. TAVI: Trans-catheter aortic valve implantation.  
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5.4.4.   Late gadolinium enhancement 
Those with no LGE at baseline experienced the most post-procedure LV mass regression 
(13.9±7.1%) compared to those with mid-wall/focal fibrosis pattern LGE (7.4±5.8%) and infarct 
pattern LGE (7.2±7.0%) (One-way ANOVA p=0.005).  A Tukey post-hoc test revealed that there 
was a statistically significant difference between those with no fibrosis and mid-wall/focal 
fibrosis (p=0.011) and the no fibrosis and infarct pattern groups (p=0.017) but no difference in 
terms of mass regression between those with mid-wall/focal fibrosis and infarct pattern LGE 
(p=0.997). Longitudinal function also improved following TAVI in those with no fibrosis 
(9.68±1.99 to 11.17±2.77mm, p=0.046) whereas in those with mid-wall/focal fibrosis LGE 
(10.79±2.82 to 10.29±1.75mm, p=0.499) and infarct pattern LGE (10.69±3.78 to 11.69±3.15, 
p=0.161) there was no change.   
5.4.5.   Predictors of LV mass regression  
Variables including patient demographics, relevant clinical history, procedural characteristics and 
baseline cardiac measurements were analysed to determine univariable predictors of reverse 
remodelling (Table 5-4). Multivariable regression analysis revealed only baseline LVMi and the 
presence of LGE to be independent predictors of early LV mass regression.  
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Table 5-4  Univariable and multivariable regression analysis 
  Unstandardised 
coefficient 
 Standard 
Error 
P Value 95% CI 
Univariable analysis – change in LVMi (g/m2) 
Baseline LVMi (g/m2) 0.119 0.047 0.014 0.025 to 0.212 
Gender -0.037 1.514 0.980 -3.072 to 2.997 
Age (y) 0.032 0.097 0.747 -0.163 to 0.227 
Hypertension 3.126 1.472 0.038 0.176 to 6.076 
AVAi (cm/m2) 7.968 8.426 0.348 -8.919 to 24.855 
SBP (mmHg) -0.010 0.033 0.767 -0.077 to 0.057 
Reduction in LVEDP >5mmHg 1.740 1.609 0.284 -4.965 to 1.485 
TAVI size (mm) 0.418 0.287 0.151 -0.158 to 0.993 
Presence of fibrosis -5.042 1.467 0.001  -7.987 to -2.097 
Type of fibrosis 2.562 0.847 0.004 0.860 to 4.263 
Post-procedural AR (%) -0.120 0.120 0.321 -0.360 to 0.120 
Post-procedural aortic  valve 
gradient (mmHg) 
-0.004 0.091 0.969 -0.186 to 0.179 
Multivariable regression analysis – change in LVMi (g/m2) 
Baseline LVMi 0.126 0.043 0.005 0.040 to 0.212 
Presence of fibrosis -5.190 1.362 <0.001  -7.926 to -2.454 
LVMi: Indexed left ventricular mass. AVAi: Indexed aortic valve area. SBP: Systolic blood 
pressure. LVEDP: Left ventricular end diastolic pressure. TAVI: Transcatheter aortic valve 
implantation. AR: Aortic regurgitation. 
5.5.   Discussion 
This study is the first using CMR, the reference standard technique for LV volume and mass 
quantification, to comprehensively describe the acute changes in left ventricular mass and 
function within the first week after TAVI and its relationship to myocardial fibrosis. We have 
shown that LV reverse remodelling begins very early, with around 10% of LV mass regression 
occurring within the first week and LVEF improving in those with a reduced baseline ejection 
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fraction. Furthermore, we have demonstrated that those without fibrosis at baseline experience 
more early LV mass regression and an improvement in longitudinal left ventricular function. 
5.5.1.   Remodelling in aortic stenosis and acute reverse remodelling following TAVI  
Our baseline characteristics were similar to other TAVI-based studies, representing a population 
with high levels of co-morbidity at elevated surgical risk [264].  Our patients were elderly with 
an equal gender split in keeping with other studies of patients undergoing TAVI, reported by both 
our group and elsewhere [167, 169]. Our rates of baseline mid-wall/focal and infarct fibrosis are 
congruent with those reported in other centres. Dweck et al [49] reported rates of mid-wall/focal 
fibrosis in 38% of patients and infarct pattern LGE in 28% of patients with moderate or severe 
aortic stenosis. Weidemann et al reported rates of fibrosis in 62% of patients undergoing aortic 
valve replacement for aortic stenosis [193]. In our population, there was no association between 
baseline LVMi and presence or type of fibrosis in keeping with Weidemann’s study, although 
differing from the results of Dweck et al [49] who found that those with mid-wall fibrosis had an 
elevated LV mass at baseline. In our study, those with fibrosis had a higher pre-implant LVEDP, 
suggesting that those with fibrosis may have more severe disease at baseline, with a stiffer, less 
compliant left ventricle leading to elevated filling pressures. In our patient population there was 
no overall acute change in LVEF which is in keeping with other CMR studies [173], however, 
those with a reduced baseline LVEF did derive a significant improvement, suggesting that acute 
afterload reduction does have a favourable effect on LVEF in those with an abnormality at 
baseline.  
This study offers further insight into the timeline of LV mass regression following TAVI for 
aortic stenosis. It is well described in the literature that most mass regression occurs within the 
first 6 months of TAVI, with mass regression rates of 18-22% reported [167, 169]  and a slower 
rate of regression thereafter [261]. In this study we have been able to show that favourable reverse 
remodelling occurs almost immediately, with around 10% of mass regression occurring within 
the first week post-TAVI.  Similar findings been suggested by echo studies following TAVI [165] 
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and SAVR [26, 265] and early LV mass regression following TAVI has been associated with 
reduced hospitalisation [165]. An echocardiographic sub-study of the PARTNER A trial 
comparing surgical and trans-catheter aortic valve replacement in high risk patients with aortic 
stenosis and severe baseline LV hypertrophy, reported mass regression of 17% at one year 
following TAVI, with around half of this occurring within the first 30 days [165].  Christakis et 
al investigated 57 patients before and 5 days following surgical aortic valve replacement, and 
reported very similar results with a mean LV mass reduction of 10% [265].  
Assessment of LV mass by echocardiography is calculated on the basis of a number of anatomical 
and mathematical assumptions, potentially reducing accuracy that may be compounded by the 
higher inter-operator variability rendering them relatively inaccurate [266]. Due to the excellent 
endocardial definition and the 3D nature of the technique,  LV mass quantification using modern 
CMR SSFP pulse sequences are highly correlated with autopsy studies (r=0.95) [267] and 
therefore can give an acute assessment of LV mass pre- and post-TAVI. CMR LV mass 
quantitation is also more reproducible than by echo, as evidenced by the low inter and intra-
observer variability reported in this study and in others [268] allowing smaller sample sizes to 
detect a treatment effect.  
The mechanism for acute LV mass reduction remains poorly understood. A number of 
mechanisms are possible; it is conceivable that the decreased afterload leads to an acute reduction 
in myocyte stretch and hence a decrease in myocyte diameter and volume. Other mechanisms 
may relate to a reduction in oedema or an overall reduction in extra-cellular volume.  Evidence 
from animal models support the notion that LV mass regression occurs acutely; a regression in 
myocyte volume and myocyte cross sectional area has been demonstrated in hypertensive rats 
one week following the initiation of anti-hypertensive treatment [168], and novel CMR 
techniques using tissue characterisation have been developed to investigate cardiomyocyte size 
in murine models of hypertension.  If this is successfully translated into humans, it may allow 
144 
 
future investigation into the pathogenesis of the mass regression, discriminating between an acute 
reduction in myocyte size or a reduction in extracellular volume [269].   
5.5.2.   Myocardial fibrosis 
Myocardial fibrosis manifests as a result of myocyte apoptosis and subsequent replacement 
fibrosis and expansion of the extra-cellular volume [52]. It is a well-defined phenomenon in 
patients with severe AS [193] although the pathogenesis of the myocyte death remains unclear. 
Potential mechanisms include sub-endocardial ischaemia as a result of chronic supply demand 
mis-match in the context of LVH [270], myocardial stretch as a result of increased systolic wall 
stress [271] and angiotensin II mediated cell damage [272].  Myocardial fibrosis is important; it 
has been found to be an adverse prognostic marker in patients with aortic stenosis, with a 6-8x 
risk of mortality, incremental to that of baseline LVEF [49]. Postulated mechanisms of this excess 
in mortality include fibrosis associated arrhythmogenicity and adverse ventricular remodelling. 
Our study provides further insights into the mechanism of excess mortality. Although LV mass 
regression was seen in all 3 groups of patients, those without fibrosis at baseline had more acute 
LV mass regression than those with both focal/mid wall fibrosis and infarct pattern fibrosis. This 
favourable LV mass regression in those without fibrosis may allow a mechanistic explanation for 
the survival advantage seen by Dweck et al [49].  The lack of relationship between myocardial 
fibrosis and LVEF is perhaps not surprising, as LVEF is derived predominantly from radial 
contraction, which is not significantly contributed to by the sub-endocardial layers. Sub-
endocardial fibres are the most sensitive to myocardial ischaemia (resulting from supply-demand 
mismatch) and systolic wall stress [273] and are responsible for longitudinal function [274]. This 
is therefore a plausible explanation for the improvement in longitudinal function seen in our group 
with no fibrosis and the lack of improvement in longitudinal function in both the mid-wall/focal 
and infarct pattern fibrosis groups.  
5.6.   Limitations 
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As with many studies investigating ‘real world’ patients, our study population included a 
heterogeneous patient mix including those with and without coronary artery disease and differing 
baseline LVEF, which may have influenced the results. Although the dropout rate was low for a 
CMR based study and the recruited population did not appear to differ from the analysed 
population, there is still the potential for bias.  Although we were careful to include all possible 
factors in the study that may have influenced LV reverse remodelling, there may have been other 
factors involved. Specifically, no echocardiographic data regarding post-procedure valve 
gradients was acquired as a part of this study. However, we were able to report CMR derived 
values for post-procedural valve gradient and did not find this to be a predictor of LV mass 
regression on univariate analysis. CMR derived flow gradients are less accurate than 
echocardiographically derived Doppler gradients and therefore an in-depth analysis of any 
influence of patient-prosthesis mismatch was not possible. This study was not designed as an 
outcome study, nonetheless, demonstrating a link between acute LV reverse remodelling and 
mortality would strengthen these data.  
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Chapter 6:   The impact of trans-catheter aortic valve implantation 
induced left bundle branch block on cardiac reverse remodelling  
6.1.   Abstract 
Background: Left bundle branch block is common following TAVI and has been linked to 
increased mortality, although whether this is due to less favourable cardiac reverse remodelling 
is unclear. Using CMR prior to and 6 months following TAVI and a carefully matched patient 
population, we investigated the impact of TAVI-induced LBBB on cardiac reverse remodelling.  
Methods: 48 patients undergoing TAVI for severe aortic stenosis were evaluated. 24 patients 
with new LBBB (LBBB-T) following TAVI were matched with 24 patients with a narrow post-
procedure QRS (nQRS). Patients underwent CMR imaging prior to and 6 months post-TAVI. 
Measured cardiac reverse remodelling parameters included LV size, LVEF and global 
longitudinal strain (GLS). Inter- and intra-ventricular dyssynchrony was determined using time 
to peak radial strain derived from CMR Feature Tracking. 
Results: Change in LVESVi, LVEF and GLS was significantly different between the two groups 
(LVESVi: nQRS -7.9±14.0 vs. LBBB-T -0.6±10.2ml/m2, p=0.020, LVEF: nQRS +4.6±7.8 vs 
LBBB-T -2.1±6.9%, p=0.002; GLS: nQRS -2.1±3.6 vs. LBBB-T +0.2±3.2%, p=0.024).  The 
nQRS group had a significant improvement in LVEF (54.1±11.5 to 58.7±9.0%, p=0.010) and 
GLS (15.6±3.9 to 17.7±2.7, p=0.010) at follow-up. There was significant post-procedure inter- 
and intra-ventricular dyssynchrony in the LBBB-T group (inter: LBBB-T 130±73ms vs. nQRS 
23±86ms, p=<0.001; intra: LBBB-T 118±103ms vs. nQRS 13±106ms, p= 0.001). Post-procedure 
QRS duration was an independent predictor of change in LVEF and GLS at 6 months.  
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Conclusion: TAVI-induced LBBB is associated with less favourable cardiac reverse remodelling 
at medium term follow-up. In view of this, every effort should be made to prevent TAVI-induced 
LBBB, especially as TAVI is now being extended to a younger, lower risk population. 
6.2.   Introduction 
The aortic valve lies close to the electrical conduction system of the heart and is prone to damage 
at the time of aortic valve intervention, often manifesting as new left-bundle branch block. New 
LBBB is infrequent following SAVR [127], but much more common following TAVI with 
reported rates of up to 65%, depending on valve design [128]. TAVI-induced left-bundle branch 
block (LBBB-T) has been linked to reduced survival [152-155] and increased hospitalisation 
[112], in keeping with population based studies suggesting reduced overall survival in healthy 
individuals with LBBB [156] and in patients with heart failure and LBBB [157]. The mechanism 
for this increased mortality is debated.  One hypothesis is that LBBB-T is a precursor to further 
more lethal conduction abnormalities, suggested by studies reporting high levels of 
atrioventricular block on those receiving post-TAVI permanent pacemaker insertion [158]. 
Another hypothesis is that LBBB-T leads to adverse LV remodelling and ultimately heart failure 
death via a LBBB-induced cardiomyopathy [160]. Even in normal hearts it is recognised that the 
mechanical dyssynchrony of LBBB results in an increase in left ventricular end systolic volume, 
a reduction in stroke volume and a reduction in LVEF, leading some to believe that it is the LBBB 
itself that provokes cardiomyopathy in a certain sub-set of patients rather than an intrinsic 
cardiomyopathic process triggering the LBBB [275]. Over the long term, a similar mechanism 
may exist in patients with TAVI-induced LBBB.  
 
Current evidence on the impact of LBBB-T on cardiac reverse remodelling is limited to 
echocardiographic studies, with a heterogeneous patient mix including those with post-procedural 
permanent pacemaker implantation, trans-apical access route and unmatched patient groups [160, 
184, 276], all of which are potential confounders in the reverse remodelling process. The impact 
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of LBBB-T on cardiac reverse remodelling has never been investigated using CMR imaging. 
Furthermore, the novel technique of CMR feature tracking allows accurate estimation of global 
longitudinal strain and inter- and intraventricular dyssynchrony which are of interest in this 
population [277]. 
6.3.   Methods specific to this chapter 
6.3.1.   Patient selection 
90 patients undergoing either Boston Lotus or Medtronic CoreValve TAVI for severe 
symptomatic aortic stenosis were recruited at a single tertiary centre from April 2009 to April 
2015. Exclusion criterion included pre-existing QRS prolongation (>120ms), pre-TAVI 
pacemaker implantation or contra-indication to CMR scanning.  Patients were excluded from the 
analysis in the case of new right bundle branch block, post-procedural myocardial infarction and 
post-procedural permanent pacemaker implantation.  
6.3.2.   Matching 
24 patients with LBBB-T were identified. These were matched with 24 patients with a narrow 
post-procedure QRS for sex, valve type, and CMR variables known to impact on reverse 
remodelling following TAVI including baseline LVEF, baseline LVMi and baseline LVEDVi. 
The results of Chapter 3 (gender differences) suggested that it was the baseline variable which 
most strongly predicts the change in that variable following valve replacement, therefore by 
matching for baseline CMR variables, the true effect of the QRS prolongation could be 
determined by reducing as many of the confounding factors as possible. The sample size did not 
permit true propensity matching, however, patients were matched on a case by case basis so that 
were of the same valve type and sex, and that each baseline variable was within 10% of the nQRS 
patient that they were matched with.  
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6.3.3.   Electrocardiographic data 
12-lead electrocardiogram recordings, acquired immediately prior to TAVI and at the time of 
post-procedure, hospital discharge were reviewed by a reader (OJB) blinded to clinical and 
procedural data. Heart rhythm, PR interval and QRS duration were recorded. LBBB-T was 
defined as post-procedural v1-negative QRS complex with a duration of >120ms and a notched 
or slurred R wave in at least one of the lateral leads according to international guidelines (I, aVL, 
V5, V6) [278]. 
6.3.4.   CMR protocol 
Details of the CMR pulse sequence acquisition protocol are outlined in the Methods chapter. 
Briefly, identical CMR scans were obtained at baseline (median 1 day pre-procedure, IQR 1) and 
at a median of 181 days (IQR 20 days) following TAVI using a 1.5T scanner (Intera, Philips 
Healthcare, Best, Netherlands or Avanto, Siemens Medical Systems, Erlangen, Germany).  
6.3.5.   CMR analysis 
CMR analysis was performed by a single operator (LED) with 5 years’ experience in CMR, 
blinded to clinical data using dedicated computer software (cmr42, Circle Cardiovascular Imaging 
Inc, Calgary, Alberta, Canada). Feature tracking analysis was performed on cine imaging of the 
mid ventricular short axis slice at the papillary muscle level to determine time to peak LV and 
right ventricular radial strain and the 4 chamber cine to measure global longitudinal strain as 
previously described [279]. Endo- and epicardial LV borders were manually drawn and a 
reference point was established to mark the inferior and anterior right ventricular insertion point. 
Borders were also traced around the right ventricle in short axis to generate time to peak radial 
strain values for the right ventricular free wall. The level of the mitral valve was demarcated and 
the left ventricular apex highlighted to allow longitudinal segmentation of the ventricle. Strain 
and strain rate curves were then generated for both longitudinal and radial strain parameters. If 
these were of sub-optimal quality, the endo- and epicardial contours were manually adjusted to 
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allow accurate tracking of the endocardial border.  LV global longitudinal strain was calculated 
form the 4 chamber cine image. Time to peak strain was generated from the short axis mid 
ventricular cine slice. Interventricular dyssynchrony was calculated as the difference between 
time to peak radial strain of the right ventricular free wall and the lateral LV wall (an average of 
segments 11 and 12 of the American Heart Association 17 segment model). Intraventricular 
dyssynchrony was calculated as the difference between time to peak radial strain of the LV septal 
(an average of AHA segments 8 and 9) and LV segments (an average of AHA segments 11 and 
12), as recommended by Gorksan et al [280]. Segments with LGE suggestive of previous 
myocardial infarction were excluded from strain analysis.  Direct comparison of LGE images pre 
and post-procedure scans was performed by a single operator blinded to clinical and procedural 
data to determine the presence of new myocardial infarction.  
6.3.6.   Statistical analysis 
Linear regression analysis (Enter model) was performed to establish univariate and multivariate 
predictors of change in LVEF and GLS post-procedure. Univariate predictors with P<0.1 were 
included in the multivariate analysis. According to the paper by Bellenger et al[183], 15 patients 
are required to detect a 3% change in LVEF with a power of 90% and an α error of 0.05 using 
1.5T cine imaging.  From the paper by Singh et al[180], a sample size of 14 is required to detect 
a 10% difference in global longitudinal strain with a 90% power and an α error of 0.05 using 1.5T 
SSFP cine imaging.  
6.4.   Results 
90 Patients were recruited into the study. Patients undergoing post-procedure permanent 
pacemaker implantation (n=12), those with post-procedure right bundle branch block (n=2) and 
those with CMR LGE evidence of post-procedural myocardial infarction (n=3) were excluded 
from analysis. In addition, 3 patients died within the 6 month follow-up period and 5 patients 
declined follow-up. 24 patients with LBBB-T and 41 patients with a narrow QRS (nQRS) on 
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discharge electrocardiogram completed both baseline and 6 month scans and were available for 
retrospective matching in a 1:1 fashion for variables known to effect reverse remodelling 
following TAVI including sex, valve type, baseline LVEF, baseline LVMi and baseline LVEDVi. 
48 patients were included in the final analysis, 24 with LBBB-T and 24 with nQRS. Demographic, 
clinical, procedural and baseline CMR details for each group can be seen in Table 6-1. 14 (29%) 
patients underwent Lotus valve and 34 (71%) patients underwent Medtronic CoreValve 
implantation. Balloon valvuloplasty was performed in 43 (90%) patients. Mean valve size was 
28±2mm, procedure time 164±52 mins and contrast dose 153±61ml. Access approach was 
femoral in 43 (90%) patients, subclavian in 4 (8%) patients and carotid in one patient. 
 
Table 6-1  Demographic, clinical and baseline CMR details of the nQRS and LBBB-T 
groups 
 nQRS (n=24) LBBB-T (n=24) P value 
Demographic details  
Age, years 80.5±6.2 79.6±9.6 0.670 
Gender, male 13 (54) 13 (54) 1 
Body surface area, m2 1.82±0.29 1.86±0.19 0.332 
Clinical details 
STS Mortality, % 4.5±2.4 5.1±2.8 0.397 
STS Morbidity/mortality, % 21.7±7.5 24.5±8.8 0.452 
Systolic blood pressure, mmHg 134±25.9 138±18 0.558 
Atrial fibrillation 2 (8.3) 5 (20.8) 0.220 
Hypertension 12 (57.1) 9 (37.5) 0.383 
Cerebrovascular disease 4 (16.7) 4 (16.7) 1 
Previous myocardial infarction 5 (20.8) 2 (8.3) 0.220 
Chronic obstructive pulmonary disease 6 (25) 5 (20.8) 0.731 
Peripheral vascular disease 6 (25) 7 (29.2) 0.745 
Diabetes mellitus 4 (16.7) 8 (33.3) 0.182 
Any epicardial coronary stenosis >50% 9 (37.5) 13 (54.2) 0.247 
Pre-procedure CMR characteristics 
Baseline LVEF, % 54.1±11.5 56.6±10.5 0.386 
Baseline GLS, % -15.6±3.9 -16.1±4.2 0.638 
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Baseline Indexed left ventricular mass, 
g/m2 
74.3±14.7 73.3±17.4 0.650 
Baseline LVEDVi, ml/m2 97.8±22.8 93.4±22.1 0.500 
Baseline aortic regurgitation fraction, % 9.6±8.7 10.7±5.9 0.444 
Infarct pattern LGE 6 (26) 4 (18) 0.391 
Data are expressed as mean±SD or number (%). STS: Society of Thoracic Surgeons. CMR: 
Cardiovascular magnetic resonance. LVEF: Left ventricular ejection fraction. GLS: Global 
Longitudinal Strain. LVEDVi: Indexed left ventricular end diastolic volume. LGE: Late 
gadolinium enhancement. 
6.4.1.   Electrocardiographic Characteristics 
Mean heart rate at baseline was 67±11bpm and at 6 months was 68±13bpm. 7 patients (15%) 
(nQRS n=2, LBBB-T n=5) had atrial fibrillation at baseline. There were no new cases of post-
procedural AF. For those in sinus rhythm, mean PR interval remained similar pre and post 
procedure in both the nQRS group (179±33 to 191±39ms, p=0.053) and the LBBB-T group 
(181±30 to 192±37ms, p=0.171). In the nQRS group there was no change in QRS duration (93±17 
to 96±11ms, p=0.098). In the LBBB-T group, QRS duration increased from 96±14 to 151±12ms 
(p=<0.001).  
6.4.2.   Reverse remodelling according to post-procedure QRS duration 
Change in LVEF and GLS was significantly different between the two groups (LVEF: nQRS 
+4.6±7.8 vs LBBB-T -2.1±6.9%, p=0.002 and GLS: nQRS -2.1±3.6 vs. LBBB-T +0.2±3.2%, 
p=0.024) (Figure 6-1). The change in LVEF was driven by a reduction in LVESVi in the nQRS 
group not seen in the LBBB-T group (nQRS -7.9±14.0 vs. LBBB-T -0.6±10.2ml/m2, p=0.02).  
Pre- and post-procedure values for all CMR characteristics can be seen in Table 6-2. Change in 
indexed left ventricular mass was similar between the two groups (nQRS -15.9±10.4 vs LBBB-
T -13.3±9.6g/m2, p=0.367) as was change in LVEDVi (nQRS -7.3±17.4 vs LBBB-T -
3.2±14.5ml/m2, p=0.373). Neither group experienced any change in right ventricular longitudinal 
function (nQRS 21.7±7.0 to 21.5±6.2mm, p=0.817, LBBB-T 18.9±5.8 to 18.6±5.8mm, p=0.773). 
Post-procedure aortic regurgitant fraction was similar between groups (nQRS 5.4±5.7 vs LBBB-
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T 5.5±3.3%, p=0.948). The relationship between post-procedure QRS duration and change in 
LVESVi, LVEF and GLS can be seen in Figure 6-1.  
 
 
Figure 6-1  Line graphs and scatterplots 
Line graphs depicting change in LVESVi (Panel A), LVEF (Panel B) and global 
longitudinal strain (Panel C) before and 6 months following TAVI according to 
post-procedure QRS duration, the vertical lines represent the 95% confidence 
intervals. Panels D, E and F demonstrate the relationship between post-procedure 
QRS duration and change in LVESVi, LVEF and GLS. 
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Table 6-2  CMR parameters pre and 6 months post-TAVI according to post-procedure QRS 
status 
 nQRS 
(n=24) 
LBBB-T 
(n=24) 
Left ventricular ejection fraction, % 
Pre-procedure 
Post-procedure 
 
54.1±11.5 
58.7±9.0 
 
56.6±10.5 
54.4±9.3 
P Value 0.010 0.092 
Global longitudinal strain, % 
Pre-procedure 
Post-procedure 
 
-15.6±3.9 
-17.7±2.7 
 
-16.2±4.2 
-15.9±3.4 
P Value 0.009 0.771 
Indexed left ventricular mass, g/m2 
Pre-intervention 
Post-intervention 
 
74.3±14.7 
58.4±12.6 
 
73.3±17.4 
60.0±13.7 
P Value <0.001 <0.001 
Indexed left ventricular end diastolic volume, ml/m2 
Pre-intervention 
Post-intervention 
 
97.8±22.8 
90.5±21.0 
 
93.4±22.1 
90.3±21.0 
P Value 0.051 0.298 
Indexed left ventricular end systolic volume, ml/m2 
Pre-intervention 
Post-intervention 
 
46.6±20.4 
38.7±16.2 
 
41.8±17.7 
42.4±17.8 
P Value 0.011 0.886 
Indexed left ventricular stroke volume, ml/m2 
Pre-intervention 
Post-intervention 
 
51.2±10.3 
51.8±8.7 
 
51.4±10.5 
47.9±8.5 
P Value 0.742 0.035 
Indexed left atrial volume, ml/m2 
Pre-intervention 
Post-intervention 
 
67.9±19.2 
60.0±18.2 
 
72.9±23.3 
67.9±23.8 
P Value 0.002 0.180 
Septal thickness , mm 
Pre-intervention 
 
12.18±2.61 
 
12.00±4.00 
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Post-intervention 10.49±2.98 9.22±2.52 
P Value 0.002 <0.001 
Lateral wall thickness , mm 
Pre-intervention 
Post-intervention 
 
7.55±1.65 
6.75±1.78 
 
7.25±2.00 
6.44±1.75 
P Value 0.017 0.022 
Data are expressed as mean±SD. nQRS: Narrow QRS post-procedure. LBBB-T: New LBBB 
post-procedure. 
6.4.3.   Inter- and intra-ventricular dyssynchrony 
A typical LV contraction pattern in nQRS and LBBB-T can be seen in Figure 6-2. There was 
evidence of significant inter- and intra-ventricular dyssynchrony in the LBBB-T group at 6 
months compared with the nQRS population (Inter: LBBB-T 130±73 vs. nQRS 23±86ms, 
p=<0.001, intra: LBBB-T 118±103 vs. nQRS 13±13ms, p=0.001). There was a correlation 
between post-procedure QRS and inter- and intra-ventricular dyssynchrony (r=0.57, p=<0.001 
and r=0.49, p=<0.001 respectively).  
 
Figure 6-2  Radial strain in nQRS and LBBB-T 
Radial strain in the mid-ventricular short axis cine. Panel A shows the typical 
contraction pattern in a patient with a narrow post-procedure QRS, the red 
colour depicts positive radial strain occurring in all segments of the left ventricle 
at end systole. Panel B depicts radial strain at end systole in a patient with TAVI-
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induced LBBB. Peak positive septal radial strain occurs in early systole and 
therefore by end-systole the septum is relaxing (negative strain), depicted by the 
blue colour. 
6.4.4.    Reverse remodelling according to narrow, intermediate and broad post-
procedure QRS  
Table 6-3 shows reverse remodelling characteristics with the LBBB-T split into intermediate 
QRS duration (iQRS 120-150ms) and very broad QRS (bQRS, >150ms).  
 
Table 6-3  CMR parameters according to post-procedure QRS duration 
 nQRS 
<120ms 
(n=24) 
iQRS 120-
150ms 
(n=12) 
bQRS >150ms 
(n=12) 
Change in LVEF, % 4.6±7.8 -2.1±5.5* -2.1±7.3* 
Change in GLS, % -2.1±3.6 0.48±3.5* -0.10±3.06 
Change in LVMi, g/m2 -15.9±10.4 -9.5±9.3* -17.0±8.6 
Post-procedure septal thickness, mm 10.5±3.0 8.9±2.4 9.6±2.7 
Post-procedure lateral thickness, mm 6.8±1.8 5.5±1.4* 7.3±1.6† 
Change in septal thickness, mm -1.69±2.3 -1.39±2.88 -4.2±2.4*† 
Change in lateral wall thickness, mm -0.79±1.50 -0.70±1.84 -0.92±1.43 
Post-procedure interventricular dyssynchrony, ms 23±86 109±77* 149±19* 
Post-procedure intraventricular dyssynchrony, ms 13±106 112±130* 124±72* 
Data expressed as mean±SD. nQRS: Narrow QRS. iQRS: intermediate QRS. bQRS: Broad QRS. 
LVEF: left ventricular ejection fraction. GLS: Global Longitudinal Strain. LVMi: Indexed left 
ventricular mass. *P<0.05 compared with nQRS (<120ms). †p<0.05 compared with iQRS (120-
150ms). 
6.4.5.   Predictors of change in LVEF and change in GLS 
Baseline variables which may affect cardiac reverse remodelling following TAVI (including 
clinical, baseline CMR characteristics and post-procedural AR) were analysed to determine 
univariable predictors of change in LVEF and GLS (Table 6-4 and Figure 6-3). Baseline LVEF 
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(beta -0.414, p=0.015) and post-procedure QRS (beta -0.422, p=<0.001) remained significant 
independent predictors of change in LVEF on multiple regression analysis. Baseline LVEF 
(beta=-0.502, p=0.001), baseline GLS (beta -1.02, p=<0.001) and post-procedure QRS 
(beta=0.322, p=0.001) were independent predictors of a change in GLS at 6 months. Infarct 
pattern LGE at baseline did not impact on post-procedural change in LVEF or change in GLS on 
univariate analysis.  
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Table 6-4  Univariate and multivariate analysis 
 Unstandardised 
coefficient  
Standard 
Error 
P Value Unstandardised 
coefficient  
Standard 
error 
P Value 
 Univariate analysis – change in LVEF (%) Multiple regression analysis – change in LVEF (%) 
Age (y) -0.201 0.141 0.160    
Sex 2.844 2.246 0.212    
Diabetes mellitus -1.092 2.624 0.679    
Infarct pattern LGE at baseline 1.647 2.819 0.562    
STS PROM (%) -0.020 0.448 0.965    
Post-procedure QRS duration (ms) -0.119 0.034 0.001 -0.110 0.028 <0.001 
AVAi (cm/m2) 7.888 14.638 0.593    
Baseline GLS (%) -0.963 0.249 <0.001 -0.292 0.319 0.365 
Baseline LVEF (%) -0.393 0.088 <0.001 -0.295 0.117 0.015 
Baseline fibrosis mass (g) -0.007 0.242 0.975    
Post procedure aortic regurgitation fraction (%) 0.089 0.252 0.725    
 Univariate analysis – change in GLS (%) Multiple regression analysis – change in GLS (%) 
Age (y) 0.090 0.064 0.167    
Sex -1.161 1.028 0.265    
Diabetes mellitus -0.467 1.197 0.698    
Infarct pattern LGE at baseline -0.078 1.291 0.952    
STS PROM (%) -0.108 0.204 0.600    
Post-procedure QRS duration (ms) 0.044 0.016 0.010 0.038 0.011 0.001 
159 
 
AVAi (cm/m2) -4.954 6.658 0.461    
Baseline GLS (%) -0.588 0.098 <0.001 -0.904 0.122 <0.001 
Baseline LVEF (%) 0.094 0.046 0.046 -0.163 0.044 0.001 
Post-procedure aortic regurgitation fraction (%) -0.015 0.116 0.895    
Baseline fibrosis mass (g) -0.004 0.112 0.970    
LVEF: Left ventricular ejection fraction. LGE: Late gadolinium enhancement, STS PROM: Society of thoracic surgeons predicted risk of mortality. AVAi: 
Indexed aortic valve area. GLS: Global longitudinal strain 
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Figure 6-3  Scatterplots showing main predictors of change in LVEF and GLS 
Relationship between change in LVEF and post-procedure QRS duration (Graph A), baseline GLS (Graph B), and baseline LVEF (Graph C). 
Relationship of change in GLS and baseline LVEF (Graph D), baseline GLS (Graph E) and post-procedure QRS duration (Graph F). Note that a 
more negative GLS is a favourable finding, and that a negative value for change in GLS represents positive reverse remodelling. The line represents 
a line of best fit.  
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6.5.   Discussion 
This is the first study using CMR to investigate the impact of TAVI-induced LBBB on cardiac 
reverse remodelling. The main findings of this study are: 1) Patients with a narrow QRS post-
TAVI have better LVEF and GLS compared to those with LBBB-T 6 months post-procedure, 2) 
Patients with TAVI-induced LBBB exhibit significant inter- and intra-ventricular dyssynchrony 
compared with those with narrow QRS and 3) Post-procedure QRS duration remained a 
significant independent predictor of change in LVEF and GLS following TAVI on multivariable 
analysis.  
6.5.1.   Impact of TAVI-induced LBBB on cardiac reverse remodelling 
TAVI-induced LBBB is common, occurring in 16 to 65% patients depending on valve type [128]. 
Although predictors of LBBB-T have been extensively studied [128], the impact of LBBB-T on 
cardiac reverse remodelling is less well described, with studies limited to echocardiographic 
evaluation and containing a heterogeneous mix of patients. A PARTNER echocardiographic sub-
study investigating the effects of LBBB-T on those undergoing TAVI reported a lower LVEF at 
12 months in patients with LBBB on discharge electrocardiogram compared to those with a 
narrow QRS, however, there was an increased number of those undergoing trans-apical TAVI in 
the LBBB-T group [112, 158]. A similar failure of improvement in LVEF following balloon-
expandable TAVI was seen by Urena et al in 79 patients with LBBB-T at hospital discharge, 
again with more patients undergoing trans-apical TAVI in the LBBB-T group [163]. Tzikas et al 
[160] reported unfavourable reverse remodelling in 27 patients (including those with pre-existing 
conduction defects) following self-expanding TAVI prior to and 6 days post-procedure. They 
observed an 8% difference in LVEF between the 2 groups. Longitudinal strain was also reduced 
in those with new conduction abnormalities, however this failed to reach statistical significance, 
likely due to being under-powered with small study numbers for an echocardiographic study 
[183]. Hoffman et al [184] investigated 90 patients using 2D and speckle tracking trans-thoracic 
echocardiography prior to and at 1 and 12 months following Edwards Sapien and Medtronic 
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CoreValve TAVI. Patients with new conduction defects had a significantly larger LVESVi at 12 
months compared with those with a narrow QRS, with less difference in LVEDVi, mirroring the 
findings in our study. New conduction defects and baseline LVEF were independent predictors 
of reduction in LVEF at 12 months. The inclusion of patients with trans-apical access in the 
majority of these studies [112, 163, 184] and those with post-procedural pacemaker insertion 
[112, 160, 163, 184] is a significant confounder, given that trans-apical access has been linked to 
reduced LVEF in a number of studies [163, 185] and pacing induced LBBB has been shown to 
cause different patterns of strain to those with idiopathic LBBB [186].  
 
Our study adds further insight into the impact of LBBB-T on cardiac reverse remodelling.  
Groups were matched for clinical and baseline CMR characteristics, all parameters which have 
been found to strongly influence reverse remodelling following valve intervention [167].  None 
of the patients in our study received trans-apical TAVI or permanent pacemaker insertion and 
the unique ability of CMR LGE imaging allowed us to identify and exclude any patients who 
had a post-procedural myocardial infarction, another factor that may have confounded the earlier 
echocardiographically based studies. Finally, the two groups experienced similar amounts of 
post-procedural aortic regurgitation, which is an important modulator of post-TAVI reverse 
remodelling [281] and which was not reported in many of the echocardiographic studies [112, 
160, 184]. This group of patients may be able to provide unique insight into whether there is a 
LBBB-induced cardiomyopathy; it is certainly suggestive in the intermediate term that LBBB 
induced unfavourable effects on reverse remodelling. It would be interesting to study this group 
of patients over a longer period of time to investigate whether these unfavourable effects are 
sustained, or indeed continue to worsen with time.   
6.5.2.   Inter and intra-ventricular dyssynchrony 
The novel use of CMR feature tracking allows us to report values for intra- and inter-ventricular 
dyssynchrony. In LBBB, the normally functioning right bundle conducts the electrical impulse 
to the right ventricle prompting early right ventricular contraction followed by activation of the 
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interventricular septum and finally lateral wall contraction resulting in inter- and intra-ventricular 
dyssynchrony. Inter-ventricular dyssynchrony leads to the classical abnormal septal motion 
pattern of contraction seen in LBBB which is felt to impair LV filling and ejection in its own 
right. This dysynchronous contraction leads to an increase in LVESVi, as seen in our LBBB-T 
group and it is this, rather than a change in LVEDVi, that is the largest driver of reduction in 
LVEF. We have also shown that LBBB-T impacted on change in GLS, with no improvement in 
this group compared to a significant improvement in the nQRS group. Although GLS may be 
affected by dyssynchrony [282], this, coupled with the reduction in left atrial volume in the 
nQRS, but not the LBBB-T group, and the reduction in LV stroke volume in those with LBBB-
T, suggests that the effects of LBBB-T may go beyond that of simple mechanical dyssynchrony.   
6.5.3.   Patterns of reverse remodelling 
With the accurate information that CMR is able to provide on LV wall thickness, our study offers 
new insights into reverse remodelling patterns in LBBB-T. Those with the broadest QRS 
(>150ms) had greater regression of septal hypertrophy compared with those with a narrower 
post-procedure QRS. Asynchronous electrical activation, similar to that seen in LBBB, leads to 
redistribution of mechanical load within the left ventricle and chronic pacing has been shown to 
produce thinning of the early activated wall and thickening of the late activated wall in dogs, 
resulting in asymmetrical left ventricular wall thickness [283]. In our study numbers were small 
and follow up was short but this is hypothesis generating and would be interesting to investigate 
in a larger, longer term follow-up study. 
6.5.4.   Conduction system damage during TAVI 
It is well established that TAVI is associated with a high rate of conduction abnormality [128]. 
On a cellular level, the mechanical trauma is thought to result in transient tissue inflammation 
and oedema and autopsy studies report haematoma formation compressing on the bundle of His 
[129]. The LV outflow tract where the conduction fibres lie has the potential to be traumatised 
at multiple time-points during the TAVI procedure; from damage by the guidewire, to during 
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balloon valvuloplasty, device manipulation and deployment. It is likely that the different valve 
designs can cause differing degrees of compression to the conduction system, with the lower 
cage design of the self-expanding CoreValve felt to cause more compression to the LV outflow 
tract than the balloon expandable Edwards Sapien device [161]. The unique design of the 
mechanically expandable and repositionable Lotus valve with its adaptive seal, may also be 
associated with more conduction system trauma, although reports to date are limited [284]. 
Global ischaemia during rapid pacing required for valve deployment may exacerbate the issue 
[128].  Other procedure-related factors felt to be implicated include pre-implant valvuloplasty, 
deep implant, low ratio of the annulus:balloon or annulus:prosthesis and operator experience 
[285].  
6.5.5.   Clinical implications 
The impact of TAVI-induced LBBB on mortality is a subject of debate, however, it has been 
shown in many studies to be a predictor of mortality [152-155] and has been associated with 
increased hospitalisation [112]. Other studies have failed to demonstrate a link [151, 163, 276]. 
Nonetheless, LVEF is a strong independent predictor of long term survival [286]. This study has 
shown that TAVI-induced LBBB results in reduced global longitudinal and radial systolic 
function compared with those with a narrow post-procedure QRS, which could partially explain 
the link with mortality. Given the adverse effect of TAVI-induced LBBB on cardiac reverse 
remodelling, restoring inter- and intra-ventricular dyssynchrony using cardiac resynchronisation 
therapy, could be considered, especially if another conventional indication for device therapy 
exists [287]. Every effort should be made by the operator, in terms of device selection, avoidance 
of valvuloplasty and device positioning and sizing, to reduce the risk of TAVI-induced LBBB 
given the adverse effects on ventricular remodelling seen. As newer devices are being developed, 
designs should be focused on minimising damage to the electrical conducting system in order to 
prevent the deleterious effects on the LV that this entails.  
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6.6.   Limitations 
Although patients were recruited in a prospective manner, they were matched retrospectively and 
hence the study is prone to the selection bias of this type of study. Patients with LBBB-T were 
matched according to those factors known to influence cardiac reverse remodelling but other 
factors may be unaccounted for. Specifically, patients with coronary artery disease and previous 
myocardial infarction were included in the study, however, numbers in each group were similar 
and infarct pattern LGE at baseline was not a univariate predictor of change in LVEF or GLS. 
Group allocation was based on the discharge electrocardiogram and not re-confirmed at 6 
months, however, there are evidence to suggest (at least in patients undergoing CoreValve 
implantation) that virtually all those with LBBB at discharge have persistent LBBB at 30 days 
[151]. Furthermore, the demonstration of ongoing dyssynchrony at 6 month follow up in the 
LBBB-T group suggests that the conduction abnormality was persistent.  
 
Given the low temporal resolution of CMR, strain measurements are only able to give estimate 
values, and echocardiographic values may allow a more detailed assessment of dyssynchrony, 
albeit with their own but differing set of limitations. Finally, only limited conclusions can be 
made from the sub-group analysis of the QRS width as the groups were small, and any statements 
pertaining to differing remodelling patterns are merely hypothesis generating.  
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Chapter 7:   Conclusion 
 
This body of work is an important collection of findings with conclusions going beyond those of 
simply investigating patterns of reverse remodelling following aortic valve intervention. From 
the work presented here, the clinician can be confident that men and women experience similar 
positive reverse cardiac remodelling as a result of aortic valve intervention and in view of this, 
referral patterns should not differ according to gender. It has also been demonstrated that there is 
improved early cardiac reverse remodelling in those without myocardial fibrosis; this supports 
data linking fibrosis with adverse outcome, and takes us one step closer to understanding which 
patients are more likely to benefit from TAVI from the outset. It also reassures clinicians that 
myocardial infarction is rare following TAVI, even in the context of non-vascularised coronary 
artery disease, and adds further weight to the argument that coronary revascularisation prior to 
TAVI may be unnecessary. Finally, it robustly demonstrates that TAVI-induced left bundle 
branch block is associated with unfavourable cardiac reverse remodelling. This is especially 
important given the high rates of LBBB associated with certain valve types as TAVI is extended 
to a younger population.  
 
Aortic stenosis is the commonest valvular lesion of the developed world and its incidence is 
expected to grow due to the ageing population [4]. The left ventricle adapts to the increased 
afterload by developing hypertrophy which allows normalisation of wall stress and maintenance 
of cardiac output. Eventually, however, the left ventricle starts to fail with a resultant reduction 
in cardiac output leading to the signs and symptoms of heart failure. The onset of symptoms 
resulting from aortic stenosis heralds a dismal prognosis, with 2 year survival rates of 50% if left 
untreated [5]. Surgical aortic valve replacement is the standard treatment option and has been the 
standard treatment option for nearly 5 decades. Trans-catheter aortic valve implantation was first 
performed in 2002 and since its inception, has been widely adopted to offer a permanent 
treatment option to those considered too frail or high risk for conventional surgery [288]. It has 
been an important development as previously, up to a third of those with severe AS were left 
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untreated given that AS is predominantly a disease of advanced age [288]. Although TAVI is 
less invasive than SAVR, it is still associated with significant morbidity and mortality [54, 86, 
106]. Common complications of both approaches are stroke as a result of cerebral emboli, with 
an excess of bleeding, acute kidney injury and AF seen following surgical replacement and 
increased vascular complications, significant aortic regurgitation and need for pacemaker 
implantation seen following TAVI. Despite the different co-morbid complications, contemporary 
randomised controlled trials suggest that survival is similar between the two techniques [54, 86, 
106]. Rates of clinically detected myocardial infarction are low following both procedures but 
silent infarcts may go undetected, both due to the lack of ability of patients to report symptoms 
(as the patient is under the influence of general anaesthetic or heavy sedation at the time of TAVI 
and SAVR) and due to conduction abnormalities (such as LBBB) masking important ischaemic 
changes. Biomarker levels are ubiquitously raised following both procedures and therefore prove 
to be unhelpful [113, 114]. CMR LGE allows infarction to be directly visualised and as such, 
using direct comparison of pre- and post-procedure scans is a useful tool to accurately define the 
true incidence of post-procedural MI according to procedure type. Whilst MI assessed by CMR 
LGE is an infrequent complication of TAVI it appears to be more common following SAVR. 
Absolute infarct size is small following both procedures and does not impact on post-procedural 
LVEF. The importance of bystander coronary artery disease at the time of TAVI is further 
explored by the results presented in this thesis. Initially, it was feared that the period of global 
hypotension experienced during TAVI may lead to myocardial infarction in the context of 
significant epicardial coronary artery stenoses. This study has demonstrated that the new MI rate 
is low following TAVI in the context of non-revascularised coronary artery disease, reassuring 
the operator that pre-implant percutaneous intervention may be unnecessary.  
 
Gender differences in the left ventricular response to aortic stenosis have previously been 
described [14, 22, 289], however, the studies reporting this to date have compared men and 
women with differing valvular gradients (typically higher in women) which may confound 
results. This study compares a population with matched AS severity at baseline, but greater aortic 
regurgitation in men, and demonstrates that men exhibit differing remodeling patterns in the face 
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of aortic stenosis. Men have a larger LV cavity size, greater LV mass, greater LV wall thickness 
and the same amount but a differing pattern of fibrosis than women. The referral bias of men 
over women is again seen in our study, with more men undergoing SAVR than TAVI. Following 
aortic valve replacement, both genders experienced a significant reduction in left ventricular 
mass and a similar reduction in aortic valve gradient, but there was more absolute mass regression 
in men, but similar amounts when expressed as a percentage of mass reduction. Multivariate 
analysis found baseline LV mass, but not gender, to be a predictor of LV mass regression. This 
difference was still apparent if those with significant baseline AR was excluded. It was therefore 
the more adverse remodelling profile at baseline seen in men, rather than gender per se, that was 
a predictor of reverse remodelling following valve replacement. Males also had a reduction in 
mitral regurgitation and left atrial size, suggestive of greater benefits in diastology than females, 
possibly reflecting the greater absolute mass reduction. There was no significant difference in 
post-procedural AR following valve replacement.  
 
Therefore, there were no significant differences in cardiac reverse remodelling following aortic 
valve replacement according to gender, suggesting that the improved medium and long term 
survival seen in women following aortic valve replacement is due to factors other than cardiac 
reverse remodelling.  
 
Cardiac reverse remodelling occurs in virtually all patients following valve intervention. It is 
well established by both CMR and echocardiographic studies that mass regression occurs at 
intermediate follow up [167, 169], with most mass regression occurring within the first year and 
continuing at a slower rate thereafter [166, 170]. Mass regression is associated with improved 
survival and reduced heart failure hospitalisation following both SAVR and TAVI [164, 165]. 
The link between myocardial fibrosis and mass regression is less clear, with differing reports in 
the limited studies where it is described [167, 190, 191]. The results presented in this thesis show 
that at least half of the LV mass regression occurs prior to hospital discharge, which supports the 
findings of previously published echocardiographic studies [26, 170].  
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The ability of CMR LGE to assess for myocardial fibrosis permits further insight to be gained 
with regard to early reverse remodelling. Those with no fibrosis experience more acute LV mass 
regression than those with either myocardial infarct pattern or mid-wall/focal fibrosis pattern 
LGE, suggesting that the process may begin earlier in those without fibrosis at baseline. We have 
also demonstrated that in those with an abnormal LVEF at baseline, there is an acute 
improvement in LVEF, suggesting that the afterload reduction seen acutely following TAVI is 
associated with favourable acute cardiac reverse remodelling.  
 
Left bundle branch block is commonly seen following TAVI, with rates differing according to 
valve design and procedural factors such as valve positioning and valve over-expansion [128]. It 
is thought to occur due to damage to the cardiac conduction fibres contained within the left 
ventricular outflow tract which lies adjacent to the aortic valve annulus. The conduction fibres 
have the potential to be damaged at many points during the TAVI procedure, with the constant 
pressure of the self-expanding TAVI design felt to lead to more permanent damage, especially 
in the context of pre-existing conduction system degeneration.  
 
Some registry studies suggest reduced survival and increased hospitalisation in those with TAVI-
induced LBBB [112, 152]. The mechanism for this excess mortality may relate to less favourable 
reverse remodelling in this group. We have demonstrated in a matched group of patients 
undergoing TAVI that those with TAVI-induced LBBB have ongoing inter- and intra-ventricular 
dyssynchrony 6 months following TAVI and that this is associated with reduced LVEF compared 
to those with a narrow QRS at 6 months, driven by a reduction in LV end-systolic volume in 
those with a narrow QRS not seen in those with TAVI-induced LBBB. The differences in 
LVESVi between the groups is perhaps not surprising given the clear LBBB-induced 
dyssynchrony, however, those with TAVI-induced LBBB also exhibited reduced global 
longitudinal strain compared with those with  a narrow post-procedure QRS, suggesting that the 
negative effects may go beyond that of simple dyssynchrony. Post-procedure QRS duration 
remained an independent predictor of change in LVEF and change in GLS on multivariable 
analysis, confirming the negative effects of this. As TAVI is extended to a lower risk population, 
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it is important therefore that LBBB is avoided where possible in order to maximise positive 
cardiac reverse remodelling. The operator should therefore be mindful of this both during device 
selection and at the time of implantation, to maximise the chance of maintaining normal cardiac 
electrical conduction.  
 
This body of work presents a comprehensive assessment of remodeling in aortic stenosis and 
reverse remodelling and the impact of fibrosis following aortic valve intervention, using 
cardiovascular magnetic resonance imaging. As TAVI is extended to a younger, lower risk 
population, the findings of this thesis help further the understanding of the cardiac response to 
AS and aortic valve replacement.   
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7.1.   Future directions 
Although this body of work sheds light on some of the unanswered questions with regard to the 
cardiac response to aortic stenosis and its treatment, there is still scope for further research. One 
of the limitations of this thesis is the limited study size, inherent to many CMR based studies, 
and the lack of outcome data presented. In order to fully understand the true impact of aortic 
stenosis and myocardial fibrosis on cardiac remodelling, and the relationship to outcomes, larger 
scale studies are required. The ‘British Society of Cardiovascular Magnetic Resonance Imaging’ 
AS-700 study is currently underway, whereby data from several centres’ across the United 
Kingdom are being collated. This will allow the analysis of over 700 CMR scans of patients with 
severe AS. Large scale data like this will allow robust conclusions to be made about the 
importance CMR can have in predicting outcome in AS and further insights into topics such as 
the importance of myocardial fibrosis and gender differences will be possible.   
 
Although now a widely used and accepted technique, the literature regarding TAVI is still in its 
infancy.  Due to the fact that the initial cohort of TAVI patients treated were frail and elderly, 
long-term outcome data, including long-term effects on mortality, cardiac remodelling and valve 
durability are still relatively unknown and will be an interesting focus of future research, 
especially as the technology has recently been extended to a younger, lower surgical risk cohort. 
The extension of the technology to this group will allow for prospective studies comparing SAVR 
and TAVI to be better matched for co-morbidity, gender and age, a factor which has been a 
limitation in inter-group comparisons in this and many other studies to date. Also, as more valve 
designs become available, the operator is left with a bewildering choice of designs, each with 
their own pros and cons. CMR has a role to play in the evaluation of these different TAVI valve 
designs; from the differing effects on cardiac reverse remodelling and aortic regurgitation to the 
impact on cerebral embolisation and should be a focus for future investigation to help facilitate 
the decision making process.  
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The data presented in this thesis regarding acute remodelling are of particular interest and was a 
surprising finding of the study. The mechanism for acute LV mass reduction is unknown but may 
be related to an acute reduction in extracellular volume or indeed an acute shrinkage in myocyte 
size. The mechanism for this could be further explored using CMR. Extracellular volume can be 
estimated from T1 Mapping techniques. T1 Mapping works by allowing the T1 relaxation time 
of each voxel of the myocardium to be calculated and quantified on a standardised scale to 
directly evaluate the composition of myocardial tissue. Using State-of-the-art techniques, high 
resolution TI mapping can be readily performed during a single breath hold using modified Look-
Locker inversion recovery (MOLLI) imaging [211, 290]. TI mapping is usually performed at a 
pre-specified timepoints pre and post gadolinium contrast administration. Extracellular volume 
can then be estimated via a mathematical equation which takes into account of the circulating 
haematocrit levels [291]. More recently, CMR has been used to detect cardiomyocyte size in 
murine models with hypertension [269]. Via mathematical modelling, T1 relaxation times 
following gadolinium contrast agent were obtained in order to calculate the intracellular lifetime 
in water. This technique demonstrated a non-invasive measure of cardiomyocyte size. To our 
knowledge, T1 mapping to calculate extracellular volume or cardiomyocyte size has not been 
performed acutely following TAVI or SAVR for AS, and would be an interesting topic of future 
research to help delineate the pathophysiology behind the acute reduction in LV mass observed 
in our study.  
 
TAVI is now an accepted treatment option, with excellent short to medium term outcome data 
[54] leading to its adoption worldwide and inclusion in international guidelines [65, 292]. The 
huge success of transcatheter aortic valve technology opens the door for the development of new 
approaches in the treatment of other valvular heart disease. Mitral regurgitation is the second 
most prevalent valve lesion requiring surgery in the developed world [4] and is associated with 
significant morbidity and mortality [293]. To date, the only catheter based therapy in widespread 
use had been the Mitraclip device, although results in the only head-to-head trial to date have 
been disappointing [294] possibly due to the design of the device (an Alfieri stitch-like 
mechanism) offering only a partial resolution of the regurgitation. The short term results of the 
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first in-man transcatheter mitral valve replacement have recently been reported [295] and are 
promising. CMR, with its capabilities to provide robust evaluation of cardiac mass, volume, scar, 
fibrosis and flow data, alongside more novel techniques such as 4D flow [296] and T1 mapping, 
is ideally placed to evaluate the impact these new devices have on the heart, and it will be 
interesting to use this as a tool to evaluate these therapies as they become more widespread.  
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